US20090062148A1 - Substrate preparation process - Google Patents

Substrate preparation process Download PDF

Info

Publication number
US20090062148A1
US20090062148A1 US11/500,411 US50041106A US2009062148A1 US 20090062148 A1 US20090062148 A1 US 20090062148A1 US 50041106 A US50041106 A US 50041106A US 2009062148 A1 US2009062148 A1 US 2009062148A1
Authority
US
United States
Prior art keywords
substrate
synthesis
support
sealing member
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/500,411
Inventor
Martin Goldberg
Martin Diggelman
Earl Hubbell
Glenn McGall
Nam Quoc Ngo
Macdonald Morris
Mel Yamamoto
Jennifer Tan
Richard P. Rava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affymetrix Inc
Original Assignee
Affymetrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/716,507 external-priority patent/US6706875B1/en
Application filed by Affymetrix Inc filed Critical Affymetrix Inc
Priority to US11/500,411 priority Critical patent/US20090062148A1/en
Publication of US20090062148A1 publication Critical patent/US20090062148A1/en
Priority to US12/634,475 priority patent/US8067578B2/en
Priority to US13/273,399 priority patent/US8309496B2/en
Priority to US13/629,861 priority patent/US8637434B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00351Means for dispensing and evacuation of reagents
    • B01J2219/00427Means for dispensing and evacuation of reagents using masks
    • B01J2219/00432Photolithographic masks
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • B01J2219/00529DNA chips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00585Parallel processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/0059Sequential processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00596Solid-phase processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00608DNA chips
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/0061The surface being organic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00614Delimitation of the attachment areas
    • B01J2219/00621Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/00626Covalent
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00632Introduction of reactive groups to the surface
    • B01J2219/00637Introduction of reactive groups to the surface by coating it with another layer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068Means for controlling the apparatus of the process
    • B01J2219/00686Automatic
    • B01J2219/00689Automatic using computers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00709Type of synthesis
    • B01J2219/00711Light-directed synthesis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00722Nucleotides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11Compounds covalently bound to a solid support
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809Multifield plates or multicontainer arrays

Definitions

  • arrays of polymer sequences on solid substrates have wide ranging applications and are of substantial importance to the pharmaceutical, biotechnology and medical industries.
  • the arrays may be used in screening large numbers of molecules for biological activity, i.e., receptor binding capability.
  • arrays of oligonucleotide probes can be used to identify mutations in known sequences, as well as in methods for de novo sequencing of target nucleic acids.
  • the present invention generally provides novel processes for the efficient, large scale preparation of arrays of polymer sequences wherein each array includes a plurality of different, positionally distinct polymer sequences having known monomer sequences.
  • the methods of the present invention provide for the cleaning and stripping of substrate wafers to remove oil and dirt from the surface, followed by the derivatization of the wafers to provide photoprotected functional groups on the surface.
  • Polymer sequences are then synthesized on the surface of the substrate wafers by selectively exposing a plurality of selected regions on the surface to an activation radiation to remove the photolabile protecting groups from the functional groups and contacting the surface with a monomer containing solution to couple monomers to the surface in the selected regions.
  • Each polymer array includes a plurality of different polymer sequences coupled to the surface of the substrate wafer in a different known location.
  • the wafers are then separated into a plurality of individual substrate segments, each segment having at least one polymer array formed thereon, and packaged in a cartridge whereby the surface of said substrate segment having the polymer array formed thereon is in fluid contact with the cavity.
  • the present invention provides methods of forming polymer arrays by providing a substrate having a first surface coated with functional groups protected with a photolabile protecting group, and a second surface having a layer that includes one or more of an index matching compound, a light absorbing compound and an antireflective compound. The method then provides for the sequential activation and coupling of monomers in different selected regions of the first surface of the substrate to form a plurality of different polymer sequences in different known locations on the surface of the substrate, by directing an activation radiation at the first surface of the substrate.
  • the present invention provides a method of forming a plurality of polymer arrays using a batch process.
  • this method comprises the steps of activating a plurality of substrate wafers by exposing selected regions on each of a plurality of substrate wafers then contacting them with a monomer containing solution in a batch.
  • the present invention provides a method of synthesizing polymers on substrates by first derivatizing the substrate with an aminoalkyltrialkoxysilane.
  • the present invention provides a method for forming an array of polymers on a substrate using light-directed synthesis wherein the exposing step comprises directing an activation radiation at selected regions on the surface of said substrate by shining the activation radiation through a photolithographic mask having transparent regions and opaque regions where the transparent regions are smaller than the selected regions. As a result, the activation radiation shone through the transparent regions in the mask is diffracted to expose the selected regions.
  • the present invention also provides methods of forming arrays of polymer sequences having enhanced synthesis efficiencies through the incorporation of monomers which have lipophilic chemical groups coupled thereto.
  • the present invention also provides methods of forming polymer arrays using the above-described methods, but wherein the deprotection and coupling steps in adjacent selected regions of the substrate surface are aligned to minimize differences in synthesis steps between adjacent regions.
  • the present invention provides polymer arrays and methods of forming them on a tubular substrate by the sequential activation of and coupling of monomers to selected segments of the tubular substrate surface.
  • the present invention provides methods of photoprotecting functional groups that are coupled to solid supports by exposing the functional group to a photoprotecting group transfer agent having the formula:
  • R 1 is a photolabile protecting group and X is a leaving group.
  • FIG. 1 schematically illustrates light directed oligonucleotide synthesis using photolithographic methods.
  • FIGS. 2A-C are flow diagrams illustrating the overall process of substrate preparation.
  • FIG. 2A is a flow diagram illustrating the overall process.
  • FIGS. 2B and 2C are flow diagrams of the synthesis steps for individual and batch processes, respectively.
  • FIGS. 3A and 3B show schematic illustrations of alternate reactor systems for carrying out the combined photolysis/chemistry steps of used in the methods of the present invention.
  • FIGS. 4A and 4B schematically illustrate different isolated views of a flow cell incorporated into the reactor systems of FIGS. 3A and 3B .
  • FIG. 4C shows a schematic illustration of an integrated reactor system including computer control and substrate translation elements.
  • FIG. 5A shows the alkylation of the exocyclic amine functional group of deoxyguanosine with dimethoxytritylchloride (DMT-Cl) and subsequent coupling of a MenPOC protecting group to the 3′ hydroxyl group of a nucleoside phosphoramidite.
  • FIG. 5B shows the synthetic route for production of Fmoc-phosphoramidites.
  • FIG. 5C shows a synthetic route for introduction of a lipophilic substituent to the photoprotecting group MeNPOC.
  • FIG. 6A shows a schematic representation of a device including a six vessel reaction chamber bank, for carrying out multiple parallel monomer addition steps separate from the photolysis step in light directed synthesis of oligonucleotide arrays.
  • FIG. 6B shows a detailed view of a single reaction chamber.
  • FIG. 7 illustrates a substrate wafer fabricated with a plurality of probe arrays which wafer also includes alignment marks.
  • FIG. 8 illustrates one embodiment of an array cartridge into which an array substrate is placed for use.
  • FIGS. 9A and 9B show the coupling of fluorescent nucleotides to a substrate surface using photolithographic methods in 50 and 100 ⁇ m features, using back-side and frontside exposure, respectively.
  • FIGS. 9C and 9D show a plot of fluorescence intensity as a function of substrate position at the border between two features for back-side and front-side exposure as indicated.
  • FIG. 9C illustrates the contrast difference from a top view of the plots while FIG. 9D shows a side view.
  • FIG. 10 is a bar chart showing a comparison of silanation methods using 5 different silanes to derivatize the surface of glass substrates (3-acetoxypropyltrimethoxysilane (“OAc”); 3-glycidoxypropyltrimethoxysilane (“Epoxy”); 4-(hydroxybutyramido)propyltriethoxysilane (“Mono”); 3-aminopropyltriethoxysilane (“APS”); and 3-N,N-bis(2-hydroxyethyl)aminopropyl; triethoxysilane (“bis”)).
  • OAc acetoxypropyltrimethoxysilane
  • Epoxy 3-glycidoxypropyltrimethoxysilane
  • APS 3-aminopropyltriethoxysilane
  • bis 3-N,N-bis(2-hydroxyethyl)aminopropyl; triethoxysilane
  • FIG. 11 shows the reprotection of deprotected hydroxyl groups on a glass substrate with MeNPOC-tetrazolide as a function of time of exposure to the MeNPOC-tetrazolide and addition of catalyst.
  • a probe as defined herein, is a surface-immobilized molecule that is recognized by a particular target. These may also be referred to as ligands. Examples of probes encompassed by the scope of this invention include, but are not limited to, agonists and antagonists of cell surface receptors, toxins and venoms, viral epitopes, hormone receptors, peptides, peptidomimetics, enzymes, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, nucleic acids, oligosaccharides, proteins or monoclonal antibodies, natural or modified, e.g., reshaped, chimeric, etc.
  • An array is a preselected collection of different polymer sequences or probes which are associated with a surface of a substrate.
  • An array may include polymers of a given length having all possible monomer sequences made up of a specific basis set of monomers, or a specific subset of such an array.
  • an array of all possible oligonucleotides of length 8 includes 65,536 different sequences.
  • an oligonucleotide array also may include only a subset of the complete set of probes.
  • a given array may exist on more than one separate substrate, e.g., where the number of sequences necessitates a larger surface area in order to include all of the desired polymer sequences.
  • a functional group is a reactive chemical moiety present on a given monomer, polymer or substrate surface.
  • Examples of functional groups include, e.g., the 3′ and 5′ hydroxyl groups of nucleotides and nucleosides, as well as the reactive groups on the nucleobases of the nucleic acid monomers, e.g., the exocyclic amine group of guanosine, as well as amino and carboxyl groups on amino acid monomers.
  • a monomer or building block is a member of the set of smaller molecules which can be joined together to form a larger molecule or polymer.
  • the set of monomers includes but is not restricted to, for example, the set of common L-amino acids, the set of D-amino acids, the set of natural or synthetic amino acids, the set of nucleotides (both ribonucleotides and deoxyribonucleotides, natural and unnatural) and the set of pentoses and hexoses.
  • monomer refers to any member of a basis set for synthesis of a larger molecule.
  • a selected set of monomers forms a basis set of monomers.
  • the basis set of nucleotides includes A, T (or U), G and C.
  • dimers of the 20 naturally occurring L-amino acids form a basis set of 400 monomers for synthesis of polypeptides.
  • Different basis sets of monomers may be used in any of the successive steps in the synthesis of a polymer.
  • each of the sets may include protected members which are modified after synthesis.
  • a feature is defined as a selected region on a surface of a substrate in which a given polymer sequence is contained. Thus, where an array contains, e.g., 100,000 different positionally distinct polymer sequences on a single substrate, there will be 100,000 features.
  • Edge An edge is defined as a boundary between two features on a surface of a substrate. The sharpness of this edge, in terms of reduced bleed over from one feature to another, is termed the “contrast” between the two features.
  • a protecting group is a material which is chemically bound to a reactive functional group on a monomer unit or polymer and which protective group may be removed upon selective exposure to an activator such as a chemical activator, or another activator, such as electromagnetic radiation or light, especially ultraviolet and visible light.
  • an activator such as a chemical activator, or another activator, such as electromagnetic radiation or light, especially ultraviolet and visible light.
  • Protecting groups that are removable upon exposure to electromagnetic radiation, and in particular light, are termed “photolabile protecting groups.”
  • the present invention generally provides processes and devices for reproducibly and efficiently preparing arrays of polymer sequences on solid substrates.
  • the overall process is illustrated in FIG. 2A .
  • the process 1 begins with a series of substrate preparation steps 10 which may include such individual processing steps as stripping cleaning and derivatization of the substrate surface to provide uniform reactive surfaces for synthesis.
  • the polymer sequences are then synthesized on the substrate surface in the synthesis step 20 .
  • the substrates are then separated into individual arrays 40 , and assembled in cartridges that are suitable for ultimate use 60 .
  • the present invention also provides for the synthesis of the polymer sequences on the substrate surface using either an individual or batch process mode. A comparison of these two synthesis modes is shown in FIG. 2B .
  • the activation and monomer addition steps are combined in a single unit operation 22 .
  • a single substrate wafer is placed in a reactor system where it is first subjected to an activation step to activate selected regions of the substrate.
  • the substrate is then contacted with a first monomer which is coupled to the activated region.
  • Activation and coupling steps are repeated until the desired array of polymer sequences is created.
  • the arrays of polymer sequences are then subjected to a final deprotection step 30 .
  • a number of substrate wafers are subjected to an activating step 24 .
  • the activated substrate wafers are then pooled 26 and subjected to a monomer addition step 28 .
  • Each substrate wafer is then subjected individually to additional activation steps followed by pooling and monomer addition. This is repeated until a desired array of polymer sequences is formed on the substrate wafers in a series of individual arrays.
  • These arrays of polymer sequences on the substrate wafers are then subjected to a final deprotection step 30 .
  • substrate refers to a material having a rigid or semi-rigid surface. In many embodiments, at least one surface of the substrate will be substantially flat or planar, although in some embodiments it may be desirable to physically separate synthesis regions for different polymers with, for example, wells, raised regions, etched trenches, or the like. According to other embodiments, small beads may be provided on the surface which may be released upon completion of the synthesis.
  • Preferred substrates generally comprise planar crystalline substrates such as silica based substrates (e.g. glass, quartz, or the like), or crystalline substrates used in, e.g., the semiconductor and microprocessor industries, such as silicon, gallium arsenide and the like. These substrates are generally resistant to the variety of synthesis and analysis conditions to which they may be subjected. Particularly preferred substrates will be transparent to allow the photolithographic exposure of the substrate from either direction.
  • Aerogel substrates may be used as free standing substrates or as a surface coating for another rigid substrate support. Aerogel substrates provide the advantage of large surface area for polymer synthesis, e.g., 400 to 1000 m 2 /gm, or a total useful surface area of 100 to 1000 cm 2 for a 1 cm 2 piece of aerogel substrate.
  • Such aerogel substrates may generally be prepared by methods known in the art, e.g., the base catalyzed polymerization of (MeO) 4 Si or (EtO) 4 Si in ethanol/water solution at room temperature. Porosity may be adjusted by altering reaction condition by methods known in the art.
  • wafer generally refers to a substantially flat sample of substrate from which a plurality of individual arrays or chips may be fabricated.
  • array or “chip” is used to refer to the final product of the individual array of polymer sequences, having a plurality of different positionally distinct polymer sequences coupled to the surface of the substrate.
  • the size of a substrate wafer is generally defined by the number and nature of arrays that will be produced from the wafer.
  • more complex arrays e.g., arrays having all possible polymer sequences produced from a basis set of monomers and having a given length, will generally utilize larger areas and thus employ larger substrates, whereas simpler arrays may employ smaller surface areas, and thus, less substrate.
  • the substrate wafer will range in size of from about 1′′ ⁇ 1′′ to about 12′′ ⁇ 12′′, and will have a thickness of from about 0.5 mm to about 5 mm.
  • Individual substrate segments which include the individual arrays, or in some cases a desired collection of arrays are typically much smaller than the wafers, measuring from about 0.2 cm ⁇ 0.2 cm 20 to about 5 cm ⁇ 5 cm. In particularly preferred aspects, the substrate wafer is about 5′′ ⁇ 5′′ whereas the substrate segment is approximately 1.28 cm ⁇ 1.28 cm.
  • a wafer can be used to fabricate a single large substrate segment, typically, a large number of substrate segments will be prepared from a single wafer. For example, a wafer that is 5′′ ⁇ 5′′ can be used to fabricate upwards of 49 separate 1.28 cm ⁇ 1.28 cm substrate segments. The number of segments prepared from a single wafer will generally vary depending upon the complexity of the array, and the desired feature size.
  • the present invention may also be practiced with substrates having substantially different conformations.
  • the substrate may exist as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc.
  • the substrate is a glass tube or microcapillary.
  • the capillary substrate provides advantages of higher surface area to volume ratios, reducing the amount of reagents necessary for synthesis. Similarly, the higher surface to volume ratio of these capillary substrates imparts more efficient thermal transfer properties. Additionally, preparation of the polymer arrays may be simplified through the use of these capillary based substrates.
  • the capillary will encounter linear reticles (translucent regions of the mask), one at a time, thereby exposing selected regions within the capillary or capillary.
  • linear reticles translucent regions of the mask
  • This can allow bundling of parallel capillaries during synthesis wherein the capillaries are exposed to thicker linear reticles, simultaneously, for a batch processing mode, or individual capillaries may be placed on a mask having all of the linear reticles lined up so that the capillary can be stepped down the mask in one direction. Subsequent capillaries may be stepped down the mask at least one step behind the previous capillary. This employs an assembly line structure to the substrate preparation process.
  • a standard optimization chip for detecting 36 simultaneous mutations using a flat geometry chip and an optimization tiling strategy is 44 ⁇ 45 features (1980 probes and blanks), with 36 blocks of 40 probes each (1440 probes), plus 15 blanks per block (540 blank probes).
  • a capillary format can incorporate the same number of test probes in a smaller space. Specifically, in a capillary substrate, 36 strings of 40 probes will have only one blank space separating each probe group (35 blank probes), for a total of 1475 features.
  • linear capillary based substrates can provide the advantage of reduced volume over flat geometries.
  • typical capillary substrates have a volume in the 1-101 range, whereas typical flow cells for synthesizing or screening flat geometry chips have volumes in the range of 100 ⁇ l.
  • the substrate is stripped to remove any residual dirt, oils or other fluorescent materials which may interfere with the synthesis reactions, or subsequent analytical use of the array.
  • the process of stripping the substrate typically involves applying, immersing or otherwise contacting the substrate with a stripping solution.
  • Stripping solutions may be selected from a number of commercially available, or readily prepared chemical solutions used for the removal of dirt and oils, which solutions are well known in the art.
  • Particularly preferred stripping solutions are composed of a mixture of concentrated H 2 SO 4 and H 2 O 2 .
  • Such solutions are generally available from commercial sources, e.g., NanostripTM from Cyantek Corp.
  • the substrate is rinsed with water and in preferred aspects, is then contacted with a solution of NaOH, which results in regeneration of an even layer of hydroxyl functional groups on the surface of the substrate.
  • the substrate is again rinsed with water, followed by a rinse with HCl to neutralize any remaining base, followed again by a water rinse.
  • the various stripping and rinsing steps may generally be carried out using a spin-rinse-drying apparatus of the type generally used in the semiconductor manufacturing industry.
  • Gas phase cleaning and preparation methods may also be applied to the substrate wafers using, e.g., H 2 O or O 2 plasma or reactive ion etching (RIE) techniques that are well known in the art.
  • RIE reactive ion etching
  • the surface is derivatized to provide sites or functional groups on the substrate surface for synthesizing the various polymer sequences on that surface.
  • derivatization provides reactive functional groups, e.g., hydroxyl, carboxyl, amino groups or the like, to which the first monomers in the polymer sequence may be attached.
  • the substrate surface is derivatized using silane in either water or ethanol.
  • silanes include mono- and dihydroxyalkylsilanes, which provide a hydroxyl functional group on the surface of the substrate.
  • aminoalkyltrialkoxysilanes which can be used to provide the initial surface modification with a reactive amine functional group.
  • 3-aminopropyltriethoxysilane and 3-aminopropyltrimethoxysilane (“APS”).
  • APS 3-aminopropyltriethoxysilane and 3-aminopropyltrimethoxysilane
  • the aminoalkyltrialkoxysilanes are inexpensive and can be obtained commercially in high purity from a variety of sources, the resulting primary and secondary amine functional groups are more reactive nucleophiles than hydroxyl groups, the aminoalkyltrialkoxysilanes are less prone to polymerization during storage, and they are sufficiently volatile to allow application in a gas phase in a controlled vapor deposition process (See below).
  • silanes can be prepared having protected or “masked” hydroxyl groups and which possess significant volatility. As such, these silanes can be readily purified by, e.g., distillation, and can be readily employed in gas-phase deposition methods of silanating substrate surfaces. After coating these silanes onto the surface of the substrate, the hydroxyl groups may be deprotected with a brief chemical treatment, e.g., dilute acid or base, which will not attack the substrate-silane bond, so that the substrate can then be used for polymer synthesis.
  • a brief chemical treatment e.g., dilute acid or base
  • silanes examples include acetoxyalkylsilanes, such as acetoxyethyltrichlorosilane, acetoxypropyltrimethoxysilane, which may bedeprotected after application using, e.g., vapor phase ammonia and methylamine or liquid phase aqueous or ethanolic ammonia and alkylamines.
  • Epoxyalkylsilanes may also be used, such as glycidoxypropyltrimethoxysilane which may be deprotected using, e.g., vapor phase HCl, trifluoroacetic acid or the like, or liquid phase dilute HCl.
  • the physical operation of silanation of the substrate generally involves dipping or otherwise immersing the substrate in the silane solution. Following immersion, the substrate is generally spun as described for the substrate stripping process, i.e., laterally, to provide a uniform distribution of the silane solution across the surface of the substrate. This ensures a more even distribution of reactive functional groups on the surface of the substrate.
  • the silanated substrate may be baked to polymerize the silanes on the surface of the substrate and improve the reaction between the silane reagent and the substrate surface. Baking typically takes place at temperatures in the range of from 90° C. to 120° C. with 110° C. being most preferred, for a time period of from about 1 minute to about 10 minutes, with 5 minutes being preferred.
  • the silane solution may be contacted with the surface of the substrate using controlled vapor deposition methods or spray methods. These methods involve the volatilization or atomization of the silane solution into a gas phase or spray, followed by deposition of the gas phase or spray upon the surface of the substrate, usually by ambient exposure of the surface of the substrate to the gas phase or spray. Vapor deposition typically results in a more even application of the derivatization solution than simply immersing the substrate into the solution.
  • the efficacy of the derivatization process may generally be assessed by adding a fluorophore which binds the reactive groups, e.g., a fluorescent phosphoramidite such as FluoreprimeTM from Pharmacia, Corp., FluorediteTM from Millipore, Corp. or FAMTM from ABI, and looking at the relative fluorescence across the surface of the substrate.
  • a fluorophore which binds the reactive groups
  • a fluorescent phosphoramidite such as FluoreprimeTM from Pharmacia, Corp., FluorediteTM from Millipore, Corp. or FAMTM from ABI
  • the synthesis of oligonucleotides on the surface of a substrate may be carried out using light directed methods as described in., e.g., U.S. Pat. Nos. 5,143,854 and 5,384,261 and Published PCT Application No WO 92/10092, or mechanical synthesis methods as described in 5,384,261 and Published PCT Application No. 93/09668, each of which is incorporated herein by reference.
  • synthesis is carried out using light-directed synthesis methods.
  • these light-directed or photolithographic synthesis methods involve a photolysis step and a chemistry step.
  • the substrate surface, prepared as described herein comprises functional groups on its surface.
  • photolabile protecting groups also as described herein.
  • photoprotected portions of the surface of the substrate are exposed to light or other activators to activate the functional groups within those portions, i.e., to remove photoprotecting groups.
  • the substrate is then subjected to a chemistry step in which chemical monomers that are photoprotected at least one functional group are then contacted with the surface of the substrate. These monomers bind to the activated portion of the substrate through an unprotected functional group.
  • Subsequent activation and coupling steps couple monomers to other preselected regions, which may overlap with all or part of the first region.
  • the activation and coupling sequence at each region on the substrate determines the sequence of the polymer synthesized thereon.
  • light is shown through the photolithographic masks which are designed and selected to expose and thereby activate a first particular preselected portion of the substrate.
  • Monomers are then coupled to all or part of this portion of the substrate.
  • the masks used and monomers coupled in each step can be selected to produce arrays of polymers having a range of desired sequences, each sequence being coupled to a distinct spatial location on the substrate which location also dictates the polymer's sequence.
  • the photolysis steps and chemistry steps are repeated until the desired sequences have been synthesized upon the surface of the substrate.
  • FIG. 1 Basic strategy for light directed synthesis of oligonucleotides on a VLSIPSTM Array is outlined in FIG. 1 .
  • the surface of a substrate or solid support, modified with photosensitive protecting groups (X) is illuminated through a photolithographic mask, yielding reactive hydroxyl groups in the illuminated regions.
  • a selected nucleotide typically in the form of a 3′-O-phosphoramidite-activated deoxynucleoside (protected at the 5′ hydroxyl with a photosensitive protecting group), is then presented to the surface and coupling occurs at the sites that were exposed to light.
  • the substrate is rinsed and the surface is illuminated through a second mask, to expose additional hydroxyl groups for coupling.
  • a second selected nucleotide (e.g., 5′-protected, 3′-O-phosphoramidite-activated deoxynucleoside) is presented to the surface.
  • the selective deprotection and coupling cycles are repeated until the desired set of products is obtained.
  • Pease et al. Proc. Natl. Acad. Sci . (1994) 91:5022-5026. Since photolithography is used, the process can be readily miniaturized to generate high density arrays of oligonucleotide probes. Furthermore, the sequence of the oligonucleotides at each site is known.
  • Such photolithographic methods are also described in U.S. Pat. No. 5,143,854, U.S. Pat. No. 5,489,678 and Published PCT Application No. WO 94/10128 each of which is incorporated herein by reference in its entirety for all purposes. In the large scale processes of the present invention, it is typically preferred to utilize photolithographic synthesis methods.
  • arrays may be prepared having all polymer sequences of a given length which are composed of a basis set of monomers.
  • Such an array of oligonucleotides made up of the basis set of four nucleotides, for example, would contain up to 4 n oligonucleotides on its surface, where n is the desired length of the oligonucleotide probe.
  • n is the desired length of the oligonucleotide probe.
  • arrays could have upwards of about 65,536 and 1,048,576 different oligonucleotides respectively.
  • a simple binary masking strategy can be used, as described in U.S. Pat. No. 5,143,854.
  • Alternate masking strategies can produce arrays of probes which contain a subset of polymer sequences, i.e., polymers having a given subsequence of monomers, but are systematically substituted at each position with each member of the basis set of monomers.
  • these alternate synthesis strategies may be used to lay down or “tile” a range of probes that are complementary to, and span the length of a given known nucleic acid segment.
  • the tiling strategy will also include substitution of one or more individual positions within the sequence of each of the probe groups with each member of the basis set of nucleotides.
  • introgation positions By reading the hybridization pattern of the target nucleic acid, one can determine if and where any mutations lie in the sequence, and also determine what the specific mutation is by identifying which base is contained within the interogation position. Tiling methods and strategies are discussed in substantial detail in U.S. patent application Ser. No. 08/143,312 filed Oct. 26, 1993, and incorporated herein by reference in its entirety for all purposes.
  • Tiled arrays may be used for a variety of applications, such as identifying mutations within a known oligonucleotide sequence or “target”.
  • the probes on the array will have a subsequence which is complementary to a known nucleic acid sequence, but wherein at least one position in that sequence has been systematically substituted with the other three nucleotides.
  • photolabile protecting groups generally have the following characteristics: they prevent selected reagents from modifying the group to which they are attached; they are stable to synthesis reaction conditions (that is, they remain attached to the molecule); they are removable under conditions that minimize potential adverse effects upon the structure to which they are attached; and, once removed, they do not react appreciably with the surface or surface bound oligomer.
  • liberated byproducts of the photolysis reaction can be rendered unreactive toward the growing oligomer by adding a reagent that specifically reacts with the byproduct.
  • the removal rate of the photolabile protecting groups generally depends upon the wavelength and intensity of the incident radiation, as well as the physical and chemical properties of the protecting group itself. Preferred protecting groups are removed at a faster rate and with a lower intensity of radiation. Generally, photoprotecting groups that undergo photolysis at wavelengths in the range from 300 nm to approximately 450 nm are preferred.
  • photolabile or photosensitive protecting groups include ortho-nitrobenzyl and ortho-nitrobenzyloxycarbonyl protecting groups.
  • the use of these protecting groups has been proposed for use in photolithography for electronic device fabrication (see, e.g., Reichmanis et al., J. Polymer Sci. Polymer Chem. Ed . (1985) 23:1-8, incorporated herein by reference for all purposes).
  • photosensitive protecting groups which may be used in the light directed synthesis methods herein described, include, e.g., 1-pyrenylmethyloxycarbonyl, ⁇ , ⁇ -dimethyl-3,5-dimethoxybenzyloxycarbonyl, 4-methoxyphenacyloxycarbonyl, 3′-methoxybenzoinyloxycarbonyl, 3′,5′-dimethoxybenzoinyl-oxycarbonyl 2′,3′-dimethoxybenzoinyl-oxycarbonyl, 2′,3′-(methylenedioxy) benzoinyloxycarbonyl, N-(5-bromo-7-nitroindolinyl)carbonyl 3,5-dimethoxybenzyloxycarbonyl, and ⁇ -(2-methyleneanthraquinone)oxycarbonyl.
  • 1-pyrenylmethyloxycarbonyl ⁇ , ⁇ -dimethyl-3,5-dimethoxybenzyloxycarbonyl
  • photolabile protecting groups for protection of either the 3′ or 5′-hydroxyl groups of nucleotides or nucleic acid polymers include the o-nitrobenzyl protecting groups described in Published PCT Application No. WO 92/10092.
  • photolabile protecting groups include, e.g., nitroveratryloxycarbonyl (NVOC), nitropiperonyl oxycarbonyl (NPOC), ⁇ -methyl-nitroveratryloxycarbonyl (MeNVOC), ⁇ -methyl-nitropiperonyloxycarbonyl (MeNPOC), 1-pyrenylmethyloxycarbonyl (PYMOC), and the benzylic forms of each of these (i.e., NV, NP, MeNV, MeNP and PYM, respectively), with MeNPOC being most preferred.
  • Protection strategies may be optimized for different phosphoramidite nucleosides to enhance synthesis efficiency. Examples of such optimized synthesis methods are reported in, e.g., U.S. patent application Ser. No. 08/445,332 filed May 19, 1995. Generally, these optimization methods involve selection of particular protecting groups for protection of the O 6 group of guanosine, which can markedly improve coupling efficiencies in the synthesis of guanosine containing oligonucleotides. Similarly, selection of the appropriate protecting group for protection of the N 2 group of guanosine can also result in such an improvement, in absence of protection of the O 6 group.
  • suitable protecting groups for protection of the N 2 group, where the O 6 group is also protected include, e.g., mono- or diacyl protecting groups, triarylmethyl protecting groups, e.g., DMT and MMT, and amidine type protecting groups, e.g., N,N-dialkylformamidines.
  • Particularly preferred protecting groups for the N 2 group include, e.g., DMF, DMF, PAC, Bz and Ibu.
  • Protection of the O 6 group will generally be carried out using carbamate protecting groups such as —C(O)NX 2 , where X is alkyl, or aryl; or the protecting group —CH 2 CH 2 Y, where Y is an electron withdrawing group such as cyano, p-nitrophenyl, or alkyl- or aryl-sulfonyl; and aryl protecting groups.
  • carbamate protecting groups such as —C(O)NX 2 , where X is alkyl, or aryl; or the protecting group —CH 2 CH 2 Y, where Y is an electron withdrawing group such as cyano, p-nitrophenyl, or alkyl- or aryl-sulfonyl; and aryl protecting groups.
  • the O 6 group is protected using a diphenylcarbamoyl protecting group (DPC).
  • DPC diphenylcarbamoyl protecting group
  • improved coupling efficiencies may be achieved by selection of an appropriate protecting group for only the N 2 group.
  • an appropriate protecting group for example, where the N 2 —PAC protecting group is substituted with an Ibu protecting group, a substantial improvement in coupling efficiency is seen, even without protection of the O 6 group.
  • R 1 is a photocleavable protecting group and X is a leaving group, i.e., from the parent acid HX.
  • the stronger acids typically correspond to better leaving groups and thus, more reactive acylating agents.
  • Suitable leaving groups include a number of derivatives having a range of properties, e.g., relative reactivity, solubility, etc. These groups generally include simple inorganic ions, i.e., halides, N 3 —, and the like, as well as compounds having the following structures:
  • R 2 is alkyl, substituted alkyl or aryl
  • R 3 is hydrogen, alkyl, thioalkyl, aryl
  • R 4 is an electron withdrawing group such as NO 2 , SO 2 —R 2 , or CN
  • R 5 is a sterically hindered alkyl or aryl group such as adamantyl, t-butyl and the like
  • R 6 is alkyl or aryl substituted with electronegative substituents. Examples of these latter leaving groups include:
  • Solid phase amine, hydroxyl or thiol groups are exposed to a solution of the protecting group coupled to the leaving group, e.g., MeNPOC—X in a non-nucleophilic organic solvent, e.g., DMF, NMP, DCM, THF, ACN, and the like, in the presence of a base catalysts, such as pyridine, 2,6-lutidine, TEA; DIEA and the like.
  • a base catalysts such as pyridine, 2,6-lutidine, TEA; DIEA and the like.
  • nucleophilic catalysts such as DMAP, NMI, HOBT, HOAT and the like, may also be included to accelerate the reaction through the in situ generation of more reactive acylating agents. This would typically be the case where a derivative is preferred for its longer term stability in solution, but is not sufficiently reactive without the addition of one or more of the catalysts mentioned above.
  • a reagent which can be stored for longer terms as a stable solution and then activated with the catalysts only when needed, i.e., in the reactor system flow cell, or just prior to the addition of the reagent to the flow cell.
  • the reagents and methods described herein may be used to transfer photolabile protecting groups directly to any nucleophilic group, either tethered to a solid support or in solution.
  • the substrate preparation process of the present invention combines the photolysis and chemistry steps in a single unit operation.
  • the substrate wafer is mounted in a flow cell during both the photolysis and chemistry or monomer addition steps.
  • the substrate is mounted in a reactor system that allows for the photolytic exposure of the synthesis surface of the substrate to activate the functional groups thereon. Solutions containing chemical monomers are then introduced into the reactor system and contacted with the synthesis surface, where the monomers can bind with the active functional groups on the substrate surface. The monomer containing solution is then removed from the reactor system, and another photolysis step is performed, exposing and activating different selected regions of the substrate surface. This process is repeated until the desired polymer arrays are created.
  • Reactor systems and flow cells that are particularly suited for the combined photolysis/chemistry process include those described in, e.g., U.S. Pat. No. 5,424,186, which is incorporated herein by reference in its entirety for all purposes,
  • FIGS. 3A and 3B show a cross-sectional view of alternate embodiments of the reactor system 100 .
  • the device includes a flow cell which is made up of a body 102 having a cavity 104 disposed in one surface.
  • the cavity generally includes fluid inlets 108 and outlets 110 for flowing fluid into and through the cavity.
  • the cavity may optionally include ridges 106 on the back surface of the cavity to aid in mixing the fluids as they are pumped into and through the cavity.
  • the substrate 112 is mounted over the cavity whereby the front surface of the substrate wafer 114 (the surface upon which the arrays are to be synthesized) is in fluid communication with the cavity.
  • the device also includes a fluid delivery system in fluid connection with the fluid inlet 108 for delivering selected fluids into the cavity to contact the first surface of the substrate.
  • the fluid delivery system typically delivers selected fluids, e.g., monomer containing solutions, index matching fluids, wash solutions, etc., from one or more reagent reservoirs 118 , into the cavity via the fluid inlet 108 .
  • the delivery system typically includes a pump 116 and one or more valves to select from the various reagent reservoirs.
  • the device 100 also typically includes a light source 124 , as described above.
  • the light source is shown through a photolithographic mask 128 and is directed at the substrate 112 . Directing the light source at the substrate may generally be carried out using, e.g., mirrors 122 and/or lenses 120 and 126 .
  • the mask 128 may be placed directly over the substrate 112 , i.e., immediately adjacent to the substrate, thereby obviating the need for intervening lenses.
  • FIGS. 4A and 4B show different views of schematic illustrations of one embodiment of the flow cell portion of the device, e.g., the body substrate combination.
  • a panel 320 is mounted to the body 102 to form the bottom surface of the cavity 104 . Silicone cement or other adhesive may be used to mount the panel and seal the bottom of the cavity.
  • panel 320 will be a light absorptive material, such as yellow glass, RG1000 nm long pass filter, or other material which absorbs light at the operating wavelengths, for eliminating or minimizing reflection of impinging light. As a result, the burden of filtering stray light at the incident wavelength during synthesis is significantly lessened.
  • the glass panel also provides a durable surface for forming the cavity since it is relatively immune to corrosion in the high salt environments or other conditions common in DNA synthesis reactions or other chemical reactions.
  • the substrate wafer 112 is mated to a surface 300 .
  • the first surface 114 of wafer comprises the photalabile protecting groups coupled to functional groups coupled to the substrate surface, as described above.
  • vacuum pressure may be used to mate the wafer to the surface 300 .
  • a groove 304 which may be about 2 mm deep and 2 mm wide, is formed on surface 300 .
  • the groove communicates with an opening 303 that is connected to a vacuum source, e.g., a pump.
  • the vacuum source creates a vacuum in the groove and causes the substrate wafer to adhere to surface 300 .
  • a groove 310 may be formed on surface 300 for seating a gasket 311 therein.
  • the gasket ensures that the cavity is sealed when the wafer is mated to the flow cell.
  • Alignment pins 315 may be optionally provided on surface 300 to properly align the substrate wafer on the flow cell.
  • Inlet port 307 and outlet port 306 are provided for introducing fluids into and flowing fluids out of the cavity.
  • the flow cell provides an opening 301 in which a flow tube 340 is passed through for coupling to inlet port 307 .
  • a flow tube 341 is passed through opening 302 for coupling with outlet port 306 .
  • Fittings 345 are employed to maintain the flow tubes in position. Openings 301 and 302 advantageously position the flow tubes so that the flow cell can easily and conveniently be mounted on the synthesis system.
  • a pump which is connected to one of the flow tubes, circulates a selected fluid into the cavity and out through the outlet port for recirculation or disposal.
  • the selected fluids may include, e.g., monomer containing solutions, index matching fluids, wash solutions or the like.
  • pressurized delivery systems may be used to deliver fluids to the cavity. Examples of these alternate systems utilize argon gas to circulate the selected fluid into and through the cavity. Simultaneously, the flow of argon gas may be regulated to create bubbles for agitating the fluid as it is circulated through the system. Agitation is used to mix the fluid contents in order to improve the uniformity and/or yield of the reactions.
  • inlet and outlet ports 306 and 307 are located at opposite ends of the panel. This configuration improves fluid circulation and regulation of bubble formation in the cavity.
  • the outlet and inlet are located at the top and bottom ends of the cavity, respectively, when the flow cell is mounted vertically on the synthesizer. Locating the outlet and inlet at the highest and lowest positions in the cavity, respectively, facilitates the removal of bubbles from the cavity.
  • the flow cell may be configured with a temperature control system to permit the synthesis reactions to be conducted under optimal temperature conditions.
  • temperature control systems include refrigerated or heated baths, refrigerated air circulating devices, resistance heaters, thermoelectric peltier devices and the like.
  • volume of the flow cell cavity may be desirable to maintain the volume of the flow cell cavity as small as possible so as to more accurately control reaction parameters, such as temperature or concentration of chemicals.
  • reaction parameters such as temperature or concentration of chemicals.
  • smaller cavity volumes may reduce waste, as a smaller volume requires a smaller amount of material to carry out the reaction.
  • a difficulty may arise where bubbles in the reaction fluids can become trapped in the cavity, which may result in incomplete exposure of the substrate surface to the reaction fluid.
  • a fluid fills into a very shallow channel or slit, it will tend to fill the shallowest areas first, due to relatively strong capillary forces in those areas. If the channel is too shallow, inconsistency and non-flatness of the substrate which results in uneven capillary forces, will lead to an uneven fluid front during filling. As the liquid front loses its even shape, liquid may surround air or gas pockets to produce trapped bubbles.
  • a flow cell may be employed wherein the top and bottom surfaces of the flow cell are nonparallel, being narrower at the inlet of the flow cell, and growing wider toward the outlet. Uniform filling of the flow cell ensures that the fluid front maintains a straight shape, thereby minimizing the potential of having bubbles trapped between the surfaces.
  • the device includes an automated peptide synthesizer 401 .
  • the automated peptide synthesizer is a device which flows selected reagents through a flow cell 402 under the direction of a computer 404 .
  • the synthesizer is an ABI Peptide Synthesizer, model no. 431A.
  • the computer may be selected from a wide variety of computers or discrete logic including, for example, an IBM PC-AT or similar computer linked with appropriate internal control systems in the peptide synthesizer.
  • the PC is provided with signals from the ABI computer indicative of, for example, the beginning of a photolysis cycle.
  • Substrate 406 is mounted on the flow cell, forming a cavity between the substrate and the flow cell. Selected reagents flow through this cavity from the peptide synthesizer at selected times, forming an array of peptides on the face of the substrate in the cavity.
  • Mounted above the substrate, and preferably in contact with the substrate is a mask 408 .
  • Mask 408 is transparent in selected regions to a selected wavelength of light and is opaque in other regions to the selected wavelength of light.
  • the mask is illuminated with a light source 410 such as a UV light source. In one specific embodiment the light source 410 is a model No. 82420 made by Oriel.
  • the mask is held and translated by an x-y translation stage 412 . Translation stages may be obtained commercially from, e.g., Newport Corp.
  • the computer coordinates the action of the peptide synthesizer, translation stage, and light source. Of course, the invention may be used in some embodiments with translation of the substrate instead of the mask.
  • photolithographic methods are used to activate selected regions on the surface of the substrate. Specifically, functional groups on the surface of the substrate or present on growing polymers on the surface of the substrate, are protected with photolabile protecting groups. Activation of selected regions of the substrate is carried out by exposing selected regions of the substrate surface to activation radiation, e.g., light within the effective wavelength range, as described previously. Selective exposure is typically carried out by shining a light source through a photolithographic mask. Alternate methods of exposing selected regions may also be used, e.g., fiberoptic faceplates, etc.
  • the substrate is mounted in the reactor system or flow cell such that the synthesis surface of the substrate is facing the cavity and away from the light source.
  • this method of exposure is termed “backside” photolysis.
  • the effects of reflected or refracted light at the surface of the substrate can have significant effects upon the ability to expose and activate features of this size.
  • One method of reducing the occurrence of reflected light is to incorporate a light absorptive material as the back surface of the flow cell, as described above. Refraction of the light as it enters the flow cell, i.e., crosses the substrate/flow cell interface, through the back surface of the substrate can also result in a loss in feature resolution at the synthesis surface of the substrate resulting from refraction and reflection.
  • an index matching fluid (“IMF”) to match the refractive index of the substrate, thereby reducing refraction of the incident light and the associated losses in feature resolution.
  • the index matching fluid will typically have a refractive index that is close to that of the substrate.
  • the refractive index of the IMF will be within about 10% that of the substrate, and preferably within about 5% of the refractive index of the substrate. Refraction of the light entering the flow cell, as it contacts the interface between the substrate and the IMF is thereby reduced.
  • a particularly preferred IMF is dioxane which has a refractive index roughly equivalent to the silica substrate.
  • the light source used for photolysis is selected to provide a wavelength of light that is photolytic to the particular protecting groups used, but which will not damage the forming polymer sequences.
  • a light source which produces light in the UV range of the spectrum will be used.
  • the light source typically provides light having a wavelength above 340 nm, to effect photolysis of the photolabile protecting groups without damaging the forming oligonucleotides.
  • This light source is generally provided by a Hg-Arc lamp employing a 340 nm cut-off filter (i.e., passing light having a wavelength greater than 340-350 nm).
  • Typical photolysis exposures are carried out at from about 6 to about 10 times the exposed half-life of the protecting group used, with from 8-10 times the half-life being preferred.
  • MeNPOC a preferred photolabile protecting group
  • Photolithographic masks used during the photolysis step typically include transparent regions and opaque regions, for exposing only selected portions of the substrate during a given photolysis step.
  • the masks are fabricated from glass that has been coated with a light-reflective or absorptive material, e.g., a chrome layer.
  • the light-reflective or absorptive layer is etched to provide the transparent regions of the mask. These transparent regions correspond to the regions to be exposed on the surface of the substrate when light is shown through the mask
  • contrast is meant the sharpness of the line separating an exposed region and an unexposed region.
  • the gradient of activated to nonactivated groups running from an activated orexposed region to a nonexposed region is a measure of the contrast. Where the gradient is steep, the contrast is high, while a gradual gradient indicates low or poor contrast.
  • contrast between features is enhanced through the front side exposure of the substrate.
  • Front side exposure reduces effects of diffraction or divergence by allowing the mask to be placed closer to the synthesis surface. Additionally, and perhaps more importantly, refractive effects from the light passing through the substrate surface prior to exposure of the synthesis surface are also reduced or eliminated by front-side exposure. This is discussed in greater detail below.
  • Contrast between features may also be enhanced using a number of other methods.
  • the level of contrast degradation between two regions generally increases as a function of the number of differential exposures or photolysis steps between the two regions, i.e., incidences where one region is exposed while the other is not. The greater the number of these incidences, the greater the opportunity for bleed over from one region to the other during each step and the lower the level of contrast between the two regions.
  • Translated into sequence information it follows that greater numbers of differences between polymers synthesized in adjacent regions on a substrate can result in reduced contrast between the regions. Namely, the greater the number of differences in two polymer sequences, the greater the number of incidences of a region bearing the first polymer being exposed while the other was not. These effects are termed “edge” effects as they generally occur at the outer edges of the feature.
  • the present invention provides a method of enhancing contrast by reducing the number of differential synthesis/photolysis steps between adjacent polymer sequence containing regions throughout an array.
  • One method of edge minimization is to divide the polymers to be sequenced into blocks of related polymers, leaving blank lanes between the blocks to prevent bleed-over into other blocks. While this method is effective in reducing edge effects, it requires the creation of a specific algorithm for each new tiling strategy. That is, the layout of each block in terms of probe location will depend upon the tiled sequence.
  • the present invention provides methods for aligning polymer synthesis steps on an array whereby the number of differential synthesis steps is reduced, and/or the syntheses in adjacent regions optimized for similarity.
  • each probe has been exposed to a minimal number of differential exposures, as described above.
  • the monomer addition steps following the substituted monomer give rise to some difficulties in this regard. For example, it would be possible to couple the “T” in the fourth position in probe #1 at the sixth cycle while the “T” in the remaining probes would have to be added at the tenth cycle, because they could not be added before the preceding monomer in the sequence.
  • the remaining synthesis steps for probe 1 would then be out of sequence with those of the remaining probes, resulting in an increased number of differential sequence steps between probe 1 and the remaining probes.
  • the number of differential synthesis steps is minimized. Specifically, by waiting until the tenth cycle to add the “T” in probe #1, the number of differential exposures between the probes is minimized to only that number necessary to incorporate the various mutations or substitutions.
  • the methods described herein utilize a generalized synthesis method for aligning synthesis steps to accomplish the above-described goal. These generalized methods can be followed regardless of the particular tiling strategy used or targeted sequence.
  • each probe by a generic structure which is effectively independent of the actual targeted sequence.
  • This generic description of a probe sequence is termed an “image”, a collection of polymer sequences is termed a “picture”, and a local translation, e.g., in a larger targeted sequence, is termed a “frame”.
  • the entire picture and frame structure is termed a “collage”.
  • Each position in the probe is designated by the position number in the frame, or targeted sequence segment, followed by a number that indicates the rotation from the wild type monomer, with the wild type monomer being “0”.
  • rotation is meant the number of cycles required to go from the wild type monomer to the substituted monomer in the addition cycle (note that a “0” and a “4” are the same monomer in terms of nucleotides). For example, if a given wild type sequence has an “A” in a given position, a substitution to a “G” would be identified by a rotation of “3”, assuming a monomer addition or synthesis cycle of A, C, T, G.
  • probe #1 being the same as the wild type target as also described above, would be identified as:
  • Sequence positions which are in the same layer are aligned to be added in the same synthesis cycle.
  • the “depth” of the sequence or the “layer” in which a given monomer is found are determined by counting each occurrence where an unmodified base follows a modified base.
  • Each sequence has a depth of at least one.
  • the sequence “X” indicated by the ⁇ 1,1> ⁇ 2,0> ⁇ 3,0> has a depth of 2, where ⁇ 2,0> and ⁇ 3,0> are in the second layer.
  • the sequence “Y” identified as ⁇ 1,0> ⁇ 2,1> ⁇ 3,0> has a depth of two where ⁇ 1,0> is in the first layer and ⁇ 3,0> is in the second layer. Aligning these two sequences, it can be seen that the monomer ⁇ 3,0> in sequences X and Y may be aligned as it exists in the same layer.
  • sequence “Z” ⁇ 1,0> ⁇ 2,0> ⁇ 3,1> has a depth of one with ⁇ 1,0> ⁇ 2,0> in the first layer.
  • the position ⁇ 2,0> in the sequence X would not be aligned with the same position in sequence Z as they exist in different layers.
  • a specific example of the collage method is illustrated using the following sequence/tiling strategy.
  • a targeted sequence is complementary to the sequence CTTA.
  • the wild type sequence would be designated ⁇ 1,0> ⁇ 2,0> ⁇ 3,0> ⁇ 4,0>.
  • the array would have the generic description:
  • the bases in the first layer are assigned the cycles closest to the start of the synthesis.
  • the modified bases (between the layers) are assigned the next available cycles.
  • the second layer is assigned a set of cycles as close as possible to the start of synthesis consistent with the bases already assigned (i.e., without altering the base ordering of any of the probes).
  • Subsequent layers are assigned in a similar manner. This method allows maximum alignment of synthesis cycles throughout the frame being synthesized, while minimizing the total length of synthesis (e.g., number of steps).
  • Another method of minimizing bleed-over in the photolysis steps is to reduce the size of the transmissive or translucent portion of the mask, thus preventing unintentional exposure of adjoining regions caused by diffraction of the light shown through the mask.
  • typical photolysis steps can have a duration of up to 8 to 10 times the half-life of the photodeprotection reaction.
  • photoprotection can be up to 50% complete where the light intensity is only 12% of optimal levels, i.e., the level required for complete or near complete photodeprotection.
  • intensity levels may be reached well outside the feature boundary as defined by the transmissive portion of the mask.
  • the present invention provides a method of minimizing bleed-over in adjoining cells by reducing the size of the transmissive portion of the mask, such that the zone of divergent light shown through the mask is centered on the desired feature border.
  • a mask exposing a rectangular feature can be reduced by, e.g., 20 ⁇ m in each dimension, thus allowing greater homogeneity at the edges of 100 ⁇ m features.
  • the translucent region of the mask will be from about 2% to about 25% smaller in each dimension of the size of the region which is to be exposed.
  • the translucent portion of the mask will be from about 10% to about 25% smaller in each dimension.
  • a monomer building block is introduced or contacted with the synthesis surface of the substrate.
  • the added monomer includes a single active functional group, for example, in the case of oligonucleotide synthesis, a 3′-hydroxyl group.
  • the remaining functional group that is involved in linking the monomer within the polymer sequence e.g., the 5′-hydroxyl group of a nucleotide, is generally photoprotected.
  • the monomers then bind to the reactive moieties on the surface of the substrate, activated during the preceding photolysis step, or at the termini of linker molecules or polymers being synthesized on the substrate.
  • the chemistry step involves solid phase polymer synthesis methods that are well known in the art.
  • solid phase polymer synthesis methods that are well known in the art.
  • detailed descriptions of the procedures for solid phase synthesis of oligonucleotides by phosphoramidite, phosphite-triester, phosphotriester, and H-phosphonate chemistries are widely available. See, for example, Itakura, U.S. Pat. No. 4,401,796; Caruthers et al., U.S. Pat. Nos. 4,458,066 and 4,500,707; Beaucage et al., Tetrahedron Lett., 22:1859-1862 (1981); Matteucci et al., J. Amer. Chem.
  • the IMF is removed from the flow cell through an outlet port.
  • the flow cell is then rinsed, e.g., with water and/or acetonitrile.
  • a solution containing an appropriately protected monomer to be coupled in the particular synthesis step is added.
  • a solution containing a 3′-O-activated phosphoramidite nucleoside, photoprotected at the 5′ hydroxyl is introduced into the flow cell for coupling to the photoactivated regions of the substrate.
  • the phosphoramidite nucleoside is present in the monomer solution at a concentration of from 1 mM to about 100 mM, with 10 mM nucleoside concentrations being preferred.
  • the coupling reaction takes from 30 seconds to 5 minutes and preferably takes about 1.5 minutes.
  • the monomer solution is removed from the flow cell, the substrate is again rinsed, and the IMF is reintroduced into the flow cell for another photolysis step.
  • the photolysis and chemistry steps are repeated until the substrate has the desired arrays of polymers synthesized on its surface.
  • Coupling efficiencies may be improved through a number of methods.
  • coupling efficiency may be increased by increasing the lipophilicity of the building blocks used in synthesis. Without being bound to any theory of operation, it is believed that such lipophilic building blocks have enhanced interaction at the surface of the preferred crystalline substrates.
  • the lipophilicity of the building blocks may generally be enhanced using a number of strategies.
  • the lipophilicity of the nucleic acid monomers may be increased in a number of ways. For example, one can increase the lipophilicity of the nucleoside itself, the phosphoramidite group, or the protecting group used in synthesis.
  • Modification of the nucleoside to increase its lipophilicity generally involves specific modification of the nucleobases.
  • deoxyguanosine (dG) may be alkylated on the exocyclic amino group (N2) with DMT-Cl, after in situ protection of both hydroxyl groups as trimethylsilylethers (See, FIG. 5A ).
  • Liberation of the free DMT protected nucleoside is achieved by base catalyzed methanolosis of the di-TMS ether.
  • two further steps are used resulting in the formation of 5′-MeNPOC-dG-phosphoramidites.
  • the DMT group is used because the normally used 5′-DMT-phosphoramidites show high coupling efficiencies on silica substrate surfaces and because of the ease of synthesis for the overall compound.
  • the use of acid labile protecting groups on the exocyclic amino groups of dG allows continued protection of the group throughout light-directed synthesis. Similar protection can be used for other nucleosides, e.g., deoxycytosine (dC). Protection strategies for nucleobase functional groups, including the exocyclic groups are discussed in U.S.
  • a more lipophilic phosphoramidite group may also be used to enhance synthesis efficiencies.
  • Typical phosphoramidite synthesis utilizes a cyanoethyl-phosphoramidite.
  • lipophilicity may be increased through the use of, e.g., an Fmoc-phosphoramidite group.
  • Fmoc-phosphoramidites is shown in FIG. 5B .
  • a phosphorus-trichloride is reacted with four equivalents of diisopropylamine, which leads to the formation of the corresponding monochloro-bisamino derivative. This compound reacts with the Fmoc-alcohol to generate the appropriate phosphatidylating agent.
  • the photolabile protecting groups may also be made more lipophilic.
  • a lipophilic substituent e.g., benzyl, naphthyl, and the like, may be introduced as an alkylhalide, through ⁇ -alkylation of a nitroketone, as shown in FIG. 5C .
  • chloroformate needed to introduce the photoactive lipophilic group to the 5′ position of a deoxyribonucleoside.
  • each of the photolysis and chemistry steps involved in the synthesis operation are provided as separate unit operations.
  • This method provides advantages of efficiency and higher feature resolution over the single unit operation process.
  • the separation of the photolysis and chemistry steps allows photolysis to be carried out outside of the confines of the flow cell. This permits application of the light directly to the synthesis surface, i.e., without first passing through the substrate.
  • This “front-side” exposure allows for greater definition at the edges of the exposed regions (also termed “features”) by eliminating the refractive influence of the substrate and allowing placement of the mask closer to the synthesis surface.
  • FIGS. 8A-8D A comparison illustrating the improved resolution of front-side synthesis is shown in FIGS. 8A-8D .
  • the batch method provides advantages in the surface area of a substrate wafer that may be used in synthesizing arrays.
  • the operation of mounting the substrate wafer on the flow call can result in less than the entire surface of the substrate wafer being used for synthesis.
  • the substrate wafer is used to form one wall of the flow cell, as is typically the case in these combined methods, engineering constraints involved in mounting of the flow cell can result in a reduction in the available substrate surface area. This is particularly the case where a vacuum chuck system is used to mount the substrate on the flow cell, where the vacuum chuck system requires a certain amount of surface area to hold the substrate on the flow cell with sufficient force.
  • the chemistry step is generally carried out by immersing the entire substrate wafer in the monomer solution, thus allowing synthesis over most if not all of the substrate wafer's synthesis surface. This results in a higher chip yield per substrate wafer than in the individual processing methods. Additionally, as the chemistry steps are generally the time limiting steps in the synthesis process, monomer addition by immersion permits monomer addition to multiple substrates at a given time, while more substrates are undergoing the photolysis steps.
  • a substrate wafer having dimensions of 5′′ ⁇ 5′′ has only 2.5′′ ⁇ 2.5′′ available as a synthesis surface, which when separated into chips of typical dimensions (e.g., 1.28 cm ⁇ 1.28 cm) typically results in 16 potential chips per wafer.
  • the same sized wafer, when subjected to the batch mode synthesis can have a synthesis area of about 4.3′′ ⁇ 4.3′′, which can produce approximately 49 chips per wafer.
  • a number of substrate wafers is subjected to the photolysis step. Following photolysis, the number of wafers is placed in a rack or “boat” for transport to the station which performs the chemistry steps, whereupon one or more chemistry steps are performed on the wafers, simultaneously. The wafers are then returned to the boat and transported back to the station for further photolysis.
  • the boat is a rack that is capable of carrying several wafers at a time and is also compatible with automated systems, e.g., robotics, so that the wafers may be loaded into the boat, transported and placed into the chemistry station, and following monomer addition returned to the boat and the photolysis station, all through the use of automated systems.
  • Initial substrate preparation is the same for batch processing as described in the individual processing methods, above. However, beyond this initial substrate preparation, the two process take divergent paths. In batch mode processing, the photolysis and chemistry steps are performed separately. As is described in greater detail below, the photolysis step is generally performed outside of the flow cell. This can cause some difficulties, as there is no provision of an IMF behind the substrate to prevent the potentially deleterious effects of refraction and reflection of the photolytic light source. In some embodiments, however, the same goal is accomplished by applying a coating layer to the back-side of the substrate, i.e., to the non-synthesis surface of the substrate. The coating layer is typically applied after the substrate preparation process, but prior to derivatization.
  • This coating is typically selected to perform one or more of the following functions: (1) match the refractive index of the substrate to prevent refraction of light passing through the substrate which may interfere with the photolysis; and (2) absorb light at the wavelength of light used during photolysis, to prevent back reflection which may also interfere with photolysis.
  • suitable coating materials may be selected from a number of suitable materials which have a refractive index approximately equal to that of the substrate and/or absorb light at the appropriate wavelength.
  • index matching coatings are typically selected to have a refractive index that is within at about 10% that of the substrate, and preferably within about 5%.
  • light absorbing coatings are typically selected whereby light at the photolytic wavelength is absorbed, which in preferred aspects is light in the ultraviolet range, e.g., between 280 nm and 400 nm.
  • Light absorbing coatings and index matching coatings may be combined to provide combined protection against refraction and reflection, or a single coating material may be selected which possesses both of the desired properties.
  • Preferred polymers will typically be selected to be compatible with the various reaction conditions which would be encountered during the synthesis process, e.g., insoluble in and non-reactive with synthesis reagents, and resistant to the mechanical forces involved in handling and manipulating the substrate, throughout the synthesis process. Additionally, preferred coating materials are easily removable upon completion of the synthesis process, e.g., in the final deprotection step or in a final coating removal step.
  • suitable coating materials include anti-reflective coatings that are well known in the art and generally commercially available, e.g., magnesium fluoride compounds, which are light-absorbing in the desired wavelength range, polymethylmethacrylate coatings (PMMA), which have a refractive index comparable to glass substrates, and polyimide coatings which are both light-absorbing in the desired wavelength range, and have a refractive index close to that of a glass substrate.
  • PMMA polymethylmethacrylate coatings
  • polyimide coatings which are both light-absorbing in the desired wavelength range, and have a refractive index close to that of a glass substrate.
  • Polyimide coatings are most preferred.
  • the coating materials may be carried out by a variety of methods, including, e.g., vapor deposition, spray application, and the like.
  • the coating solution will be applied to the substrate using a spin-coating method. Typically, this involves spinning the substrate during deposition of the coating solution on the substrate surface that is to be coated. The spinning substrate results in spreading of the coating solution radially outward on the surface of the substrate.
  • Application of the coating material using the spin-coating process usually employs a two-speed spinning of the substrate.
  • the application of the coating material to the surface of the substrate and initial spreading of the coating solution are usually carried out at low rotational speeds and for relatively short duration. For example, to apply 1 ml of a 12% solids w/v polymer coating solution to a 4.3′′ ⁇ 4.3′′ substrate, initial spreading is carried out at 500 r.p.m. for 10 seconds. Elimination of excess polymer solution and evening of the polymer layer are carried out at higher rotational speeds and for substantially longer durations.
  • the second spinning step is carried out at approximately 3000 r.p.m. for 30 seconds.
  • the polymer coating is then cured on the surface of the substrate. Curing is typically carried out by heating the coated substrate.
  • the curing process involves a two-step heating process. The first step involves a “soft-bake” heating of the coated substrate to initially cure the polymer coating. This soft-bake step typically takes place at relatively low temperatures for relatively short periods, i.e., 85° C. for 5 minutes.
  • the second step of the curing process is a final curing of the polymer coating which is typically carried out at higher temperatures for longer periods, i.e., 220-360° C., for approximately 60 minutes.
  • a polymer coating applied to the back side of the substrate will be from about 1 to about 50 ⁇ m thick, and more preferably, from about 5 to about 20 ⁇ m thick, with polymer coating of about 10 ⁇ m thick being most preferred.
  • the back-side coated substrate is then subjected to derivitization, rinsing and baking, according to the above described methods.
  • the steps of photolysis and monomer addition in the batch mode aspects of the present invention are performed in separate unit operations. Separation of photolysis and chemistry steps allows a more simplified design for a photolyzing apparatus. Specifically, the apparatus need not employ a flow cell. Additionally, the apparatus does not need to employ a particular orientation to allow better filling of the flow cell. Accordingly, the apparatus will typically incorporate one or more mounting frames to immobilize the substrate and mask during photolysis, as well as a light source.
  • the device may also include focusing optics, mirrors and the like for directing the light source through the mask and at the synthesis surface of the substrate.
  • the substrate is also placed in the device such that the light from the light source impacts the synthesis surface of the substrate before passing through the substrate. As noted above, this is termed “front-side” exposure.
  • a photolysis step requires far less time than a typical chemistry step, e.g., 60 seconds as compared to 10 minutes.
  • the photolysis machinery sits idle for long periods of time during the chemistry step.
  • Batch mode operation allows numerous substrates to be photolyzed while others are undergoing a particular chemistry step. For example, a number of substrate wafers may be exposed for a given photolysis step. Following photolysis, the several substrate wafers may be transferred to a number of reaction chambers for the monomer addition step. While monomer addition is being carried out, additional substrate wafers may be undergoing photolysis.
  • FIG. 6A schematically illustrates a bank of reaction chambers for carrying simultaneous monomer addition steps on a number of separate substrates in parallel.
  • the bank of reaction chambers is configured to simultaneously perform identical synthesis steps in each of the several reaction chambers.
  • Each reaction chamber 602 is equipped with a fluid inlet 604 and outlet 606 for flowing various fluids into and through the reaction chamber.
  • the fluid inlet of each chamber is generally fluidly connected to a manifold 608 which connects all of the reaction chambers, in parallel, to a single valve assembly 610 .
  • rotator valves are preferred for this aspect of the apparatus.
  • the valve assembly allows the manifold to be fluidly connected to one of a plurality of reagent vessels 612 - 622 .
  • a pump 624 for delivering the various reagents to the reaction chamber.
  • a pump 624 for delivering the various reagents to the reaction chamber.
  • the outlet ports 606 from the reaction chambers 602 are typically fluidly connected to a waste vessel (not shown).
  • FIG. 6B shows a schematic representation of a single reaction chamber for performing the chemistry steps of the batch process, e.g., monomer addition.
  • the reaction chamber employs a “clam-shell” design wherein the substrate is enclosed in the reaction chamber 602 when the door 652 is closed against the body 654 of the apparatus. More particularly, the substrate wafer 660 is mounted on the chamber door and held in place, e.g., by a vacuum chuck shown as vacuum groove 670 .
  • the substrate wafer 668 is placed into the reactor cavity 656 on the body of the device.
  • the reactor cavity is surrounded by a gasket 658 , which provides the seal for the reaction chamber when the door is closed.
  • the substrate water is pressed against the gasket and the pressure of this contact seals the reaction chamber.
  • the reaction chamber includes a fluid inlet 604 and a fluid outlet 606 , for flowing monomer solutions into and out of the reaction chamber.
  • the apparatus may also include latches 666 , for locking the reaction chamber in a sealed state. Once sealed, reagents are delivered into the reaction chamber through fluid inlet 662 and out of the reaction chamber through fluid outlet 664 .
  • the reaction chamber also typically includes a temperature control element for maintaining the reaction chamber at the optimal synthesis temperature. As shown, the reaction chamber includes automatic alignment pins 672 , e.g., solenoid or servo operated, for aligning a substrate wafer on the vacuum groove 670 .
  • the substrate wafers are each subjected to a further photolysis step.
  • the process may generally be timed whereby during a particular chemistry step, a new series of wafers is being subjected to a photolysis step. This dramatically increases the throughput of the process.
  • permanent protecting groups typically remain on nucleobases and the phosphate backbone of synthetic oligonucleotides. Removal of these protecting groups is usually accomplished with a concentrated solution of aqueous ammonium hydroxide. While this method is effective for the removal of the protecting groups, these conditions can also cleave the synthetic oligomers from the support (usually porous silica particles) by hydrolyzing an ester linkage between the oligo and a functionalized silane derivative that is bonded to the support.
  • final deprotection of the polymer sequences is carried out using anhydrous organic amines.
  • primary and secondary alkylamines are used to effect final deprotection.
  • the alkylamines may be used undiluted or in a solution of an organic solvent, e.g. ethanol, acetonitrile, or the like.
  • the solution of alkyl amine will be at least about 50% alkylamine (v/v).
  • a variety of primary and secondary amines are suitable for use in deprotection, including ammonia, simple low molecular weight (C 1-4 )alkylamines, and substituted alkylamines, such as ethanolamine and ethylenediamine.
  • More volatile amines are preferred where removal of the deprotection agent is to be carried out by evaporation, whereas the less volatile amines are preferred in instances where it is desirable to maintain containment of the deprotection agent and where the solutions are to be used in repeated deprotections.
  • Solutions of ethanolamine or ethylenediamine in ethanol have been used in deprotecting synthetic oligonucleotides in solution. See, Barnett, et al., Tet. Lett. (1981) 22:991-994, Polushin, et al, (1991) N.A.R. Symp. Ser. No. 24:49-50 and Hogrefe, et al. N.A.R. (1993) 21:2031-2038.
  • the time required for complete deprotection in these solutions ranges from several minutes for “fast” base-protecting groups, e.g. PAC or DMF-protected A, C or G and Ibu-protected C, to several hours for the standard protecting groups, e.g. benzoyl-protected A, C or G and Ibu-protected G.
  • “fast” base-protecting groups e.g. PAC or DMF-protected A, C or G and Ibu-protected C
  • the standard protecting groups e.g. benzoyl-protected A, C or G and Ibu-protected G.
  • the substrate wafer is assembled for use as individual substrate segments. Assembly typically employs the steps of separating the substrate wafer into individual substrate segments, and inserting or attaching these individual segments to a housing which includes a reaction chamber in fluid communication with the front surface of the substrate segment, e.g., the surface having the polymers synthesized thereon.
  • the arrays are synthesized on the substrate wafer in a grid pattern, with each array being separated from each other array by a blank region where no compounds have been synthesized. These separating regions are termed “streets”.
  • the wafer typically includes a number of alignment marks located in these streets. These marks serve a number of purposes, including aligning the masks during synthesis of the arrays as described above, separation of the wafer into individual chips and placement of each chip into its respective housing for subsequent use, which are both described in greater detail below.
  • An illustration of a wafer including these alignment marks is shown in FIG. 7 .
  • substrate wafer 700 includes individual arrays 710 separated by streets 720 and includes alignment marks 730 .
  • the substrate wafer can be separated into a number of individual substrates using scribe and break methods that are well known in the semiconductor manufacturing industry.
  • well known scribe and break devices may be used for carrying out the separation steps, e.g., a fully programmable computer controlled scribe and break devices, such as a DX-III Scriber-Breaker manufactured by Dynatex InternationalTM, or the LCD-1 scriber/dicer manufactured by Loomis Industries.
  • the steps typically involve scribing along the desired separation points, e.g., between the individual synthesized arrays on the substrate wafer surface, followed by application of a breaking force along the scribe line.
  • typical scribe and break devices break the wafer by striking the bottom surface of the wafer along the scribe lines with an impulse bar, or utilizing a three point beam substrate bending operation.
  • the shock from the impulse bar fractures the wafer along the scribe line. Because the majority of force applied by the impulse bar is dissipated along the scribe line, the device is able to provide high breaking forces without exerting significant force on the substrate itself, allowing separation of the wafer without damaging the individual chips.
  • the wafer may be separated into individual segments by, e.g., sawing methods, such as those described in U.S. Pat. No. 4,016,855.
  • the housing includes a body having a cavity disposed within it.
  • the substrate segment is mounted over the cavity on the body such that the front side of the segment, e.g., the side upon which the polymers have been synthesized, is in fluid communication with the cavity.
  • the bottom of the cavity may optionally include a light absorptive material, such as a glass filter or carbon dye, to prevent impinging light from being scattered or reflected during imaging by detection systems. This feature improves the signal-to-noise ratio of such systems by significantly reducing the potential imaging of undesired reflected light.
  • a light absorptive material such as a glass filter or carbon dye
  • the cartridge also typically includes fluid inlets and fluid outlets for flowing fluids into and through the cavity.
  • a septum, plug, or other seal may be employed across the inlets and/or outlets to seal the fluids in the cavity.
  • the cartridge also typically includes alignment structures, e.g., alignment pins, bores, and/or an asymmetrical shape to ensure correct insertion and/or alignment of the cartridge in the assembly devices, hybridization stations, and reader devices.
  • FIG. 8 shows a top view 802 , end view 804 , side view 806 and bottom view 808 of the array cartridge 800 .
  • the body of the array cartridge may generally be fabricated from one or more parts or casings 810 - 814 that are made using a number of manufacturing techniques.
  • the cartridge is fabricated from two or more injection molded plastic parts. Injection molding enables the parts to be formed inexpensively. Also, assembling the cartridge from two parts simplifies the construction of various features, such as the internal channels for introducing fluids into the cavity. As a result, the cartridges may be manufactured at a relatively low cost.
  • alignment holes 816 and 818 are disposed through the body of the cartridge, however, those of ordinary skill will appreciate that other alignment structures, e.g., alignment pins, etc., would be equally useful.
  • alignment holes 816 and 818 also include an annular bevelled region to assist in insertion of complementary alignment pins on the hybridization station.
  • cavity 820 includes a flat bottom peripheral portion 822 , a bevelled portion 824 extending from the flat bottom peripheral portion, and a flat upper portion 826 surrounding the beveled portion.
  • the array includes an outer periphery which rests against the flat bottom peripheral portion 822 .
  • the bevelled portion aligns the chip onto the flat bottom peripheral portion 822 .
  • the top casing 814 extends outside the middle and bottom casings, 812 and 810 , respectively, to provide a nonflush edge 828 .
  • the alignment structures 816 and 818 as well as the non flush edge 828 , ensure proper orientation of the cartridge in the hybridization station, as well as other devices used in producing and reading polymer arrays.
  • Surrounding mounting structures 816 and 818 are annular recesses 817 and 819 , respectively, which aid in guiding the cartridge onto complementary mounting structures on the various devices.
  • the cartridge includes inlet and outlet ports 830 and 834 , which include a bevelled annular region 832 and 836 surrounding these ports, respectively, to assist with fluid flow therethrough.
  • the inlet and outlet ports will include septa disposed across the ports (not shown).
  • Bottom casing 810 also includes a cavity 838 , located adjacent the array, which cavity may be adapted for receiving a temperature monitoring and/or controlling device. As shown the cavity 838 has an annular recessed region 839 surrounding it, to ensure that the temperature controller may be inserted with maximum ease.
  • the array cavity 820 is preferably located at a center of the bottom casing, but may also be at other locations.
  • the cavity may be round, square, rectangular, or any other shape, and orientation.
  • the cavity is preferably smaller than the surface area of the chip to be placed thereon, and has a volume sufficient to perform hybridization and the like.
  • the cavity includes dimensions such as a length of about 0.6 inch, a width of about 0.6 inch and a depth of about 0.07 inch.
  • the bottom casing with selected cavity dimensions may be removed from the middle and top casings, and replaced with another bottom casing with different cavity dimensions.
  • This allows a user to attach a chip having a different size or shape by changing the bottom casing, thereby providing ease in using different chip sizes, shapes, and the like.
  • the size, shape, and orientation of the cavity will depend upon the particular application.
  • the body of the cartridge may generally be fabricated from one or more parts made using a number of manufacturing techniques.
  • the cartridge is fabricated from two or more injection molded plastic parts. Injection molding enables the casings to be formed inexpensively. Also, assembling the cartridge from two parts simplifies the construction of various features, such as the internal channels for introducing fluids into the cavity. As a result, the cartridges may be manufactured at a relatively low cost.
  • the substrate segment may be attached to the body of the cartridge using a variety of methods.
  • the substrate is attached using an adhesive.
  • Preferred adhesives are resistant to degradation under conditions to which the cartridge will be subjected.
  • an ultraviolet cured adhesive attaches the substrate segment to the cartridge.
  • Devices and methods for attaching the substrate segment are described in Published PCT Application No. 95/33846, previously incorporated by reference.
  • Particularly preferred adhesives are commercially available from a variety of commercial sources, including Loctite Corp. and Dymax Corp.
  • the cartridged substrate Upon completion, the cartridged substrate will have a variety of uses.
  • the cartridge can be used in a variety of sequencing by hybridization (“SBH”) methods, sequence checking methods, diagnostic methods and the like.
  • SBH sequencing by hybridization
  • Arrays which are particularly suited for sequence checking and SBH methods are described in, e.g. U.S. patent application Ser. No. 08/505,919, filed Jul. 24, 1995, 08/441,887, filed May 16, 1995, 07/972,007, filed Nov. 5, 1992, each of which is incorporated herein by reference in its entirety for all purposes.
  • the cartridged substrate is mounted on a hybridization station where it is connected to a fluid delivery system.
  • the fluid delivery system is connected to the cartridge by inserting needles into the inlet and outlet ports through the septa disposed therein. In this manner, various fluids are introduced into the cavity for contacting the probes synthesized on the front side of the substrate segment, during the hybridization process.
  • hybridization is performed by first exposing the sample with a prehybridization solution. Next, the sample is incubated under binding conditions for a suitable binding period with a sample solution that is to be analyzed.
  • the sample solution generally contains a target molecule, e.g., a target nucleic acid, the presence or sequence of which is of interest to the investigator. Binding conditions will vary depending on the application and are selected in accordance with the general binding methods known including those referred to in: Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.
  • the solution may contain about 1 molar of salt and about 1 to 50 nanomolar of targets.
  • the fluid delivery system includes an agitator to improve mixing in the cavity, which shortens the incubation period.
  • a buffer which may be 6 ⁇ SSPE buffer, to remove the unbound targets.
  • the cavity is filled with the buffer after washing the sample.
  • the cartridged substrate may be aligned on a detection or imaging system, such as those disclosed in U.S. Pat. No. 5,143,854 (Pirrung et al.) or U.S. patent application Ser. No. 08/195,889, filed Feb. 10, 1994, 08/465,782, filed Jun. 6, 1995, 08/456,598, filed Jun. 1, 1995, incorporated herein by reference for all purposes.
  • detection systems may take advantage of the cartridge's asymmetry (i.e., non-flush edge) by employing a holder to match the shape of the cartridge specifically.
  • the imaging systems are capable of qualitatively analyzing the reaction between the probes and targets. Based on this analysis, sequence information of the targets is extracted.
  • Two substrate wafers were stripped, silanated and photoprotected.
  • the substrates were photolyzed through a mask having rectangular features of 50 and 100 ⁇ m on the short side, for 13 half lives of the photoprotecting group used.
  • the first substrate was photolyzed from the back-side of the wafer, i.e., the synthesis surface was facing away from the photolyzing light source.
  • the second substrate was photolyzed from the front-side, i.e., the synthesis surface was facing the light source and mask. Both substrates were then subjected to identical coupling reactions where a fluorescent 5′ protected phosphoramidite was coupled to the surface of the substrate.
  • FIGS. 9A and 9B illustrate the contrast difference between back-side exposure synthesis and front-side exposure synthesis, respectively.
  • FIG. 9A shows a fluorescent scan of a substrate having fluorescent groups coupled directly to the surface of the substrate using photolithographic techniques, with a mask having 50 ⁇ m and 100 ⁇ m feature sizes where the activating light was shown through the back-side of the substrate.
  • FIG. 9B shows the same synthesis where the activation light was directed at the front side of the substrate. The definition of the individual features is greatly enhanced using this front-side photolysis.
  • FIGS. 9C and 9D provide a graphic illustration of the differences in contrast among features prepared using back-side vs. front-side methods. Specifically, the front-side exposure provides a much sharper contrast and greater feature definition. This greater definition permits a much smaller feature size by reducing bleed-over effects during exposure. While front-side exposure results in subjecting the synthesis surface to ambient conditions during photolysis, this has not been found to have any deleterious effects on the synthesis.
  • oligonucleotide probes were synthesized on glass substrates derivatized with bis (2-hydroxyethyl) aminopropyltriethoxysilane, according to standard protocols.
  • a hexaethyleneglycol-based spacer phosphoramidite was coupled to the surface before the oligonucleotide sequence, and a fluorescein-based “tag” phosphoramidite was coupled to the 5′ end of the oligonucleotides, usually in a checkerboard pattern. This allowed monitoring the loss of probes from the substrates, by ascertaining a decrease in the surface fluorescence.
  • the substrates were immersed in either concentrated aqueous ammonia or 50% ethanolic ethanolamine, or 50% ethanolic ethylenediamine in sealed containers. At specific times, the substrates were removed, washed with water, and the surface fluorescence was image was obtained, against a pH 7.2 phosphate buffer. After each scan, the substrates were washed again, dried in an inert atmosphere (N 2 ), and returned to the deprotection solution. The surface fluorescence of the substrate immersed in the aqueous ammonia deprotection solution decayed with a half-time of 8-10 hours. After two days in the ethanolic amine solutions, only a 5% decay in surface fluorescence was observed.
  • oligonucleotide synthesis was compared by synthesizing a 10mer probe sequence on the substrates, deprotecting, and hybridizing them to a standard fluorescein labelled oligonucleotide target. Standard oligonucleotide synthesis cycles (couple-cap-oxidize) were used in all cases, but were modified slightly to allow for reagent delivery to flowcells for planar substrates.
  • silanes obtained from Huls America were tested:
  • Precleaned substrates were immersed in a 1% solution of the silane in 5% water, 95% ethanol, for 5 minutes with gentle agitation. The substrates were then thoroughly rinsed with alcohol, dried under N 2 , and cured at 100° C. for 15 minutes. Prior to use, the acetoxypropyl-silanated substrates were soaked in 50% ethanolic ethanolamine for 2 hours, then rinsed and dried. Similarly, the glycidoxypropyl-silanated substrates were soaked in 0.1 M aqueous HCl for 2 hours, rinsed then dried. All other substrates were used without further treatment.
  • the functional group density was then measured by fluorescent staining. Specifically, MeNPOC-hexaethyleneglycol-cyanoethyl phosphoramidite was coupled to the substrate and unreacted sites were then capped with (MeO) 2 PNiPr 2 . A portion of the surface was illuminated through a photolithographic mask for 300 seconds at 365 nm (15 mW/cm 2 ) to remove the MeNPOC protecting groups. The free hydroxyls were then labeled with a fluorescein phosphoramidite (FluoreprimeTM, Pharmacia Biotech). The substrate was then deprotected n 50% ethanolic ethylenediamine and surface fluorescence was measured with a scanning laser confocal microscope.
  • a 10mer oligonucleotide probe sequence (5′-TACCGTTCAG-3′) was synthesized on a selected region of each substrate using light-directed synthesis. After deprotection in 50% ethanolic ethylenediamine, the substrate was incubated in a solution of a complementary fluorescein-labeled oligonucleotide target (10 nM oligonucleotide in 5 ⁇ SSPE buffer for 6 hours. After briefly washing the substrate once with 5 ⁇ SSPE, total surface-hybridized target oligonucleotide was quantitated with a scanning laser confocal microscope. Staining and hybridization data are summarized in FIG. 10 which illustrates effective silanation of glass substrates using each of the above-described silane reagents.
  • MeNPOC-tetrazolide was carried out as follows: Tetrazole (7.0 g); 100 mmole) was combined with 17.5 ml of DIEA (13 g, 100 mmole) in 100 ml of THF, and a solution of 30 g (110 mmole) MeNPOC-chloride (See, Pease, et al, supra) in 100 ml THF was added dropwise over 20 minutes while stirring under argon at 4° C. Stirring was continued for an additional hour at room temperature. 200 ml of hexane was then added.
  • MeNPOC-transfer to a hydroxylated substrate with MeNPOC-tetrazolide was carried out as follows: Using methods described in the art, e.g., Pease et al., supra, hydroxylated glass substrates were prepared by silanating the glass with bis-(hydroxyethyl)aminopropyltriethoxysilane, and then adding a linker phosphoramidite (MeNPOC-hexaethyleneglycolcyanoethyl-phosphoramidite) to the substrates using a standard couple-cap-oxidize cycle. The substrates were then exposed to light (365 nm at 25 mW/cm 2 for 240 seconds) to remove the MeNPOC protecting groups from the linker.
  • a linker phosphoramidite MeNPOC-hexaethyleneglycolcyanoethyl-phosphoramidite
  • the free hydroxylated linker substrates were exposed to freshly mixed solutions of MeNPOC-tetrazolide (0.2M) in ACN containing 10% v/v 2,6lutidine ⁇ 5% w/v NMI or DMAP activator. After varying periods of time, the MeNPOC-tetrazolide solutions were removed and N,N-diisopropyl-dimethylphosphoramidite was added using the standard couple-cap-oxidize cycle in order to cap any unreacted hydroxyl groups. To assess the extent of MeNPOC transfer, the substrate was photolysed again, and the reexposed hydroxyls were reacted with a fluorescent phosphoramidite (FluoreprimeTM, Pharmacia Biotech), added with the same couple-cap-oxidize protocol.
  • a fluorescent phosphoramidite FluoreprimeTM, Pharmacia Biotech
  • FIG. 11 shows the extent of reprotection with MeNPOC tetrazolide as a function of time and catalyst.

Abstract

The present invention provides novel processes for the large scale preparation of arrays of polymer sequences wherein each array includes a plurality of different, positionally distinct polymer sequences having known monomer sequences. The methods of the invention combine high throughput process steps with high resolution photolithographic techniques in the manufacture of polymer arrays.

Description

  • This application is a continuation of each of U.S. application Ser. Nos. 11/015,257, filed Dec. 16, 2004, 11/016,629, filed Dec. 17, 2004, 11/090,876, filed Mar. 25, 2005 and 11/224,052, filed Sep. 13, 2005, which each of U.S. application Ser. Nos. 11/015,257, 11/016,629, 11/090,876 and 11/224,052 is a continuation of U.S. application Ser. No. 10/722,032, filed Nov. 25, 2003, which is a continuation of U.S. application Ser. No. 09/716,507, filed Nov. 20, 2000, now U.S. Pat. No. 6,706,875, which is a continuation of U.S. application Ser. No. 09/244,568, filed Feb. 4, 1999, now U.S. Pat. No. 6,307,042, which is a continuation of U.S. application Ser. No. 08/634,053, filed Apr. 17, 1996, now U.S. Pat. No. 5,959,098; all of which are hereby incorporated herein by reference.
  • BACKGROUND OF THE INVENTION
  • Methods for synthesizing a variety of different types of polymers are well known in the art. For example, the “Merrifield” method, described in Atherton et al., “Solid Phase Peptide Synthesis,” IRL Press, 1989, which is incorporated herein by reference for all purposes, has been used to synthesize peptides on a solid support. In the Merrifield method, an amino acid is covalently bonded to a support made of an insoluble polymer or other material. Another amino acid with an alpha protecting group is reacted with the covalently bonded amino acid to form a dipeptide. After washing, the protecting group is removed and a third amino acid with an alpha protecting group is added to the dipeptide. This process is continued until a peptide of a desired length and sequence is obtained.
  • Methods have also been developed for producing large arrays of polymer sequences on solid substrates. These large “arrays” of polymer sequences have wide ranging applications and are of substantial importance to the pharmaceutical, biotechnology and medical industries. For example, the arrays may be used in screening large numbers of molecules for biological activity, i.e., receptor binding capability. Alternatively, arrays of oligonucleotide probes can be used to identify mutations in known sequences, as well as in methods for de novo sequencing of target nucleic acids.
  • Of particular note, is the pioneering work described in U.S. Pat. No. 5,143,854 (Pirrung et al.) and PCT Application No. 92/10092 disclose improved methods of molecular synthesis using light directed techniques. According to these methods, light is directed to selected regions of a substrate to remove protecting groups from the selected regions of the substrate. Thereafter, selected molecules are coupled to the substrate, followed by additional irradiation and coupling steps. By activating selected regions of the substrate and coupling selected monomers in precise order, one can synthesize an array of molecules having any number of different sequences, where each different sequence is in a distinct, known location on the surface of the substrate.
  • These arrays clearly embody the next step in solid phase synthesis of polymeric molecules generally, and polypeptides and oligonucleotides, specifically. Accordingly, it would be desirable to provide methods for preparation of these arrays, which methods have high throughput, high product quality, enhanced miniaturization and lower costs. The present invention meets these and other needs.
  • SUMMARY OF THE INVENTION
  • The present invention generally provides novel processes for the efficient, large scale preparation of arrays of polymer sequences wherein each array includes a plurality of different, positionally distinct polymer sequences having known monomer sequences. In one embodiment, the methods of the present invention provide for the cleaning and stripping of substrate wafers to remove oil and dirt from the surface, followed by the derivatization of the wafers to provide photoprotected functional groups on the surface. Polymer sequences are then synthesized on the surface of the substrate wafers by selectively exposing a plurality of selected regions on the surface to an activation radiation to remove the photolabile protecting groups from the functional groups and contacting the surface with a monomer containing solution to couple monomers to the surface in the selected regions. The exposure and contacting steps are repeated until a plurality of polymer arrays are formed on the surface of the substrate wafer. Each polymer array includes a plurality of different polymer sequences coupled to the surface of the substrate wafer in a different known location. The wafers are then separated into a plurality of individual substrate segments, each segment having at least one polymer array formed thereon, and packaged in a cartridge whereby the surface of said substrate segment having the polymer array formed thereon is in fluid contact with the cavity.
  • In another embodiment, the present invention provides methods of forming polymer arrays by providing a substrate having a first surface coated with functional groups protected with a photolabile protecting group, and a second surface having a layer that includes one or more of an index matching compound, a light absorbing compound and an antireflective compound. The method then provides for the sequential activation and coupling of monomers in different selected regions of the first surface of the substrate to form a plurality of different polymer sequences in different known locations on the surface of the substrate, by directing an activation radiation at the first surface of the substrate.
  • In yet another embodiment, the present invention provides a method of forming a plurality of polymer arrays using a batch process. In particular, this method comprises the steps of activating a plurality of substrate wafers by exposing selected regions on each of a plurality of substrate wafers then contacting them with a monomer containing solution in a batch.
  • In a further embodiment, the present invention provides a method of synthesizing polymers on substrates by first derivatizing the substrate with an aminoalkyltrialkoxysilane.
  • In an additional embodiment, the present invention provides a method for forming an array of polymers on a substrate using light-directed synthesis wherein the exposing step comprises directing an activation radiation at selected regions on the surface of said substrate by shining the activation radiation through a photolithographic mask having transparent regions and opaque regions where the transparent regions are smaller than the selected regions. As a result, the activation radiation shone through the transparent regions in the mask is diffracted to expose the selected regions.
  • The present invention also provides methods of forming arrays of polymer sequences having enhanced synthesis efficiencies through the incorporation of monomers which have lipophilic chemical groups coupled thereto.
  • The present invention also provides methods of forming polymer arrays using the above-described methods, but wherein the deprotection and coupling steps in adjacent selected regions of the substrate surface are aligned to minimize differences in synthesis steps between adjacent regions.
  • In still another embodiment, the present invention provides polymer arrays and methods of forming them on a tubular substrate by the sequential activation of and coupling of monomers to selected segments of the tubular substrate surface.
  • In an additional embodiment, the present invention provides methods of photoprotecting functional groups that are coupled to solid supports by exposing the functional group to a photoprotecting group transfer agent having the formula:
  • Figure US20090062148A1-20090305-C00001
  • wherein R1 is a photolabile protecting group and X is a leaving group.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 schematically illustrates light directed oligonucleotide synthesis using photolithographic methods.
  • FIGS. 2A-C are flow diagrams illustrating the overall process of substrate preparation.
  • FIG. 2A is a flow diagram illustrating the overall process. FIGS. 2B and 2C are flow diagrams of the synthesis steps for individual and batch processes, respectively.
  • FIGS. 3A and 3B show schematic illustrations of alternate reactor systems for carrying out the combined photolysis/chemistry steps of used in the methods of the present invention.
  • FIGS. 4A and 4B schematically illustrate different isolated views of a flow cell incorporated into the reactor systems of FIGS. 3A and 3B. FIG. 4C shows a schematic illustration of an integrated reactor system including computer control and substrate translation elements.
  • FIG. 5A shows the alkylation of the exocyclic amine functional group of deoxyguanosine with dimethoxytritylchloride (DMT-Cl) and subsequent coupling of a MenPOC protecting group to the 3′ hydroxyl group of a nucleoside phosphoramidite. FIG. 5B shows the synthetic route for production of Fmoc-phosphoramidites. FIG. 5C shows a synthetic route for introduction of a lipophilic substituent to the photoprotecting group MeNPOC.
  • FIG. 6A shows a schematic representation of a device including a six vessel reaction chamber bank, for carrying out multiple parallel monomer addition steps separate from the photolysis step in light directed synthesis of oligonucleotide arrays. FIG. 6B shows a detailed view of a single reaction chamber.
  • FIG. 7 illustrates a substrate wafer fabricated with a plurality of probe arrays which wafer also includes alignment marks.
  • FIG. 8 illustrates one embodiment of an array cartridge into which an array substrate is placed for use.
  • FIGS. 9A and 9B show the coupling of fluorescent nucleotides to a substrate surface using photolithographic methods in 50 and 100 μm features, using back-side and frontside exposure, respectively. FIGS. 9C and 9D show a plot of fluorescence intensity as a function of substrate position at the border between two features for back-side and front-side exposure as indicated. FIG. 9C illustrates the contrast difference from a top view of the plots while FIG. 9D shows a side view.
  • FIG. 10 is a bar chart showing a comparison of silanation methods using 5 different silanes to derivatize the surface of glass substrates (3-acetoxypropyltrimethoxysilane (“OAc”); 3-glycidoxypropyltrimethoxysilane (“Epoxy”); 4-(hydroxybutyramido)propyltriethoxysilane (“Mono”); 3-aminopropyltriethoxysilane (“APS”); and 3-N,N-bis(2-hydroxyethyl)aminopropyl; triethoxysilane (“bis”)). Shown are the surface density of reactive groups as shown by fluorescence staining (black) and fluorescence intensity of a standard hybridization experiment following synthesis of oligonucleotides on the surface of substrates derivatized using these silanes (grey).
  • FIG. 11 shows the reprotection of deprotected hydroxyl groups on a glass substrate with MeNPOC-tetrazolide as a function of time of exposure to the MeNPOC-tetrazolide and addition of catalyst.
  • DESCRIPTION OF THE PREFERRED EMBODIMENT I. Definitions
  • Probe: A probe, as defined herein, is a surface-immobilized molecule that is recognized by a particular target. These may also be referred to as ligands. Examples of probes encompassed by the scope of this invention include, but are not limited to, agonists and antagonists of cell surface receptors, toxins and venoms, viral epitopes, hormone receptors, peptides, peptidomimetics, enzymes, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, nucleic acids, oligosaccharides, proteins or monoclonal antibodies, natural or modified, e.g., reshaped, chimeric, etc.
  • Array: An array is a preselected collection of different polymer sequences or probes which are associated with a surface of a substrate. An array may include polymers of a given length having all possible monomer sequences made up of a specific basis set of monomers, or a specific subset of such an array. For example, an array of all possible oligonucleotides of length 8 includes 65,536 different sequences. However, as noted above, an oligonucleotide array also may include only a subset of the complete set of probes. Similarly, a given array may exist on more than one separate substrate, e.g., where the number of sequences necessitates a larger surface area in order to include all of the desired polymer sequences.
  • Functional group: A functional group is a reactive chemical moiety present on a given monomer, polymer or substrate surface. Examples of functional groups include, e.g., the 3′ and 5′ hydroxyl groups of nucleotides and nucleosides, as well as the reactive groups on the nucleobases of the nucleic acid monomers, e.g., the exocyclic amine group of guanosine, as well as amino and carboxyl groups on amino acid monomers.
  • Monomer/Building block: A monomer or building block is a member of the set of smaller molecules which can be joined together to form a larger molecule or polymer. The set of monomers includes but is not restricted to, for example, the set of common L-amino acids, the set of D-amino acids, the set of natural or synthetic amino acids, the set of nucleotides (both ribonucleotides and deoxyribonucleotides, natural and unnatural) and the set of pentoses and hexoses. As used herein, monomer refers to any member of a basis set for synthesis of a larger molecule. A selected set of monomers forms a basis set of monomers. For example, the basis set of nucleotides includes A, T (or U), G and C. In another example, dimers of the 20 naturally occurring L-amino acids form a basis set of 400 monomers for synthesis of polypeptides. Different basis sets of monomers may be used in any of the successive steps in the synthesis of a polymer. Furthermore, each of the sets may include protected members which are modified after synthesis.
  • Feature: A feature is defined as a selected region on a surface of a substrate in which a given polymer sequence is contained. Thus, where an array contains, e.g., 100,000 different positionally distinct polymer sequences on a single substrate, there will be 100,000 features.
  • Edge: An edge is defined as a boundary between two features on a surface of a substrate. The sharpness of this edge, in terms of reduced bleed over from one feature to another, is termed the “contrast” between the two features.
  • Protecting group: A protecting group is a material which is chemically bound to a reactive functional group on a monomer unit or polymer and which protective group may be removed upon selective exposure to an activator such as a chemical activator, or another activator, such as electromagnetic radiation or light, especially ultraviolet and visible light. Protecting groups that are removable upon exposure to electromagnetic radiation, and in particular light, are termed “photolabile protecting groups.”
  • II. Abbreviations
  • ACN Acetonitrile
  • Bz Benzoyl
  • CE β-cyanoethyl
  • CEP Cyanoethylphosphoramidite
  • DCM dichloromethane
  • DIEA Diiminoethylamine
  • dG Deoxyguanosine
  • DMAP Dimethylaminopyridine
  • DMC N,N-dimethylcarbamoyl
  • DMF Dimethylformamide
  • DMT 4,4′-Dimethoxytrityl
  • DPC Diphenylcarbamoyl
  • HOAT 1-Hydroxy-7-azabenzotriazole
  • HOBT 1-hydroxybenzotriazole
  • Ibu Isobutyryl
  • MeNP α-methylnitropiperonyl
  • MeNPOC α-methyl-o-nitropiperonyloxycarbonyl
  • MeNV α-methyl-o-nitroveratryl
  • MeNVOC α-methyl-o-nitroveratryloxycarbonyl
  • MMT 4-Methoxytrityl
  • NMI n-methylimidazole
  • NMP n-methylpyrollidinone
  • NP o-Nitropiperonyl
  • NPE 2-(p-nitrophenyl)ethyl
  • NPSE 2-(p-nitrophenylsulfonyl)ethyl
  • NV o-Nitroveratryl
  • NPOC o-Nitropiperanyloxycarbonyl
  • NVOC o-Nitroveratryloxycarbonyl
  • PAC Phenoxyacetyl
  • PYMOC 1-Pyrenylmethyloxycarbonyl
  • SSPE Saline, Sodium Phosphate, EDTA Buffer
  • TEA Triethylamine
  • THF Tetrahydrofuran
  • III. Process Overview
  • The present invention generally provides processes and devices for reproducibly and efficiently preparing arrays of polymer sequences on solid substrates. The overall process is illustrated in FIG. 2A. Generally, the process 1 begins with a series of substrate preparation steps 10 which may include such individual processing steps as stripping cleaning and derivatization of the substrate surface to provide uniform reactive surfaces for synthesis. The polymer sequences are then synthesized on the substrate surface in the synthesis step 20. Following polymer synthesis, the substrates are then separated into individual arrays 40, and assembled in cartridges that are suitable for ultimate use 60. In alternate embodiments, the present invention also provides for the synthesis of the polymer sequences on the substrate surface using either an individual or batch process mode. A comparison of these two synthesis modes is shown in FIG. 2B. In the individual processing mode, the activation and monomer addition steps are combined in a single unit operation 22. For example, a single substrate wafer is placed in a reactor system where it is first subjected to an activation step to activate selected regions of the substrate. The substrate is then contacted with a first monomer which is coupled to the activated region. Activation and coupling steps are repeated until the desired array of polymer sequences is created. The arrays of polymer sequences are then subjected to a final deprotection step 30.
  • In the batch processing mode, a number of substrate wafers are subjected to an activating step 24. The activated substrate wafers are then pooled 26 and subjected to a monomer addition step 28. Each substrate wafer is then subjected individually to additional activation steps followed by pooling and monomer addition. This is repeated until a desired array of polymer sequences is formed on the substrate wafers in a series of individual arrays. These arrays of polymer sequences on the substrate wafers are then subjected to a final deprotection step 30.
  • IV. Substrate Preparation
  • The term “substrate” refers to a material having a rigid or semi-rigid surface. In many embodiments, at least one surface of the substrate will be substantially flat or planar, although in some embodiments it may be desirable to physically separate synthesis regions for different polymers with, for example, wells, raised regions, etched trenches, or the like. According to other embodiments, small beads may be provided on the surface which may be released upon completion of the synthesis. Preferred substrates generally comprise planar crystalline substrates such as silica based substrates (e.g. glass, quartz, or the like), or crystalline substrates used in, e.g., the semiconductor and microprocessor industries, such as silicon, gallium arsenide and the like. These substrates are generally resistant to the variety of synthesis and analysis conditions to which they may be subjected. Particularly preferred substrates will be transparent to allow the photolithographic exposure of the substrate from either direction.
  • Silica aerogels may also be used as substrates. Aerogel substrates may be used as free standing substrates or as a surface coating for another rigid substrate support. Aerogel substrates provide the advantage of large surface area for polymer synthesis, e.g., 400 to 1000 m2/gm, or a total useful surface area of 100 to 1000 cm2 for a 1 cm2 piece of aerogel substrate. Such aerogel substrates may generally be prepared by methods known in the art, e.g., the base catalyzed polymerization of (MeO)4Si or (EtO)4Si in ethanol/water solution at room temperature. Porosity may be adjusted by altering reaction condition by methods known in the art.
  • Individual planar substrates generally exist as wafers which can have varied dimensions. The term “wafer” generally refers to a substantially flat sample of substrate from which a plurality of individual arrays or chips may be fabricated. The term “array” or “chip” is used to refer to the final product of the individual array of polymer sequences, having a plurality of different positionally distinct polymer sequences coupled to the surface of the substrate. The size of a substrate wafer is generally defined by the number and nature of arrays that will be produced from the wafer. For example, more complex arrays, e.g., arrays having all possible polymer sequences produced from a basis set of monomers and having a given length, will generally utilize larger areas and thus employ larger substrates, whereas simpler arrays may employ smaller surface areas, and thus, less substrate.
  • Typically, the substrate wafer will range in size of from about 1″×1″ to about 12″×12″, and will have a thickness of from about 0.5 mm to about 5 mm. Individual substrate segments which include the individual arrays, or in some cases a desired collection of arrays, are typically much smaller than the wafers, measuring from about 0.2 cm×0.2 cm 20 to about 5 cm×5 cm. In particularly preferred aspects, the substrate wafer is about 5″×5″ whereas the substrate segment is approximately 1.28 cm×1.28 cm. Although a wafer can be used to fabricate a single large substrate segment, typically, a large number of substrate segments will be prepared from a single wafer. For example, a wafer that is 5″×5″ can be used to fabricate upwards of 49 separate 1.28 cm×1.28 cm substrate segments. The number of segments prepared from a single wafer will generally vary depending upon the complexity of the array, and the desired feature size.
  • Although primarily described in terms of flat or planar substrates, the present invention may also be practiced with substrates having substantially different conformations. For example, the substrate may exist as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc. In a preferred alternate embodiment, the substrate is a glass tube or microcapillary. The capillary substrate provides advantages of higher surface area to volume ratios, reducing the amount of reagents necessary for synthesis. Similarly, the higher surface to volume ratio of these capillary substrates imparts more efficient thermal transfer properties. Additionally, preparation of the polymer arrays may be simplified through the use of these capillary based substrates. For example, minimizing differences between the regions on the array, or “cells”, and their “neighboring cells” is simplified in that there are only two neighboring cells for any given cell (see discussion below for edge minimization in chip design). Spatial separation of two neighboring cells on an array merely involves the incorporation of a single blank cell, as opposed to full blank lanes as generally used in a flat substrate conformation. This substantially conserves the surface area available for polymer synthesis. Manufacturing design may also be simplified by the linear nature of the substrate. In particular, the linear substrate may be moved down a single mask in a direction perpendicular to the length of the capillary. As it is moved, the capillary will encounter linear reticles (translucent regions of the mask), one at a time, thereby exposing selected regions within the capillary or capillary. This can allow bundling of parallel capillaries during synthesis wherein the capillaries are exposed to thicker linear reticles, simultaneously, for a batch processing mode, or individual capillaries may be placed on a mask having all of the linear reticles lined up so that the capillary can be stepped down the mask in one direction. Subsequent capillaries may be stepped down the mask at least one step behind the previous capillary. This employs an assembly line structure to the substrate preparation process.
  • As an example, a standard optimization chip for detecting 36 simultaneous mutations using a flat geometry chip and an optimization tiling strategy, is 44×45 features (1980 probes and blanks), with 36 blocks of 40 probes each (1440 probes), plus 15 blanks per block (540 blank probes). A capillary format, however, can incorporate the same number of test probes in a smaller space. Specifically, in a capillary substrate, 36 strings of 40 probes will have only one blank space separating each probe group (35 blank probes), for a total of 1475 features.
  • Finally, linear capillary based substrates can provide the advantage of reduced volume over flat geometries. In particular, typical capillary substrates have a volume in the 1-101 range, whereas typical flow cells for synthesizing or screening flat geometry chips have volumes in the range of 100 μl.
  • A. Striping and Rinsing
  • In order to ensure maximum efficiency and accuracy in synthesizing polymer arrays, it is generally desirable to provide a clean substrate surface upon which the various reactions are to take place. Accordingly, in some processing embodiments of the present invention, the substrate is stripped to remove any residual dirt, oils or other fluorescent materials which may interfere with the synthesis reactions, or subsequent analytical use of the array.
  • The process of stripping the substrate typically involves applying, immersing or otherwise contacting the substrate with a stripping solution. Stripping solutions may be selected from a number of commercially available, or readily prepared chemical solutions used for the removal of dirt and oils, which solutions are well known in the art. Particularly preferred stripping solutions are composed of a mixture of concentrated H2SO4 and H2O2. Such solutions are generally available from commercial sources, e.g., Nanostrip™ from Cyantek Corp. After stripping, the substrate is rinsed with water and in preferred aspects, is then contacted with a solution of NaOH, which results in regeneration of an even layer of hydroxyl functional groups on the surface of the substrate. In this case, the substrate is again rinsed with water, followed by a rinse with HCl to neutralize any remaining base, followed again by a water rinse. The various stripping and rinsing steps may generally be carried out using a spin-rinse-drying apparatus of the type generally used in the semiconductor manufacturing industry.
  • Gas phase cleaning and preparation methods may also be applied to the substrate wafers using, e.g., H2O or O2 plasma or reactive ion etching (RIE) techniques that are well known in the art.
  • B. Derivatization
  • Following cleaning and stripping of the substrate surface, the surface is derivatized to provide sites or functional groups on the substrate surface for synthesizing the various polymer sequences on that surface. In particular, derivatization provides reactive functional groups, e.g., hydroxyl, carboxyl, amino groups or the like, to which the first monomers in the polymer sequence may be attached. In preferred aspects, the substrate surface is derivatized using silane in either water or ethanol. Preferred silanes include mono- and dihydroxyalkylsilanes, which provide a hydroxyl functional group on the surface of the substrate. Also preferred are aminoalkyltrialkoxysilanes which can be used to provide the initial surface modification with a reactive amine functional group. Particularly preferred are 3-aminopropyltriethoxysilane and 3-aminopropyltrimethoxysilane (“APS”). Derivatization of the substrate using these latter amino silanes provides a linkage that is stable under synthesis conditions and final deprotection conditions (for oligonucleotide synthesis, this linkage is typically a phosphoramidate linkage, as compared to the phosphodiester linkage where hydroxyalkylsilanes are used). Additionally, this amino silane derivatization provides several advantages over derivatization with hydroxyalkylsilanes. For example, the aminoalkyltrialkoxysilanes are inexpensive and can be obtained commercially in high purity from a variety of sources, the resulting primary and secondary amine functional groups are more reactive nucleophiles than hydroxyl groups, the aminoalkyltrialkoxysilanes are less prone to polymerization during storage, and they are sufficiently volatile to allow application in a gas phase in a controlled vapor deposition process (See below).
  • Additionally, silanes can be prepared having protected or “masked” hydroxyl groups and which possess significant volatility. As such, these silanes can be readily purified by, e.g., distillation, and can be readily employed in gas-phase deposition methods of silanating substrate surfaces. After coating these silanes onto the surface of the substrate, the hydroxyl groups may be deprotected with a brief chemical treatment, e.g., dilute acid or base, which will not attack the substrate-silane bond, so that the substrate can then be used for polymer synthesis. Examples of such silanes include acetoxyalkylsilanes, such as acetoxyethyltrichlorosilane, acetoxypropyltrimethoxysilane, which may bedeprotected after application using, e.g., vapor phase ammonia and methylamine or liquid phase aqueous or ethanolic ammonia and alkylamines. Epoxyalkylsilanes may also be used, such as glycidoxypropyltrimethoxysilane which may be deprotected using, e.g., vapor phase HCl, trifluoroacetic acid or the like, or liquid phase dilute HCl.
  • The physical operation of silanation of the substrate generally involves dipping or otherwise immersing the substrate in the silane solution. Following immersion, the substrate is generally spun as described for the substrate stripping process, i.e., laterally, to provide a uniform distribution of the silane solution across the surface of the substrate. This ensures a more even distribution of reactive functional groups on the surface of the substrate. Following application of the silane layer, the silanated substrate may be baked to polymerize the silanes on the surface of the substrate and improve the reaction between the silane reagent and the substrate surface. Baking typically takes place at temperatures in the range of from 90° C. to 120° C. with 110° C. being most preferred, for a time period of from about 1 minute to about 10 minutes, with 5 minutes being preferred.
  • In alternative aspects, as noted above, the silane solution may be contacted with the surface of the substrate using controlled vapor deposition methods or spray methods. These methods involve the volatilization or atomization of the silane solution into a gas phase or spray, followed by deposition of the gas phase or spray upon the surface of the substrate, usually by ambient exposure of the surface of the substrate to the gas phase or spray. Vapor deposition typically results in a more even application of the derivatization solution than simply immersing the substrate into the solution.
  • The efficacy of the derivatization process, e.g., the density and uniformity of functional groups on the substrate surface, may generally be assessed by adding a fluorophore which binds the reactive groups, e.g., a fluorescent phosphoramidite such as Fluoreprime™ from Pharmacia, Corp., Fluoredite™ from Millipore, Corp. or FAM™ from ABI, and looking at the relative fluorescence across the surface of the substrate.
  • V. Synthesis
  • General methods for the solid phase synthesis of a variety of polymer types have been previously described. Methods of synthesizing arrays of large numbers of polymer sequences, including oligonucleotides and peptides, on a single substrate have also been described. See U.S. Pat. Nos. 5,143,854 and 5,384,261 and Published PCT Application No WO 92/10092, each of which is incorporated herein by reference in its entirety for all purposes.
  • As described previously, the synthesis of oligonucleotides on the surface of a substrate may be carried out using light directed methods as described in., e.g., U.S. Pat. Nos. 5,143,854 and 5,384,261 and Published PCT Application No WO 92/10092, or mechanical synthesis methods as described in 5,384,261 and Published PCT Application No. 93/09668, each of which is incorporated herein by reference. Preferably, synthesis is carried out using light-directed synthesis methods. In particular, these light-directed or photolithographic synthesis methods involve a photolysis step and a chemistry step. The substrate surface, prepared as described herein comprises functional groups on its surface. These functional groups are protected by photolabile protecting groups (“photoprotected”), also as described herein. During the photolysis step, portions of the surface of the substrate are exposed to light or other activators to activate the functional groups within those portions, i.e., to remove photoprotecting groups. The substrate is then subjected to a chemistry step in which chemical monomers that are photoprotected at least one functional group are then contacted with the surface of the substrate. These monomers bind to the activated portion of the substrate through an unprotected functional group.
  • Subsequent activation and coupling steps couple monomers to other preselected regions, which may overlap with all or part of the first region. The activation and coupling sequence at each region on the substrate determines the sequence of the polymer synthesized thereon. In particular, light is shown through the photolithographic masks which are designed and selected to expose and thereby activate a first particular preselected portion of the substrate. Monomers are then coupled to all or part of this portion of the substrate. The masks used and monomers coupled in each step can be selected to produce arrays of polymers having a range of desired sequences, each sequence being coupled to a distinct spatial location on the substrate which location also dictates the polymer's sequence. The photolysis steps and chemistry steps are repeated until the desired sequences have been synthesized upon the surface of the substrate.
  • Basic strategy for light directed synthesis of oligonucleotides on a VLSIPS™ Array is outlined in FIG. 1. The surface of a substrate or solid support, modified with photosensitive protecting groups (X) is illuminated through a photolithographic mask, yielding reactive hydroxyl groups in the illuminated regions. A selected nucleotide, typically in the form of a 3′-O-phosphoramidite-activated deoxynucleoside (protected at the 5′ hydroxyl with a photosensitive protecting group), is then presented to the surface and coupling occurs at the sites that were exposed to light. Following capping and oxidation, the substrate is rinsed and the surface is illuminated through a second mask, to expose additional hydroxyl groups for coupling. A second selected nucleotide (e.g., 5′-protected, 3′-O-phosphoramidite-activated deoxynucleoside) is presented to the surface. The selective deprotection and coupling cycles are repeated until the desired set of products is obtained. Pease et al., Proc. Natl. Acad. Sci. (1994) 91:5022-5026. Since photolithography is used, the process can be readily miniaturized to generate high density arrays of oligonucleotide probes. Furthermore, the sequence of the oligonucleotides at each site is known. Such photolithographic methods are also described in U.S. Pat. No. 5,143,854, U.S. Pat. No. 5,489,678 and Published PCT Application No. WO 94/10128 each of which is incorporated herein by reference in its entirety for all purposes. In the large scale processes of the present invention, it is typically preferred to utilize photolithographic synthesis methods.
  • Using the above described methods, arrays may be prepared having all polymer sequences of a given length which are composed of a basis set of monomers. Such an array of oligonucleotides, made up of the basis set of four nucleotides, for example, would contain up to 4n oligonucleotides on its surface, where n is the desired length of the oligonucleotide probe. For an array of 8mer or 10mer oligonucleotides, such arrays could have upwards of about 65,536 and 1,048,576 different oligonucleotides respectively. Generally, where it is desired to produce arrays having all possible polymers of length n, a simple binary masking strategy can be used, as described in U.S. Pat. No. 5,143,854.
  • Alternate masking strategies can produce arrays of probes which contain a subset of polymer sequences, i.e., polymers having a given subsequence of monomers, but are systematically substituted at each position with each member of the basis set of monomers. In the context of oligonucleotide probes, these alternate synthesis strategies may be used to lay down or “tile” a range of probes that are complementary to, and span the length of a given known nucleic acid segment. The tiling strategy will also include substitution of one or more individual positions within the sequence of each of the probe groups with each member of the basis set of nucleotides. These positions are termed “introgation positions.” By reading the hybridization pattern of the target nucleic acid, one can determine if and where any mutations lie in the sequence, and also determine what the specific mutation is by identifying which base is contained within the interogation position. Tiling methods and strategies are discussed in substantial detail in U.S. patent application Ser. No. 08/143,312 filed Oct. 26, 1993, and incorporated herein by reference in its entirety for all purposes.
  • Tiled arrays may be used for a variety of applications, such as identifying mutations within a known oligonucleotide sequence or “target”. Specifically, the probes on the array will have a subsequence which is complementary to a known nucleic acid sequence, but wherein at least one position in that sequence has been systematically substituted with the other three nucleotides.
  • Use of photolabile protecting groups during polymer synthesis has been previously reported, as described above. Preferred photolabile protecting groups generally have the following characteristics: they prevent selected reagents from modifying the group to which they are attached; they are stable to synthesis reaction conditions (that is, they remain attached to the molecule); they are removable under conditions that minimize potential adverse effects upon the structure to which they are attached; and, once removed, they do not react appreciably with the surface or surface bound oligomer. In some embodiments, liberated byproducts of the photolysis reaction can be rendered unreactive toward the growing oligomer by adding a reagent that specifically reacts with the byproduct.
  • The removal rate of the photolabile protecting groups generally depends upon the wavelength and intensity of the incident radiation, as well as the physical and chemical properties of the protecting group itself. Preferred protecting groups are removed at a faster rate and with a lower intensity of radiation. Generally, photoprotecting groups that undergo photolysis at wavelengths in the range from 300 nm to approximately 450 nm are preferred.
  • Generally, photolabile or photosensitive protecting groups include ortho-nitrobenzyl and ortho-nitrobenzyloxycarbonyl protecting groups. The use of these protecting groups has been proposed for use in photolithography for electronic device fabrication (see, e.g., Reichmanis et al., J. Polymer Sci. Polymer Chem. Ed. (1985) 23:1-8, incorporated herein by reference for all purposes).
  • Examples of additional photosensitive protecting groups which may be used in the light directed synthesis methods herein described, include, e.g., 1-pyrenylmethyloxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, 4-methoxyphenacyloxycarbonyl, 3′-methoxybenzoinyloxycarbonyl, 3′,5′-dimethoxybenzoinyl-oxycarbonyl 2′,3′-dimethoxybenzoinyl-oxycarbonyl, 2′,3′-(methylenedioxy) benzoinyloxycarbonyl, N-(5-bromo-7-nitroindolinyl)carbonyl 3,5-dimethoxybenzyloxycarbonyl, and α-(2-methyleneanthraquinone)oxycarbonyl.
  • Particularly preferred photolabile protecting groups for protection of either the 3′ or 5′-hydroxyl groups of nucleotides or nucleic acid polymers include the o-nitrobenzyl protecting groups described in Published PCT Application No. WO 92/10092. These photolabile protecting groups include, e.g., nitroveratryloxycarbonyl (NVOC), nitropiperonyl oxycarbonyl (NPOC), α-methyl-nitroveratryloxycarbonyl (MeNVOC), α-methyl-nitropiperonyloxycarbonyl (MeNPOC), 1-pyrenylmethyloxycarbonyl (PYMOC), and the benzylic forms of each of these (i.e., NV, NP, MeNV, MeNP and PYM, respectively), with MeNPOC being most preferred.
  • Protection strategies may be optimized for different phosphoramidite nucleosides to enhance synthesis efficiency. Examples of such optimized synthesis methods are reported in, e.g., U.S. patent application Ser. No. 08/445,332 filed May 19, 1995. Generally, these optimization methods involve selection of particular protecting groups for protection of the O6 group of guanosine, which can markedly improve coupling efficiencies in the synthesis of guanosine containing oligonucleotides. Similarly, selection of the appropriate protecting group for protection of the N2 group of guanosine can also result in such an improvement, in absence of protection of the O6 group. For example, suitable protecting groups for protection of the N2 group, where the O6 group is also protected, include, e.g., mono- or diacyl protecting groups, triarylmethyl protecting groups, e.g., DMT and MMT, and amidine type protecting groups, e.g., N,N-dialkylformamidines. Particularly preferred protecting groups for the N2 group include, e.g., DMF, DMF, PAC, Bz and Ibu.
  • Protection of the O6 group will generally be carried out using carbamate protecting groups such as —C(O)NX2, where X is alkyl, or aryl; or the protecting group —CH2CH2Y, where Y is an electron withdrawing group such as cyano, p-nitrophenyl, or alkyl- or aryl-sulfonyl; and aryl protecting groups. In a particularly preferred embodiment, the O6 group is protected using a diphenylcarbamoyl protecting group (DPC).
  • Alternatively, improved coupling efficiencies may be achieved by selection of an appropriate protecting group for only the N2 group. For example, where the N2—PAC protecting group is substituted with an Ibu protecting group, a substantial improvement in coupling efficiency is seen, even without protection of the O6 group.
  • A variety of modifications can be made to the above-described synthesis methods. For example, in some embodiments, it may be desirable to directly transfer or add photolabile protecting groups to functional groups, e.g., NH2, OH, SH or the like, on a solid support. For these methods, conventional peptide or oligonucleotide monomers or building blocks having chemically removable protecting groups are used instead of monomers having photoprotected functional groups. In each cycle of the synthesis procedure, the monomer is coupled to reactive sites on the substrate, e.g., sites deprotected in a prior photolysis step. The protecting group is then removed using conventional chemical techniques and replaced with a photolabile protecting group prior to the next photolysis step.
  • A number of reagents will effect this replacement reaction. Generally, these reagents will have the following generic structure:
  • Figure US20090062148A1-20090305-C00002
  • where R1 is a photocleavable protecting group and X is a leaving group, i.e., from the parent acid HX. The stronger acids typically correspond to better leaving groups and thus, more reactive acylating agents.
  • Examples of suitable leaving groups include a number of derivatives having a range of properties, e.g., relative reactivity, solubility, etc. These groups generally include simple inorganic ions, i.e., halides, N3—, and the like, as well as compounds having the following structures:
  • Figure US20090062148A1-20090305-C00003
  • where R2 is alkyl, substituted alkyl or aryl, R3 is hydrogen, alkyl, thioalkyl, aryl; R4 is an electron withdrawing group such as NO2, SO2—R2, or CN; R5 is a sterically hindered alkyl or aryl group such as adamantyl, t-butyl and the like; and R6 is alkyl or aryl substituted with electronegative substituents. Examples of these latter leaving groups include:
  • Figure US20090062148A1-20090305-C00004
  • Conditions for carrying out this transfer are similar to those used for coupling reaction in solid phase peptide synthesis, or for the capping reaction in solid phase oligonucleotide synthesis. The solid phase amine, hydroxyl or thiol groups are exposed to a solution of the protecting group coupled to the leaving group, e.g., MeNPOC—X in a non-nucleophilic organic solvent, e.g., DMF, NMP, DCM, THF, ACN, and the like, in the presence of a base catalysts, such as pyridine, 2,6-lutidine, TEA; DIEA and the like. In cases where acylation of surface groups is less efficient under these conditions, nucleophilic catalysts such as DMAP, NMI, HOBT, HOAT and the like, may also be included to accelerate the reaction through the in situ generation of more reactive acylating agents. This would typically be the case where a derivative is preferred for its longer term stability in solution, but is not sufficiently reactive without the addition of one or more of the catalysts mentioned above. On automated synthesizers, it is generally preferable to choose a reagent which can be stored for longer terms as a stable solution and then activated with the catalysts only when needed, i.e., in the reactor system flow cell, or just prior to the addition of the reagent to the flow cell.
  • In addition to the protection of amine groups and hydroxyl groups in peptide and oligonucleotide synthesis, the reagents and methods described herein may be used to transfer photolabile protecting groups directly to any nucleophilic group, either tethered to a solid support or in solution.
  • A. Individual Processing
  • 1. Flow Cell/Reactor System
  • In one embodiment, the substrate preparation process of the present invention combines the photolysis and chemistry steps in a single unit operation. In this embodiment, the substrate wafer is mounted in a flow cell during both the photolysis and chemistry or monomer addition steps. In particular, the substrate is mounted in a reactor system that allows for the photolytic exposure of the synthesis surface of the substrate to activate the functional groups thereon. Solutions containing chemical monomers are then introduced into the reactor system and contacted with the synthesis surface, where the monomers can bind with the active functional groups on the substrate surface. The monomer containing solution is then removed from the reactor system, and another photolysis step is performed, exposing and activating different selected regions of the substrate surface. This process is repeated until the desired polymer arrays are created.
  • Reactor systems and flow cells that are particularly suited for the combined photolysis/chemistry process include those described in, e.g., U.S. Pat. No. 5,424,186, which is incorporated herein by reference in its entirety for all purposes,
  • A schematic illustration of a device for carrying out the combined photolysis/chemistry steps of the individual process, is shown in FIGS. 3A and 3B. These figures show a cross-sectional view of alternate embodiments of the reactor system 100. Referring first to FIG. 3B, the device includes a flow cell which is made up of a body 102 having a cavity 104 disposed in one surface. The cavity generally includes fluid inlets 108 and outlets 110 for flowing fluid into and through the cavity. The cavity may optionally include ridges 106 on the back surface of the cavity to aid in mixing the fluids as they are pumped into and through the cavity. The substrate 112 is mounted over the cavity whereby the front surface of the substrate wafer 114 (the surface upon which the arrays are to be synthesized) is in fluid communication with the cavity. The device also includes a fluid delivery system in fluid connection with the fluid inlet 108 for delivering selected fluids into the cavity to contact the first surface of the substrate. The fluid delivery system typically delivers selected fluids, e.g., monomer containing solutions, index matching fluids, wash solutions, etc., from one or more reagent reservoirs 118, into the cavity via the fluid inlet 108. The delivery system typically includes a pump 116 and one or more valves to select from the various reagent reservoirs.
  • For carrying out the photolysis reactions, the device 100 also typically includes a light source 124, as described above. The light source is shown through a photolithographic mask 128 and is directed at the substrate 112. Directing the light source at the substrate may generally be carried out using, e.g., mirrors 122 and/or lenses 120 and 126. Alternatively, as shown in FIG. 3B, the mask 128 may be placed directly over the substrate 112, i.e., immediately adjacent to the substrate, thereby obviating the need for intervening lenses.
  • FIGS. 4A and 4B show different views of schematic illustrations of one embodiment of the flow cell portion of the device, e.g., the body substrate combination. As shown in FIGS. 4A and 4B, a panel 320 is mounted to the body 102 to form the bottom surface of the cavity 104. Silicone cement or other adhesive may be used to mount the panel and seal the bottom of the cavity. In particularly preferred aspects, panel 320 will be a light absorptive material, such as yellow glass, RG1000 nm long pass filter, or other material which absorbs light at the operating wavelengths, for eliminating or minimizing reflection of impinging light. As a result, the burden of filtering stray light at the incident wavelength during synthesis is significantly lessened. The glass panel also provides a durable surface for forming the cavity since it is relatively immune to corrosion in the high salt environments or other conditions common in DNA synthesis reactions or other chemical reactions.
  • The substrate wafer 112 is mated to a surface 300. The first surface 114 of wafer comprises the photalabile protecting groups coupled to functional groups coupled to the substrate surface, as described above. In some embodiments, vacuum pressure may be used to mate the wafer to the surface 300. In such embodiments, a groove 304, which may be about 2 mm deep and 2 mm wide, is formed on surface 300. The groove communicates with an opening 303 that is connected to a vacuum source, e.g., a pump. The vacuum source creates a vacuum in the groove and causes the substrate wafer to adhere to surface 300.
  • A groove 310 may be formed on surface 300 for seating a gasket 311 therein. The gasket ensures that the cavity is sealed when the wafer is mated to the flow cell. Alignment pins 315 may be optionally provided on surface 300 to properly align the substrate wafer on the flow cell.
  • Inlet port 307 and outlet port 306 are provided for introducing fluids into and flowing fluids out of the cavity. The flow cell provides an opening 301 in which a flow tube 340 is passed through for coupling to inlet port 307. Likewise, a flow tube 341 is passed through opening 302 for coupling with outlet port 306. Fittings 345 are employed to maintain the flow tubes in position. Openings 301 and 302 advantageously position the flow tubes so that the flow cell can easily and conveniently be mounted on the synthesis system.
  • A pump, which is connected to one of the flow tubes, circulates a selected fluid into the cavity and out through the outlet port for recirculation or disposal. The selected fluids may include, e.g., monomer containing solutions, index matching fluids, wash solutions or the like. Although described in terms of a pump, a variety of pressurized delivery systems may be used to deliver fluids to the cavity. Examples of these alternate systems utilize argon gas to circulate the selected fluid into and through the cavity. Simultaneously, the flow of argon gas may be regulated to create bubbles for agitating the fluid as it is circulated through the system. Agitation is used to mix the fluid contents in order to improve the uniformity and/or yield of the reactions.
  • As shown, inlet and outlet ports 306 and 307, respectively, are located at opposite ends of the panel. This configuration improves fluid circulation and regulation of bubble formation in the cavity. In one embodiment, the outlet and inlet are located at the top and bottom ends of the cavity, respectively, when the flow cell is mounted vertically on the synthesizer. Locating the outlet and inlet at the highest and lowest positions in the cavity, respectively, facilitates the removal of bubbles from the cavity.
  • In some embodiments, the flow cell may be configured with a temperature control system to permit the synthesis reactions to be conducted under optimal temperature conditions. Examples of temperature control systems include refrigerated or heated baths, refrigerated air circulating devices, resistance heaters, thermoelectric peltier devices and the like.
  • In some instances, it may be desirable to maintain the volume of the flow cell cavity as small as possible so as to more accurately control reaction parameters, such as temperature or concentration of chemicals. In addition to the benefits of improved control, smaller cavity volumes may reduce waste, as a smaller volume requires a smaller amount of material to carry out the reaction.
  • For particularly small cavity volumes, a difficulty may arise where bubbles in the reaction fluids can become trapped in the cavity, which may result in incomplete exposure of the substrate surface to the reaction fluid. In particular, when a fluid fills into a very shallow channel or slit, it will tend to fill the shallowest areas first, due to relatively strong capillary forces in those areas. If the channel is too shallow, inconsistency and non-flatness of the substrate which results in uneven capillary forces, will lead to an uneven fluid front during filling. As the liquid front loses its even shape, liquid may surround air or gas pockets to produce trapped bubbles. Accordingly, where particularly small cavity volumes are desired, a flow cell may be employed wherein the top and bottom surfaces of the flow cell are nonparallel, being narrower at the inlet of the flow cell, and growing wider toward the outlet. Uniform filling of the flow cell ensures that the fluid front maintains a straight shape, thereby minimizing the potential of having bubbles trapped between the surfaces.
  • A schematic illustration of one embodiment of an integrated reactor system is shown in FIG. 4C. The device includes an automated peptide synthesizer 401. The automated peptide synthesizer is a device which flows selected reagents through a flow cell 402 under the direction of a computer 404. In a preferred embodiment the synthesizer is an ABI Peptide Synthesizer, model no. 431A. The computer may be selected from a wide variety of computers or discrete logic including, for example, an IBM PC-AT or similar computer linked with appropriate internal control systems in the peptide synthesizer. The PC is provided with signals from the ABI computer indicative of, for example, the beginning of a photolysis cycle. One can also modify the synthesizer with a board that links the contacts of relays in the computer in parallel with the switches to the keyboard of the control panel of the synthesizer to eliminate some of the keystrokes that would otherwise be required to operate the synthesizer.
  • Substrate 406 is mounted on the flow cell, forming a cavity between the substrate and the flow cell. Selected reagents flow through this cavity from the peptide synthesizer at selected times, forming an array of peptides on the face of the substrate in the cavity. Mounted above the substrate, and preferably in contact with the substrate is a mask 408. Mask 408 is transparent in selected regions to a selected wavelength of light and is opaque in other regions to the selected wavelength of light. The mask is illuminated with a light source 410 such as a UV light source. In one specific embodiment the light source 410 is a model No. 82420 made by Oriel. The mask is held and translated by an x-y translation stage 412. Translation stages may be obtained commercially from, e.g., Newport Corp. The computer coordinates the action of the peptide synthesizer, translation stage, and light source. Of course, the invention may be used in some embodiments with translation of the substrate instead of the mask.
  • 2. Photolysis Step
  • As described above, photolithographic methods are used to activate selected regions on the surface of the substrate. Specifically, functional groups on the surface of the substrate or present on growing polymers on the surface of the substrate, are protected with photolabile protecting groups. Activation of selected regions of the substrate is carried out by exposing selected regions of the substrate surface to activation radiation, e.g., light within the effective wavelength range, as described previously. Selective exposure is typically carried out by shining a light source through a photolithographic mask. Alternate methods of exposing selected regions may also be used, e.g., fiberoptic faceplates, etc. For the individual process methods, e.g., the integrated photolysis/chemistry process, the substrate is mounted in the reactor system or flow cell such that the synthesis surface of the substrate is facing the cavity and away from the light source. As the light source is shown on the surface opposite that upon which the photoprotective groups are provided, this method of exposure is termed “backside” photolysis.
  • Because the individual feature sizes on the surface of the substrate prepared according to the processes described herein can typically range as low as 1-10 μm on a side, the effects of reflected or refracted light at the surface of the substrate can have significant effects upon the ability to expose and activate features of this size. One method of reducing the occurrence of reflected light is to incorporate a light absorptive material as the back surface of the flow cell, as described above. Refraction of the light as it enters the flow cell, i.e., crosses the substrate/flow cell interface, through the back surface of the substrate can also result in a loss in feature resolution at the synthesis surface of the substrate resulting from refraction and reflection. To alleviate this problem, during the photolysis step, it is generally desirable to fill the flow cell with an index matching fluid (“IMF”) to match the refractive index of the substrate, thereby reducing refraction of the incident light and the associated losses in feature resolution. The index matching fluid will typically have a refractive index that is close to that of the substrate. Typically, the refractive index of the IMF will be within about 10% that of the substrate, and preferably within about 5% of the refractive index of the substrate. Refraction of the light entering the flow cell, as it contacts the interface between the substrate and the IMF is thereby reduced. Where synthesis is being carried out on, e.g., a silica substrate, a particularly preferred IMF is dioxane which has a refractive index roughly equivalent to the silica substrate.
  • The light source used for photolysis is selected to provide a wavelength of light that is photolytic to the particular protecting groups used, but which will not damage the forming polymer sequences. Typically, a light source which produces light in the UV range of the spectrum will be used. For example, in oligonucleotide synthesis, the light source typically provides light having a wavelength above 340 nm, to effect photolysis of the photolabile protecting groups without damaging the forming oligonucleotides. This light source is generally provided by a Hg-Arc lamp employing a 340 nm cut-off filter (i.e., passing light having a wavelength greater than 340-350 nm). Typical photolysis exposures are carried out at from about 6 to about 10 times the exposed half-life of the protecting group used, with from 8-10 times the half-life being preferred. For example, MeNPOC, a preferred photolabile protecting group, has an exposed half-life of approximately 6 seconds, which translates to an exposure time of approximately 36 to 60 seconds.
  • Photolithographic masks used during the photolysis step typically include transparent regions and opaque regions, for exposing only selected portions of the substrate during a given photolysis step. Typically, the masks are fabricated from glass that has been coated with a light-reflective or absorptive material, e.g., a chrome layer. The light-reflective or absorptive layer is etched to provide the transparent regions of the mask. These transparent regions correspond to the regions to be exposed on the surface of the substrate when light is shown through the mask
  • In general, it is desirable to produce arrays with smaller feature sizes, allowing the incorporation of larger amounts of information in a smaller substrate area, allowing interogation of larger samples, more definitive results from an interogation and greater possibility of miniaturization. Alternatively, by reducing feature size, one can obtain a larger number of arrays, each having a given number of features, from a single substrate wafer. The result is substantially higher product yields for a given process. This technique, generally referred to as “die shrinking” is commonly used in the semiconductor industry to enhance product outputs or to reduce chip sizes following a over-sized test run of a manufacturing process.
  • In seeking to reduce feature size, it is important to maximize the contrast between the regions of the substrate exposed to light during a given photolysis step, and those regions which remain dark or are not exposed. By “contrast” is meant the sharpness of the line separating an exposed region and an unexposed region. For example, the gradient of activated to nonactivated groups running from an activated orexposed region to a nonexposed region is a measure of the contrast. Where the gradient is steep, the contrast is high, while a gradual gradient indicates low or poor contrast.
  • One cause of reduced contrast is “bleed-over” from exposed regions to non-exposed regions during a particular photolysis step. In certain embodiments, contrast between features is enhanced through the front side exposure of the substrate. Front side exposure reduces effects of diffraction or divergence by allowing the mask to be placed closer to the synthesis surface. Additionally, and perhaps more importantly, refractive effects from the light passing through the substrate surface prior to exposure of the synthesis surface are also reduced or eliminated by front-side exposure. This is discussed in greater detail below.
  • Contrast between features may also be enhanced using a number of other methods. For example, the level of contrast degradation between two regions generally increases as a function of the number of differential exposures or photolysis steps between the two regions, i.e., incidences where one region is exposed while the other is not. The greater the number of these incidences, the greater the opportunity for bleed over from one region to the other during each step and the lower the level of contrast between the two regions. Translated into sequence information, it follows that greater numbers of differences between polymers synthesized in adjacent regions on a substrate can result in reduced contrast between the regions. Namely, the greater the number of differences in two polymer sequences, the greater the number of incidences of a region bearing the first polymer being exposed while the other was not. These effects are termed “edge” effects as they generally occur at the outer edges of the feature.
  • It is thus desirable to minimize these edge effects to enhance contrast in synthesis. Accordingly, in one aspect, the present invention provides a method of enhancing contrast by reducing the number of differential synthesis/photolysis steps between adjacent polymer sequence containing regions throughout an array.
  • One method of edge minimization is to divide the polymers to be sequenced into blocks of related polymers, leaving blank lanes between the blocks to prevent bleed-over into other blocks. While this method is effective in reducing edge effects, it requires the creation of a specific algorithm for each new tiling strategy. That is, the layout of each block in terms of probe location will depend upon the tiled sequence. In one aspect, the present invention provides methods for aligning polymer synthesis steps on an array whereby the number of differential synthesis steps is reduced, and/or the syntheses in adjacent regions optimized for similarity.
  • The following example illustrates a typical synthesis strategy. Assuming a simple array where a single possible mutation is being explored at the third position in the sequence TGTATCA. An array of complementary probes might be as follows:
  • #1 ACATAGT
    #
    2 ACTTAGT
    #
    3 ACGTAGT
    #
    4 ACCTAGT

    where position 3 has been substituted with each of the four nucleotides. In synthesizing this array, monomer addition is typically cycled through the four nucleosides in a given preset order, e.g., 1-A, 2-C, 3-G, 4-T. Thus, for the array shown above, the first “A” in each of the sequences would be coupled in the first cycle. The second “C” would be coupled in the second monomer addition cycle. Each of the substituted positions would then be coupled in their respective cycle, e.g., the “A” in probe #1 would be coupled in the fifth cycle, while the “T”, “G”, and “C” would be coupled in the sixth, seventh, and eighth cycles, respectively.
  • Up to this point, each probe has been exposed to a minimal number of differential exposures, as described above. However, the monomer addition steps following the substituted monomer give rise to some difficulties in this regard. For example, it would be possible to couple the “T” in the fourth position in probe #1 at the sixth cycle while the “T” in the remaining probes would have to be added at the tenth cycle, because they could not be added before the preceding monomer in the sequence. The remaining synthesis steps for probe 1 would then be out of sequence with those of the remaining probes, resulting in an increased number of differential sequence steps between probe 1 and the remaining probes. By aligning the addition of the “T” monomer in probe #1 with that of the remaining probes, the number of differential synthesis steps is minimized. Specifically, by waiting until the tenth cycle to add the “T” in probe #1, the number of differential exposures between the probes is minimized to only that number necessary to incorporate the various mutations or substitutions.
  • The methods described herein utilize a generalized synthesis method for aligning synthesis steps to accomplish the above-described goal. These generalized methods can be followed regardless of the particular tiling strategy used or targeted sequence.
  • In particular, the methods described herein, identify each probe by a generic structure which is effectively independent of the actual targeted sequence. This generic description of a probe sequence is termed an “image”, a collection of polymer sequences is termed a “picture”, and a local translation, e.g., in a larger targeted sequence, is termed a “frame”. The entire picture and frame structure is termed a “collage”.
  • Each position in the probe is designated by the position number in the frame, or targeted sequence segment, followed by a number that indicates the rotation from the wild type monomer, with the wild type monomer being “0”. By rotation is meant the number of cycles required to go from the wild type monomer to the substituted monomer in the addition cycle (note that a “0” and a “4” are the same monomer in terms of nucleotides). For example, if a given wild type sequence has an “A” in a given position, a substitution to a “G” would be identified by a rotation of “3”, assuming a monomer addition or synthesis cycle of A, C, T, G.
  • In terms of the above example, probe #1, being the same as the wild type target as also described above, would be identified as:
  • #1 <1,0><2,0><3,0><4,0><5,0><6,0><7,0>
  • where each position is not rotated from the wild type, or is “unmodified.” The remaining sequences would be identified as:
  • #2 <1,0><2,0><3,1><4,0><5,0><6,0><7,0>
  • #3 <1,0><2,0><3,2><4,0><5,0><6,0><7,0>
  • #4 <1,0><2,0><3,3><4,0><5,0><6,0><7,0>
  • indicating a rotation in the third position for each of the nucleoside monomers.
  • Sequence positions which are in the same layer are aligned to be added in the same synthesis cycle. The “depth” of the sequence or the “layer” in which a given monomer is found, are determined by counting each occurrence where an unmodified base follows a modified base. Each sequence has a depth of at least one. For example, the sequence “X” indicated by the <1,1><2,0><3,0> has a depth of 2, where <2,0> and <3,0> are in the second layer. Similarly, the sequence “Y” identified as <1,0><2,1><3,0> has a depth of two where <1,0> is in the first layer and <3,0> is in the second layer. Aligning these two sequences, it can be seen that the monomer <3,0> in sequences X and Y may be aligned as it exists in the same layer.
  • In contrast, the sequence “Z”<1,0><2,0><3,1> has a depth of one with <1,0><2,0> in the first layer. Thus, the position <2,0> in the sequence X would not be aligned with the same position in sequence Z as they exist in different layers.
  • A specific example of the collage method is illustrated using the following sequence/tiling strategy. A targeted sequence is complementary to the sequence CTTA. Thus, written in the above-described generic style, the wild type sequence would be designated <1,0><2,0><3,0><4,0>. Assuming a simplified tiling strategy where each position was to be substituted with a monomer rotated one from the wild type, the array would have the generic description:
  • #1 <1,1><2,0><3,0><4,0>
  • #2 <1,0><2,1><3,0><4,0>
  • #3 <1,0><2,0><3,1><4,0>
  • #4 <1,0><2,0><3,0><4,1>
  • which would correspond to the sequences:
  • #1 G T T A
    #2 C A T A
    #3 C T A A
    #4 C T T C
  • The assignment of bases of each layer to a particular cycle is termed a “frame.” For example, the frame for the above synthesis would be as follows:
  • Layer 1 Layer 2
    <1, 0 > = 2 <----
    <2, 0 > = 4 <2, 0 > =8
    <3, 0 > = 8 <3, 0 > =12
    <4, 0 >= 13
  • Once monomers in the same layer are aligned, the synthesis is carried out with the following aligned cycle assignments:
  • Figure US20090062148A1-20090305-C00005
  • The bases in the first layer are assigned the cycles closest to the start of the synthesis. The modified bases (between the layers) are assigned the next available cycles. The second layer is assigned a set of cycles as close as possible to the start of synthesis consistent with the bases already assigned (i.e., without altering the base ordering of any of the probes). Subsequent layers are assigned in a similar manner. This method allows maximum alignment of synthesis cycles throughout the frame being synthesized, while minimizing the total length of synthesis (e.g., number of steps).
  • Another method of minimizing bleed-over in the photolysis steps is to reduce the size of the transmissive or translucent portion of the mask, thus preventing unintentional exposure of adjoining regions caused by diffraction of the light shown through the mask. In particular, typical photolysis steps can have a duration of up to 8 to 10 times the half-life of the photodeprotection reaction. Thus, photoprotection can be up to 50% complete where the light intensity is only 12% of optimal levels, i.e., the level required for complete or near complete photodeprotection. Typically, such intensity levels may be reached well outside the feature boundary as defined by the transmissive portion of the mask.
  • Reducing the size of the transmissive portion of the mask allows diffraction, scattering and divergence at the edges of each feature without that diffraction interfering with neighboring features. Thus, the region of incomplete photolysis can be centered on the desired boundary between features. As a result, the total area of the chip that is compromised in a multi-step synthesis is minimized because bleed-over effects from each region are centered in the boundary rather than well into the neighboring feature. Accordingly, in one aspect of the present invention provides a method of minimizing bleed-over in adjoining cells by reducing the size of the transmissive portion of the mask, such that the zone of divergent light shown through the mask is centered on the desired feature border. As an example, a mask exposing a rectangular feature can be reduced by, e.g., 20 μm in each dimension, thus allowing greater homogeneity at the edges of 100 μm features. In preferred aspects, the translucent region of the mask will be from about 2% to about 25% smaller in each dimension of the size of the region which is to be exposed. In more preferred aspects, the translucent portion of the mask will be from about 10% to about 25% smaller in each dimension.
  • 3. Chemistry Step
  • Following each photolysis step, a monomer building block is introduced or contacted with the synthesis surface of the substrate. Typically, the added monomer includes a single active functional group, for example, in the case of oligonucleotide synthesis, a 3′-hydroxyl group. The remaining functional group that is involved in linking the monomer within the polymer sequence, e.g., the 5′-hydroxyl group of a nucleotide, is generally photoprotected. The monomers then bind to the reactive moieties on the surface of the substrate, activated during the preceding photolysis step, or at the termini of linker molecules or polymers being synthesized on the substrate.
  • Typically, the chemistry step involves solid phase polymer synthesis methods that are well known in the art. For example, detailed descriptions of the procedures for solid phase synthesis of oligonucleotides by phosphoramidite, phosphite-triester, phosphotriester, and H-phosphonate chemistries are widely available. See, for example, Itakura, U.S. Pat. No. 4,401,796; Caruthers et al., U.S. Pat. Nos. 4,458,066 and 4,500,707; Beaucage et al., Tetrahedron Lett., 22:1859-1862 (1981); Matteucci et al., J. Amer. Chem. Soc., 103:3185-3191 (1981); Caruthers et al., Genetic Engineering, 4:1-17 (1982); Jones, chapter 2, Atkinson et al., chapter 3, and Sproat et al., chapter 4, in Gait, ed. Oligonucleotide Synthesis: A Practical Approach, IRL Press, Washington D.C. (1984); Froehler et al., Tetrahedron Lett., 27:469-472 (1986); Froehler et al., Nucleic Acids Res., 14:5399-5407 (1986); Sinha et al. Tetrahedron Lett., 24:5843-5846 (1983); and Sinha et al., Nucl. Acids Res., 12:4539-4557 (1984).
  • In operation, during the chemistry/monomer addition step, the IMF is removed from the flow cell through an outlet port. The flow cell is then rinsed, e.g., with water and/or acetonitrile. Following rinsing, a solution containing an appropriately protected monomer to be coupled in the particular synthesis step is added. For example, where the synthesis is of oligonucleotide probe arrays, being synthesized in the 3′ to 5′ direction, a solution containing a 3′-O-activated phosphoramidite nucleoside, photoprotected at the 5′ hydroxyl is introduced into the flow cell for coupling to the photoactivated regions of the substrate. Typically, the phosphoramidite nucleoside is present in the monomer solution at a concentration of from 1 mM to about 100 mM, with 10 mM nucleoside concentrations being preferred. Typically, the coupling reaction takes from 30 seconds to 5 minutes and preferably takes about 1.5 minutes.
  • Following coupling, the monomer solution is removed from the flow cell, the substrate is again rinsed, and the IMF is reintroduced into the flow cell for another photolysis step. The photolysis and chemistry steps are repeated until the substrate has the desired arrays of polymers synthesized on its surface.
  • For each photolysis/chemistry cycle, it will generally be desirable to maximize coupling efficiencies in order to maximize probe densities on the arrays. Coupling efficiencies may be improved through a number of methods. For example, coupling efficiency may be increased by increasing the lipophilicity of the building blocks used in synthesis. Without being bound to any theory of operation, it is believed that such lipophilic building blocks have enhanced interaction at the surface of the preferred crystalline substrates. The lipophilicity of the building blocks may generally be enhanced using a number of strategies. In oligonucleotide synthesis, for example, the lipophilicity of the nucleic acid monomers may be increased in a number of ways. For example, one can increase the lipophilicity of the nucleoside itself, the phosphoramidite group, or the protecting group used in synthesis.
  • Modification of the nucleoside to increase its lipophilicity generally involves specific modification of the nucleobases. For example, deoxyguanosine (dG) may be alkylated on the exocyclic amino group (N2) with DMT-Cl, after in situ protection of both hydroxyl groups as trimethylsilylethers (See, FIG. 5A). Liberation of the free DMT protected nucleoside is achieved by base catalyzed methanolosis of the di-TMS ether. Following standard procedures, two further steps are used resulting in the formation of 5′-MeNPOC-dG-phosphoramidites. The DMT group is used because the normally used 5′-DMT-phosphoramidites show high coupling efficiencies on silica substrate surfaces and because of the ease of synthesis for the overall compound. The use of acid labile protecting groups on the exocyclic amino groups of dG allows continued protection of the group throughout light-directed synthesis. Similar protection can be used for other nucleosides, e.g., deoxycytosine (dC). Protection strategies for nucleobase functional groups, including the exocyclic groups are discussed in U.S. patent application Ser. No. 08/445,332 filed May 19, 1995, previously incorporated herein by reference.
  • A more lipophilic phosphoramidite group may also be used to enhance synthesis efficiencies. Typical phosphoramidite synthesis utilizes a cyanoethyl-phosphoramidite. However, lipophilicity may be increased through the use of, e.g., an Fmoc-phosphoramidite group. Synthesis of Fmoc-phosphoramidites is shown in FIG. 5B. Typically, a phosphorus-trichloride is reacted with four equivalents of diisopropylamine, which leads to the formation of the corresponding monochloro-bisamino derivative. This compound reacts with the Fmoc-alcohol to generate the appropriate phosphatidylating agent.
  • As with the phosphoramidite group, the photolabile protecting groups may also be made more lipophilic. For example, a lipophilic substituent, e.g., benzyl, naphthyl, and the like, may be introduced as an alkylhalide, through α-alkylation of a nitroketone, as shown in FIG. 5C. Following well known synthesis techniques, one generates the chloroformate needed to introduce the photoactive lipophilic group to the 5′ position of a deoxyribonucleoside.
  • B. Batch Processing
  • In a second embodiment of the substrate preparation process, each of the photolysis and chemistry steps involved in the synthesis operation are provided as separate unit operations. This method provides advantages of efficiency and higher feature resolution over the single unit operation process. In particular, the separation of the photolysis and chemistry steps allows photolysis to be carried out outside of the confines of the flow cell. This permits application of the light directly to the synthesis surface, i.e., without first passing through the substrate. This “front-side” exposure allows for greater definition at the edges of the exposed regions (also termed “features”) by eliminating the refractive influence of the substrate and allowing placement of the mask closer to the synthesis surface. A comparison illustrating the improved resolution of front-side synthesis is shown in FIGS. 8A-8D.
  • In addition to the benefits of front side exposure, the batch method provides advantages in the surface area of a substrate wafer that may be used in synthesizing arrays. In particular, by combining photolysis/chemistry aspects in the individual process methods, the operation of mounting the substrate wafer on the flow call can result in less than the entire surface of the substrate wafer being used for synthesis. In particular, where the substrate wafer is used to form one wall of the flow cell, as is typically the case in these combined methods, engineering constraints involved in mounting of the flow cell can result in a reduction in the available substrate surface area. This is particularly the case where a vacuum chuck system is used to mount the substrate on the flow cell, where the vacuum chuck system requires a certain amount of surface area to hold the substrate on the flow cell with sufficient force.
  • In batch mode operation, the chemistry step is generally carried out by immersing the entire substrate wafer in the monomer solution, thus allowing synthesis over most if not all of the substrate wafer's synthesis surface. This results in a higher chip yield per substrate wafer than in the individual processing methods. Additionally, as the chemistry steps are generally the time limiting steps in the synthesis process, monomer addition by immersion permits monomer addition to multiple substrates at a given time, while more substrates are undergoing the photolysis steps.
  • For example, where synthesis is performed in the individual processing operation, as described above, the engineering constraints in vacuum mounting a substrate to a flow cell can result in a significant decrease in the size of a synthesis area on the substrate wafer. For example, in one process, a substrate wafer having dimensions of 5″×5″ has only 2.5″×2.5″ available as a synthesis surface, which when separated into chips of typical dimensions (e.g., 1.28 cm×1.28 cm) typically results in 16 potential chips per wafer. The same sized wafer, when subjected to the batch mode synthesis can have a synthesis area of about 4.3″×4.3″, which can produce approximately 49 chips per wafer.
  • In general, a number of substrate wafers is subjected to the photolysis step. Following photolysis, the number of wafers is placed in a rack or “boat” for transport to the station which performs the chemistry steps, whereupon one or more chemistry steps are performed on the wafers, simultaneously. The wafers are then returned to the boat and transported back to the station for further photolysis. Typically, the boat is a rack that is capable of carrying several wafers at a time and is also compatible with automated systems, e.g., robotics, so that the wafers may be loaded into the boat, transported and placed into the chemistry station, and following monomer addition returned to the boat and the photolysis station, all through the use of automated systems.
  • Initial substrate preparation is the same for batch processing as described in the individual processing methods, above. However, beyond this initial substrate preparation, the two process take divergent paths. In batch mode processing, the photolysis and chemistry steps are performed separately. As is described in greater detail below, the photolysis step is generally performed outside of the flow cell. This can cause some difficulties, as there is no provision of an IMF behind the substrate to prevent the potentially deleterious effects of refraction and reflection of the photolytic light source. In some embodiments, however, the same goal is accomplished by applying a coating layer to the back-side of the substrate, i.e., to the non-synthesis surface of the substrate. The coating layer is typically applied after the substrate preparation process, but prior to derivatization. This coating is typically selected to perform one or more of the following functions: (1) match the refractive index of the substrate to prevent refraction of light passing through the substrate which may interfere with the photolysis; and (2) absorb light at the wavelength of light used during photolysis, to prevent back reflection which may also interfere with photolysis.
  • Typically, suitable coating materials may be selected from a number of suitable materials which have a refractive index approximately equal to that of the substrate and/or absorb light at the appropriate wavelength. In particular, index matching coatings are typically selected to have a refractive index that is within at about 10% that of the substrate, and preferably within about 5%. Similarly, light absorbing coatings are typically selected whereby light at the photolytic wavelength is absorbed, which in preferred aspects is light in the ultraviolet range, e.g., between 280 nm and 400 nm. Light absorbing coatings and index matching coatings may be combined to provide combined protection against refraction and reflection, or a single coating material may be selected which possesses both of the desired properties.
  • Preferred polymers will typically be selected to be compatible with the various reaction conditions which would be encountered during the synthesis process, e.g., insoluble in and non-reactive with synthesis reagents, and resistant to the mechanical forces involved in handling and manipulating the substrate, throughout the synthesis process. Additionally, preferred coating materials are easily removable upon completion of the synthesis process, e.g., in the final deprotection step or in a final coating removal step.
  • Examples of suitable coating materials include anti-reflective coatings that are well known in the art and generally commercially available, e.g., magnesium fluoride compounds, which are light-absorbing in the desired wavelength range, polymethylmethacrylate coatings (PMMA), which have a refractive index comparable to glass substrates, and polyimide coatings which are both light-absorbing in the desired wavelength range, and have a refractive index close to that of a glass substrate. Polyimide coatings are most preferred.
  • Application of the coating materials may be carried out by a variety of methods, including, e.g., vapor deposition, spray application, and the like. In preferred aspects, the coating solution will be applied to the substrate using a spin-coating method. Typically, this involves spinning the substrate during deposition of the coating solution on the substrate surface that is to be coated. The spinning substrate results in spreading of the coating solution radially outward on the surface of the substrate.
  • Application of the coating material using the spin-coating process usually employs a two-speed spinning of the substrate. The application of the coating material to the surface of the substrate and initial spreading of the coating solution are usually carried out at low rotational speeds and for relatively short duration. For example, to apply 1 ml of a 12% solids w/v polymer coating solution to a 4.3″×4.3″ substrate, initial spreading is carried out at 500 r.p.m. for 10 seconds. Elimination of excess polymer solution and evening of the polymer layer are carried out at higher rotational speeds and for substantially longer durations. For example in the application described above, the second spinning step is carried out at approximately 3000 r.p.m. for 30 seconds. It will be understood by those of skill in the art, that the above described parameters for spin-coating can be varied within the scope of the present invention. For example, where higher concentration (w/v) polymer solutions are used, it may be desirable to increase one or both rotational speeds, as well as the time at a given speed. Similarly, where the polymer concentration in the polymer solution is reduced, lower speeds and shorter spin times may be used.
  • Following application, the polymer coating is then cured on the surface of the substrate. Curing is typically carried out by heating the coated substrate. In preferred processes, the curing process involves a two-step heating process. The first step involves a “soft-bake” heating of the coated substrate to initially cure the polymer coating. This soft-bake step typically takes place at relatively low temperatures for relatively short periods, i.e., 85° C. for 5 minutes. The second step of the curing process is a final curing of the polymer coating which is typically carried out at higher temperatures for longer periods, i.e., 220-360° C., for approximately 60 minutes. In preferred aspects, a polymer coating applied to the back side of the substrate will be from about 1 to about 50 μm thick, and more preferably, from about 5 to about 20 μm thick, with polymer coating of about 10 μm thick being most preferred.
  • The back-side coated substrate is then subjected to derivitization, rinsing and baking, according to the above described methods.
  • As described previously, the steps of photolysis and monomer addition in the batch mode aspects of the present invention are performed in separate unit operations. Separation of photolysis and chemistry steps allows a more simplified design for a photolyzing apparatus. Specifically, the apparatus need not employ a flow cell. Additionally, the apparatus does not need to employ a particular orientation to allow better filling of the flow cell. Accordingly, the apparatus will typically incorporate one or more mounting frames to immobilize the substrate and mask during photolysis, as well as a light source. The device may also include focusing optics, mirrors and the like for directing the light source through the mask and at the synthesis surface of the substrate. As described above, the substrate is also placed in the device such that the light from the light source impacts the synthesis surface of the substrate before passing through the substrate. As noted above, this is termed “front-side” exposure.
  • Typically a photolysis step requires far less time than a typical chemistry step, e.g., 60 seconds as compared to 10 minutes. Thus, in the individual processing mode where the photolysis and chemistry steps are combined, the photolysis machinery sits idle for long periods of time during the chemistry step. Batch mode operation, on the other hand, allows numerous substrates to be photolyzed while others are undergoing a particular chemistry step. For example, a number of substrate wafers may be exposed for a given photolysis step. Following photolysis, the several substrate wafers may be transferred to a number of reaction chambers for the monomer addition step. While monomer addition is being carried out, additional substrate wafers may be undergoing photolysis.
  • FIG. 6A schematically illustrates a bank of reaction chambers for carrying simultaneous monomer addition steps on a number of separate substrates in parallel. As shown, the bank of reaction chambers is configured to simultaneously perform identical synthesis steps in each of the several reaction chambers. Each reaction chamber 602 is equipped with a fluid inlet 604 and outlet 606 for flowing various fluids into and through the reaction chamber. The fluid inlet of each chamber is generally fluidly connected to a manifold 608 which connects all of the reaction chambers, in parallel, to a single valve assembly 610. Typically, rotator valves are preferred for this aspect of the apparatus. The valve assembly allows the manifold to be fluidly connected to one of a plurality of reagent vessels 612-622. Also included is a pump 624 for delivering the various reagents to the reaction chamber. Although primarily described as performing the same synthesis steps in parallel, the bank of reaction chambers could also be readily modified to carry out to perform multiple independent chemistry steps. The outlet ports 606 from the reaction chambers 602 are typically fluidly connected to a waste vessel (not shown).
  • FIG. 6B shows a schematic representation of a single reaction chamber for performing the chemistry steps of the batch process, e.g., monomer addition. As shown, the reaction chamber employs a “clam-shell” design wherein the substrate is enclosed in the reaction chamber 602 when the door 652 is closed against the body 654 of the apparatus. More particularly, the substrate wafer 660 is mounted on the chamber door and held in place, e.g., by a vacuum chuck shown as vacuum groove 670. When the door 652 is closed, the substrate wafer 668 is placed into the reactor cavity 656 on the body of the device. The reactor cavity is surrounded by a gasket 658, which provides the seal for the reaction chamber when the door is closed. Upon closing the door, the substrate water is pressed against the gasket and the pressure of this contact seals the reaction chamber. The reaction chamber includes a fluid inlet 604 and a fluid outlet 606, for flowing monomer solutions into and out of the reaction chamber.
  • The apparatus may also include latches 666, for locking the reaction chamber in a sealed state. Once sealed, reagents are delivered into the reaction chamber through fluid inlet 662 and out of the reaction chamber through fluid outlet 664. The reaction chamber also typically includes a temperature control element for maintaining the reaction chamber at the optimal synthesis temperature. As shown, the reaction chamber includes automatic alignment pins 672, e.g., solenoid or servo operated, for aligning a substrate wafer on the vacuum groove 670.
  • Following a monomer addition step, the substrate wafers are each subjected to a further photolysis step. The process may generally be timed whereby during a particular chemistry step, a new series of wafers is being subjected to a photolysis step. This dramatically increases the throughput of the process.
  • Following overall synthesis of the desired polymers on the substrate wafers, permanent protecting groups, e.g., those which were not removed during each synthesis step, typically remain on nucleobases and the phosphate backbone of synthetic oligonucleotides. Removal of these protecting groups is usually accomplished with a concentrated solution of aqueous ammonium hydroxide. While this method is effective for the removal of the protecting groups, these conditions can also cleave the synthetic oligomers from the support (usually porous silica particles) by hydrolyzing an ester linkage between the oligo and a functionalized silane derivative that is bonded to the support. In VLSIPS oligonucleotide arrays, it is desirable to preserve the linkage connecting the oligonucleotides to the glass after the final deprotection step. For this reason, synthesis is carried out directly on glass which is derivatized with a hydroxyalkyl-trialkoxysilane (e.g., bis(hydroxyethyl)aminopropylsilane). However, these supports are not completely stable to the alkaline hydrolysis conditions used for deprotection. Depending upon the duration, substrates left in aqueous ammonia for protracted periods can suffer a loss of probes due to hydroxide ion attack on the silane bonded phase.
  • Accordingly, in preferred embodiments, final deprotection of the polymer sequences is carried out using anhydrous organic amines. In particular, primary and secondary alkylamines are used to effect final deprotection. The alkylamines may be used undiluted or in a solution of an organic solvent, e.g. ethanol, acetonitrile, or the like. Typically, the solution of alkyl amine will be at least about 50% alkylamine (v/v). A variety of primary and secondary amines are suitable for use in deprotection, including ammonia, simple low molecular weight (C1-4)alkylamines, and substituted alkylamines, such as ethanolamine and ethylenediamine. More volatile amines are preferred where removal of the deprotection agent is to be carried out by evaporation, whereas the less volatile amines are preferred in instances where it is desirable to maintain containment of the deprotection agent and where the solutions are to be used in repeated deprotections. Solutions of ethanolamine or ethylenediamine in ethanol have been used in deprotecting synthetic oligonucleotides in solution. See, Barnett, et al., Tet. Lett. (1981) 22:991-994, Polushin, et al, (1991) N.A.R. Symp. Ser. No. 24:49-50 and Hogrefe, et al. N.A.R. (1993) 21:2031-2038.
  • Depending upon the protecting groups to be removed, the time required for complete deprotection in these solutions ranges from several minutes for “fast” base-protecting groups, e.g. PAC or DMF-protected A, C or G and Ibu-protected C, to several hours for the standard protecting groups, e.g. benzoyl-protected A, C or G and Ibu-protected G. By comparison, even the fast protecting groups require 4-8 hours for complete removal in aqueous ammonia. During this time, a significant percentage (e.g., 20-80%) of probes are cleaved from a glass substrate through hydrolytic cleavage of the silane layer, whereas after 48 hours of exposure to 50% ethanolic ethylenediamine solution, 95% of the probes remain on the substrate.
  • VI. Assembly of Probe Array Cartridges
  • Following synthesis, final deprotection and other finishing steps, e.g. polymer coat removal where necessary, the substrate wafer is assembled for use as individual substrate segments. Assembly typically employs the steps of separating the substrate wafer into individual substrate segments, and inserting or attaching these individual segments to a housing which includes a reaction chamber in fluid communication with the front surface of the substrate segment, e.g., the surface having the polymers synthesized thereon.
  • Methods of separating and packaging substrate wafers are described in substantial detail in Published PCT Application No. 95/33846, which is hereby incorporated herein by reference in its entirety for all purposes.
  • Typically, the arrays are synthesized on the substrate wafer in a grid pattern, with each array being separated from each other array by a blank region where no compounds have been synthesized. These separating regions are termed “streets”. The wafer typically includes a number of alignment marks located in these streets. These marks serve a number of purposes, including aligning the masks during synthesis of the arrays as described above, separation of the wafer into individual chips and placement of each chip into its respective housing for subsequent use, which are both described in greater detail below. An illustration of a wafer including these alignment marks is shown in FIG. 7. As shown, substrate wafer 700 includes individual arrays 710 separated by streets 720 and includes alignment marks 730.
  • Generally, the substrate wafer can be separated into a number of individual substrates using scribe and break methods that are well known in the semiconductor manufacturing industry. For example, well known scribe and break devices may be used for carrying out the separation steps, e.g., a fully programmable computer controlled scribe and break devices, such as a DX-III Scriber-Breaker manufactured by Dynatex International™, or the LCD-1 scriber/dicer manufactured by Loomis Industries. The steps typically involve scribing along the desired separation points, e.g., between the individual synthesized arrays on the substrate wafer surface, followed by application of a breaking force along the scribe line. For example, typical scribe and break devices break the wafer by striking the bottom surface of the wafer along the scribe lines with an impulse bar, or utilizing a three point beam substrate bending operation. The shock from the impulse bar fractures the wafer along the scribe line. Because the majority of force applied by the impulse bar is dissipated along the scribe line, the device is able to provide high breaking forces without exerting significant force on the substrate itself, allowing separation of the wafer without damaging the individual chips.
  • In alternative methods, the wafer may be separated into individual segments by, e.g., sawing methods, such as those described in U.S. Pat. No. 4,016,855.
  • Once the wafer is separated into individual segments, these segments may be assembled in a housing that is suited for the particular analysis for which the array will be used. Examples of methods and devices for assembling the substrate segments or arrays in cartridges are described in, e.g., U.S. patent application Ser. No. 08/485,452, previously incorporated by reference. Typically, the housing includes a body having a cavity disposed within it. The substrate segment is mounted over the cavity on the body such that the front side of the segment, e.g., the side upon which the polymers have been synthesized, is in fluid communication with the cavity. The bottom of the cavity may optionally include a light absorptive material, such as a glass filter or carbon dye, to prevent impinging light from being scattered or reflected during imaging by detection systems. This feature improves the signal-to-noise ratio of such systems by significantly reducing the potential imaging of undesired reflected light.
  • The cartridge also typically includes fluid inlets and fluid outlets for flowing fluids into and through the cavity. A septum, plug, or other seal may be employed across the inlets and/or outlets to seal the fluids in the cavity. The cartridge also typically includes alignment structures, e.g., alignment pins, bores, and/or an asymmetrical shape to ensure correct insertion and/or alignment of the cartridge in the assembly devices, hybridization stations, and reader devices.
  • An illustration of one embodiment of the array cartridge is shown in FIG. 8. FIG. 8 shows a top view 802, end view 804, side view 806 and bottom view 808 of the array cartridge 800. The body of the array cartridge may generally be fabricated from one or more parts or casings 810-814 that are made using a number of manufacturing techniques. In preferred aspects, the cartridge is fabricated from two or more injection molded plastic parts. Injection molding enables the parts to be formed inexpensively. Also, assembling the cartridge from two parts simplifies the construction of various features, such as the internal channels for introducing fluids into the cavity. As a result, the cartridges may be manufactured at a relatively low cost.
  • The top and bottom views of the cartridge include alignment structures, such as alignment holes 816 and 818. As shown, these alignment holes are disposed through the body of the cartridge, however, those of ordinary skill will appreciate that other alignment structures, e.g., alignment pins, etc., would be equally useful. As shown in the bottom view 808, alignment holes 816 and 818 also include an annular bevelled region to assist in insertion of complementary alignment pins on the hybridization station.
  • Referring to the top view 802 of the cartridge 800, cavity 820 includes a flat bottom peripheral portion 822, a bevelled portion 824 extending from the flat bottom peripheral portion, and a flat upper portion 826 surrounding the beveled portion. The array includes an outer periphery which rests against the flat bottom peripheral portion 822. The bevelled portion aligns the chip onto the flat bottom peripheral portion 822. As shown, the top casing 814 extends outside the middle and bottom casings, 812 and 810, respectively, to provide a nonflush edge 828. The alignment structures 816 and 818, as well as the non flush edge 828, ensure proper orientation of the cartridge in the hybridization station, as well as other devices used in producing and reading polymer arrays. Surrounding mounting structures 816 and 818 are annular recesses 817 and 819, respectively, which aid in guiding the cartridge onto complementary mounting structures on the various devices.
  • As shown in the bottom view 808, the cartridge includes inlet and outlet ports 830 and 834, which include a bevelled annular region 832 and 836 surrounding these ports, respectively, to assist with fluid flow therethrough. Typically, the inlet and outlet ports will include septa disposed across the ports (not shown). Bottom casing 810 also includes a cavity 838, located adjacent the array, which cavity may be adapted for receiving a temperature monitoring and/or controlling device. As shown the cavity 838 has an annular recessed region 839 surrounding it, to ensure that the temperature controller may be inserted with maximum ease.
  • The array cavity 820 is preferably located at a center of the bottom casing, but may also be at other locations. The cavity may be round, square, rectangular, or any other shape, and orientation. The cavity is preferably smaller than the surface area of the chip to be placed thereon, and has a volume sufficient to perform hybridization and the like. In one embodiment, the cavity includes dimensions such as a length of about 0.6 inch, a width of about 0.6 inch and a depth of about 0.07 inch.
  • In a preferred embodiment, the bottom casing with selected cavity dimensions may be removed from the middle and top casings, and replaced with another bottom casing with different cavity dimensions. This allows a user to attach a chip having a different size or shape by changing the bottom casing, thereby providing ease in using different chip sizes, shapes, and the like. Of course, the size, shape, and orientation of the cavity will depend upon the particular application. The body of the cartridge may generally be fabricated from one or more parts made using a number of manufacturing techniques. In preferred aspects, the cartridge is fabricated from two or more injection molded plastic parts. Injection molding enables the casings to be formed inexpensively. Also, assembling the cartridge from two parts simplifies the construction of various features, such as the internal channels for introducing fluids into the cavity. As a result, the cartridges may be manufactured at a relatively low cost.
  • The substrate segment may be attached to the body of the cartridge using a variety of methods. In preferred aspects, the substrate is attached using an adhesive. Preferred adhesives are resistant to degradation under conditions to which the cartridge will be subjected. In particularly preferred aspects, an ultraviolet cured adhesive attaches the substrate segment to the cartridge. Devices and methods for attaching the substrate segment are described in Published PCT Application No. 95/33846, previously incorporated by reference. Particularly preferred adhesives are commercially available from a variety of commercial sources, including Loctite Corp. and Dymax Corp.
  • A variety of modifications can be incorporated in the assembly methods and devices that are generally described herein, and these too are outlined in greater detail in published PCT Application No. 95/33846.
  • Upon completion, the cartridged substrate will have a variety of uses. For example, the cartridge can be used in a variety of sequencing by hybridization (“SBH”) methods, sequence checking methods, diagnostic methods and the like. Arrays which are particularly suited for sequence checking and SBH methods are described in, e.g. U.S. patent application Ser. No. 08/505,919, filed Jul. 24, 1995, 08/441,887, filed May 16, 1995, 07/972,007, filed Nov. 5, 1992, each of which is incorporated herein by reference in its entirety for all purposes.
  • Typically, in carrying out these methods, the cartridged substrate is mounted on a hybridization station where it is connected to a fluid delivery system. The fluid delivery system is connected to the cartridge by inserting needles into the inlet and outlet ports through the septa disposed therein. In this manner, various fluids are introduced into the cavity for contacting the probes synthesized on the front side of the substrate segment, during the hybridization process.
  • Usually, hybridization is performed by first exposing the sample with a prehybridization solution. Next, the sample is incubated under binding conditions for a suitable binding period with a sample solution that is to be analyzed. The sample solution generally contains a target molecule, e.g., a target nucleic acid, the presence or sequence of which is of interest to the investigator. Binding conditions will vary depending on the application and are selected in accordance with the general binding methods known including those referred to in: Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y. and Berger and Kimmel, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques (1987), Academic Press, Inc., San Diego, Calif.; Young and Davis (1983) Proc. Natl. Acad. Sci. (U.S.A.) 80: 1194, which are incorporated herein by reference. In some embodiments, the solution may contain about 1 molar of salt and about 1 to 50 nanomolar of targets. Optionally, the fluid delivery system includes an agitator to improve mixing in the cavity, which shortens the incubation period. Finally, the sample is washed with a buffer, which may be 6×SSPE buffer, to remove the unbound targets. In some embodiments, the cavity is filled with the buffer after washing the sample.
  • Following hybridization and appropriate rinsing/washing, the cartridged substrate may be aligned on a detection or imaging system, such as those disclosed in U.S. Pat. No. 5,143,854 (Pirrung et al.) or U.S. patent application Ser. No. 08/195,889, filed Feb. 10, 1994, 08/465,782, filed Jun. 6, 1995, 08/456,598, filed Jun. 1, 1995, incorporated herein by reference for all purposes. Such detection systems may take advantage of the cartridge's asymmetry (i.e., non-flush edge) by employing a holder to match the shape of the cartridge specifically. Thus, the cartridge is assured of being properly oriented and aligned for scanning. The imaging systems are capable of qualitatively analyzing the reaction between the probes and targets. Based on this analysis, sequence information of the targets is extracted.
  • VII. Examples Example-1 Comparison of Front-Side and Back-Side Photolysis
  • Two substrate wafers were stripped, silanated and photoprotected. The substrates were photolyzed through a mask having rectangular features of 50 and 100 μm on the short side, for 13 half lives of the photoprotecting group used. The first substrate was photolyzed from the back-side of the wafer, i.e., the synthesis surface was facing away from the photolyzing light source. The second substrate was photolyzed from the front-side, i.e., the synthesis surface was facing the light source and mask. Both substrates were then subjected to identical coupling reactions where a fluorescent 5′ protected phosphoramidite was coupled to the surface of the substrate.
  • FIGS. 9A and 9B illustrate the contrast difference between back-side exposure synthesis and front-side exposure synthesis, respectively. FIG. 9A shows a fluorescent scan of a substrate having fluorescent groups coupled directly to the surface of the substrate using photolithographic techniques, with a mask having 50 μm and 100 μm feature sizes where the activating light was shown through the back-side of the substrate. FIG. 9B shows the same synthesis where the activation light was directed at the front side of the substrate. The definition of the individual features is greatly enhanced using this front-side photolysis.
  • FIGS. 9C and 9D provide a graphic illustration of the differences in contrast among features prepared using back-side vs. front-side methods. Specifically, the front-side exposure provides a much sharper contrast and greater feature definition. This greater definition permits a much smaller feature size by reducing bleed-over effects during exposure. While front-side exposure results in subjecting the synthesis surface to ambient conditions during photolysis, this has not been found to have any deleterious effects on the synthesis.
  • Example-2 Final Deprotection with Ethanolamine and Ethylenediamine
  • 1-8mer oligonucleotide probes were synthesized on glass substrates derivatized with bis (2-hydroxyethyl) aminopropyltriethoxysilane, according to standard protocols. In each case, a hexaethyleneglycol-based spacer phosphoramidite was coupled to the surface before the oligonucleotide sequence, and a fluorescein-based “tag” phosphoramidite was coupled to the 5′ end of the oligonucleotides, usually in a checkerboard pattern. This allowed monitoring the loss of probes from the substrates, by ascertaining a decrease in the surface fluorescence. The substrates were immersed in either concentrated aqueous ammonia or 50% ethanolic ethanolamine, or 50% ethanolic ethylenediamine in sealed containers. At specific times, the substrates were removed, washed with water, and the surface fluorescence was image was obtained, against a pH 7.2 phosphate buffer. After each scan, the substrates were washed again, dried in an inert atmosphere (N2), and returned to the deprotection solution. The surface fluorescence of the substrate immersed in the aqueous ammonia deprotection solution decayed with a half-time of 8-10 hours. After two days in the ethanolic amine solutions, only a 5% decay in surface fluorescence was observed.
  • Example-3 Comparison of Silanation Methods and Reagents
  • For comparison, glass substrates were derivatized with a number of silanes using solution-phase deposition methods. Mean functional surface densities were compared by fluorescent staining. Performance with regard to oligonucleotide synthesis was compared by synthesizing a 10mer probe sequence on the substrates, deprotecting, and hybridizing them to a standard fluorescein labelled oligonucleotide target. Standard oligonucleotide synthesis cycles (couple-cap-oxidize) were used in all cases, but were modified slightly to allow for reagent delivery to flowcells for planar substrates.
  • The following silanes, obtained from Huls America were tested:
      • 3-acetoxypropyltrimethoxysilane (“OAc”);
      • 3-glycidoxypropyltrimethoxysilane (“Epoxy”);
      • 4-(hydroxybutyramido)propyltriethoxysilane (“Mono”);
      • 3-aminopropyltriethoxysilane (“APS”); and
      • 3-N,N-bis(2-hydroxyethyl) aminopropyl triethoxysilane (“bis”)
  • Precleaned substrates were immersed in a 1% solution of the silane in 5% water, 95% ethanol, for 5 minutes with gentle agitation. The substrates were then thoroughly rinsed with alcohol, dried under N2, and cured at 100° C. for 15 minutes. Prior to use, the acetoxypropyl-silanated substrates were soaked in 50% ethanolic ethanolamine for 2 hours, then rinsed and dried. Similarly, the glycidoxypropyl-silanated substrates were soaked in 0.1 M aqueous HCl for 2 hours, rinsed then dried. All other substrates were used without further treatment.
  • The functional group density was then measured by fluorescent staining. Specifically, MeNPOC-hexaethyleneglycol-cyanoethyl phosphoramidite was coupled to the substrate and unreacted sites were then capped with (MeO)2PNiPr2. A portion of the surface was illuminated through a photolithographic mask for 300 seconds at 365 nm (15 mW/cm2) to remove the MeNPOC protecting groups. The free hydroxyls were then labeled with a fluorescein phosphoramidite (Fluoreprime™, Pharmacia Biotech). The substrate was then deprotected n 50% ethanolic ethylenediamine and surface fluorescence was measured with a scanning laser confocal microscope.
  • A 10mer oligonucleotide probe sequence (5′-TACCGTTCAG-3′) was synthesized on a selected region of each substrate using light-directed synthesis. After deprotection in 50% ethanolic ethylenediamine, the substrate was incubated in a solution of a complementary fluorescein-labeled oligonucleotide target (10 nM oligonucleotide in 5×SSPE buffer for 6 hours. After briefly washing the substrate once with 5×SSPE, total surface-hybridized target oligonucleotide was quantitated with a scanning laser confocal microscope. Staining and hybridization data are summarized in FIG. 10 which illustrates effective silanation of glass substrates using each of the above-described silane reagents.
  • Example 4 Direct Transfer of Protecting Groups to Hydroxylated Substrates
  • Synthesis of MeNPOC-tetrazolide was carried out as follows: Tetrazole (7.0 g); 100 mmole) was combined with 17.5 ml of DIEA (13 g, 100 mmole) in 100 ml of THF, and a solution of 30 g (110 mmole) MeNPOC-chloride (See, Pease, et al, supra) in 100 ml THF was added dropwise over 20 minutes while stirring under argon at 4° C. Stirring was continued for an additional hour at room temperature. 200 ml of hexane was then added. The precipitate was collected by filtration, redissolved in 200 ml DCM and washed 3 times with 0.05 M aqueous HCl to remove DIEA.HCL. The organic layer was dried with NaSO4 and evaporated to obtain 24.5 g (80%) of the pure product, which was identified by 1H-NMR, IR and mass spectrometry.
  • MeNPOC-transfer to a hydroxylated substrate with MeNPOC-tetrazolide was carried out as follows: Using methods described in the art, e.g., Pease et al., supra, hydroxylated glass substrates were prepared by silanating the glass with bis-(hydroxyethyl)aminopropyltriethoxysilane, and then adding a linker phosphoramidite (MeNPOC-hexaethyleneglycolcyanoethyl-phosphoramidite) to the substrates using a standard couple-cap-oxidize cycle. The substrates were then exposed to light (365 nm at 25 mW/cm2 for 240 seconds) to remove the MeNPOC protecting groups from the linker. The free hydroxylated linker substrates were exposed to freshly mixed solutions of MeNPOC-tetrazolide (0.2M) in ACN containing 10% v/v 2,6lutidine±5% w/v NMI or DMAP activator. After varying periods of time, the MeNPOC-tetrazolide solutions were removed and N,N-diisopropyl-dimethylphosphoramidite was added using the standard couple-cap-oxidize cycle in order to cap any unreacted hydroxyl groups. To assess the extent of MeNPOC transfer, the substrate was photolysed again, and the reexposed hydroxyls were reacted with a fluorescent phosphoramidite (Fluoreprime™, Pharmacia Biotech), added with the same couple-cap-oxidize protocol. The substrates were finally deprotected with 50% ethanolic ethanolamine and the mean surface fluorescence was measured with a laser scanning confocal microscope. FIG. 11 shows the extent of reprotection with MeNPOC tetrazolide as a function of time and catalyst.
  • While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication or patent document were so individually denoted.

Claims (7)

1. A method of forming an array of polymers on a surface of a substrate, comprising: providing a substrate having a first surface coated with functional groups protected with a photolabile protecting group, and a second surface having a layer disposed thereon, said layer including one or more of an index matching compound, a light absorbing compound and an antireflective compound; and sequentially activating and coupling monomers in different selected regions of said substrate to form a plurality of different polymer sequences in different known locations on said surface of said substrate, wherein said activating step comprises directing an activation radiation at said first surface of said substrate.
2. A method for synthesizing an array of chemical compounds on the surface of a support wherein said synthesis comprises a plurality of steps, said method comprising performing at least two of said steps by: (a) placing a support having a functionalized surface into a chamber of a flow cell and subjecting said surface to one step of said synthesis and (b) placing said support into a chamber of another flow cell and subjecting said surface to another step of said synthesis.
3. A flow device comprising:
(a) a sealing member adapted for sealing engagement with a first surface of a support to form a reagent chamber in situ and a first mechanism adapted to move said sealing member,
(b) a second mechanism adapted to engage and hold said support on a second surface of said support opposite said first surface engaged by said sealing member and, in cooperation with said first mechanism, to move said reagent chamber,
(c) an inlet in fluid communication with said reagent chamber, and
(d) an outlet in fluid communication with said reagent chamber.
4. A flow device according to claim 3 wherein said first mechanism for moving said sealing member moves said sealing member into engagement with said support.
5. A flow device according to claim 4 comprising said support in engagement with said second mechanism adapted to engage said support on said second surface opposite said first surface engaged by said sealing member and said sealing member and said first mechanism for moving said sealing member into engagement with said support, wherein said support comprises a chemical array.
6. A flow device comprising:
(a) a sealing member adapted for sealing engagement with a first surface of a support to form a reagent chamber in situ and a first mechanism adapted to move said support relative to a sealing member,
(b) a second mechanism adapted to engage and hold said support on a second surface of said support opposite said first surface engaged by said sealing member,
(c) an inlet in fluid communication with said reagent chamber, and
(d) an outlet in fluid communication with said reagent chamber.
7. A flow device comprising:
(a) a sealing member adapted for sealing engagement with a first surface of a support to form a reagent chamber in situ and a first mechanism adapted to move said support against said sealing member,
(b) a second mechanism adapted to engage and hold said support on a second surface of said support opposite said first surface engaged by said sealing member,
(c) an inlet in fluid communication with said reagent chamber, and
(d) an outlet in fluid communication with said reagent chamber.
US11/500,411 1996-04-17 2006-08-08 Substrate preparation process Abandoned US20090062148A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/500,411 US20090062148A1 (en) 1996-04-17 2006-08-08 Substrate preparation process
US12/634,475 US8067578B2 (en) 1996-04-17 2009-12-09 Substrate preparation process
US13/273,399 US8309496B2 (en) 1996-04-17 2011-10-14 Methods for photolithographic synthesis of polymer arrays utilizing anti-reflective coatings
US13/629,861 US8637434B2 (en) 1996-04-17 2012-09-28 System for photolithographic synthesis of polymer arrays

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US08/634,053 US5959098A (en) 1996-04-17 1996-04-17 Substrate preparation process
US09/244,568 US6307042B1 (en) 1996-04-17 1999-02-04 Substrate preparation process
US09/716,507 US6706875B1 (en) 1996-04-17 2000-11-20 Substrate preparation process
US10/722,032 US20040105932A1 (en) 1996-04-17 2003-11-25 Substrate preparation process
US11/015,257 US20060160099A1 (en) 1996-04-17 2004-12-16 Substrate preparation process
US11/016,629 US20050181396A1 (en) 1996-04-17 2004-12-17 Substrate preparation process
US11/090,876 US20050181431A1 (en) 1996-04-17 2005-03-25 Substrate preparation process
US11/224,052 US20060008840A1 (en) 1996-04-17 2005-09-13 Substrate preparation process
US11/500,411 US20090062148A1 (en) 1996-04-17 2006-08-08 Substrate preparation process

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/015,257 Continuation US20060160099A1 (en) 1996-04-17 2004-12-16 Substrate preparation process
US11/224,052 Continuation US20060008840A1 (en) 1996-04-17 2005-09-13 Substrate preparation process

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/634,475 Continuation US8067578B2 (en) 1996-04-17 2009-12-09 Substrate preparation process

Publications (1)

Publication Number Publication Date
US20090062148A1 true US20090062148A1 (en) 2009-03-05

Family

ID=24542253

Family Applications (6)

Application Number Title Priority Date Filing Date
US08/634,053 Expired - Lifetime US5959098A (en) 1995-02-27 1996-04-17 Substrate preparation process
US09/244,568 Expired - Lifetime US6307042B1 (en) 1996-04-17 1999-02-04 Substrate preparation process
US11/500,411 Abandoned US20090062148A1 (en) 1996-04-17 2006-08-08 Substrate preparation process
US12/634,475 Expired - Fee Related US8067578B2 (en) 1996-04-17 2009-12-09 Substrate preparation process
US13/273,399 Expired - Fee Related US8309496B2 (en) 1996-04-17 2011-10-14 Methods for photolithographic synthesis of polymer arrays utilizing anti-reflective coatings
US13/629,861 Expired - Fee Related US8637434B2 (en) 1996-04-17 2012-09-28 System for photolithographic synthesis of polymer arrays

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/634,053 Expired - Lifetime US5959098A (en) 1995-02-27 1996-04-17 Substrate preparation process
US09/244,568 Expired - Lifetime US6307042B1 (en) 1996-04-17 1999-02-04 Substrate preparation process

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/634,475 Expired - Fee Related US8067578B2 (en) 1996-04-17 2009-12-09 Substrate preparation process
US13/273,399 Expired - Fee Related US8309496B2 (en) 1996-04-17 2011-10-14 Methods for photolithographic synthesis of polymer arrays utilizing anti-reflective coatings
US13/629,861 Expired - Fee Related US8637434B2 (en) 1996-04-17 2012-09-28 System for photolithographic synthesis of polymer arrays

Country Status (6)

Country Link
US (6) US5959098A (en)
EP (1) EP0950112A4 (en)
JP (2) JP2000508542A (en)
AU (1) AU2804797A (en)
CA (1) CA2251755C (en)
WO (1) WO1997039151A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134677A1 (en) * 2005-12-09 2007-06-14 Changhan Kim Light directed DNA synthesis using inverse capping for error reduction
US20130082448A1 (en) * 2011-09-30 2013-04-04 Electro Scientific Industries, Inc. Controlled Surface Roughness in Vacuum Retention
US20190024153A1 (en) * 2011-04-13 2019-01-24 Spatial Transcriptomics Ab Method and product for localized or spatial detection of nucleic acid in a tissue sample
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11001878B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis

Families Citing this family (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
US6706875B1 (en) * 1996-04-17 2004-03-16 Affyemtrix, Inc. Substrate preparation process
US6251691B1 (en) 1996-04-25 2001-06-26 Bioarray Solutions, Llc Light-controlled electrokinetic assembly of particles near surfaces
EP2267164B1 (en) 1997-07-28 2016-09-14 Gen-Probe Incorporated Nucleic acid sequence analysis
NO306357B1 (en) * 1997-10-16 1999-10-25 Torstein Ljungmann Color machine for preparation of tissue samples placed on slides
US6251588B1 (en) * 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US6426184B1 (en) * 1998-02-11 2002-07-30 The Regents Of The University Of Michigan Method and apparatus for chemical and biochemical reactions using photo-generated reagents
AU772531B2 (en) * 1998-02-11 2004-04-29 University Of Houston, The Method and apparatus for chemical and biochemical reactions using photo-generated reagents
ES2344772T3 (en) * 1998-02-23 2010-09-06 Wisconsin Alumni Research Foundation METHOD AND APPARATUS FOR SYNTHESIS OF MATRICES OF DNA PROBES.
US6235480B1 (en) * 1998-03-13 2001-05-22 Promega Corporation Detection of nucleic acid hybrids
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
EP1071821A4 (en) * 1998-04-20 2005-06-29 Affymetrix Inc Methods for reducing non-specific binding to a nucleic acid probe array
US6048695A (en) * 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6979728B2 (en) * 1998-05-04 2005-12-27 Baylor College Of Medicine Articles of manufacture and methods for array based analysis of biological molecules
US6271957B1 (en) * 1998-05-29 2001-08-07 Affymetrix, Inc. Methods involving direct write optical lithography
WO1999063385A1 (en) 1998-06-04 1999-12-09 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
EP1090293B2 (en) 1998-06-24 2019-01-23 Illumina, Inc. Decoding of array sensors with microspheres
DE59915204D1 (en) 1998-08-28 2010-10-28 Febit Holding Gmbh PROCESS FOR THE PRODUCTION OF BIOCHEMICAL REACTION CARRIER
DE19842164B4 (en) * 1998-09-15 2004-06-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Quality control procedures for the construction of oligomer grids
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US6262216B1 (en) 1998-10-13 2001-07-17 Affymetrix, Inc. Functionalized silicon compounds and methods for their synthesis and use
US6951682B1 (en) * 1998-12-01 2005-10-04 Syntrix Biochip, Inc. Porous coatings bearing ligand arrays and use thereof
GB9906929D0 (en) * 1999-03-26 1999-05-19 Univ Glasgow Assay system
WO2000061282A1 (en) * 1999-04-08 2000-10-19 Affymetrix, Inc. Porous silica substrates for polymers synthesis and assays
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
US20020177135A1 (en) * 1999-07-27 2002-11-28 Doung Hau H. Devices and methods for biochip multiplexing
WO2000079006A1 (en) * 1999-06-17 2000-12-28 Fred Hutchinson Cancer Research Center Oligonucleotide arrays for high resolution hla typing
JP3471664B2 (en) * 1999-07-08 2003-12-02 Nec液晶テクノロジー株式会社 Cutting device for bonded substrates for liquid crystal cells
US6994972B2 (en) * 1999-09-02 2006-02-07 Corning Incorporated Porous substrates for DNA arrays
US6750023B2 (en) * 1999-09-02 2004-06-15 Corning Incorporated Porous inorganic substrate for high-density arrays
AU7090600A (en) * 1999-09-02 2001-03-26 Corning Incorporated Porous substrates for dna arrays
US7115423B1 (en) * 1999-10-22 2006-10-03 Agilent Technologies, Inc. Fluidic structures within an array package
EP1230397A2 (en) * 1999-11-02 2002-08-14 Celine Hu Molecular microarrays and methods for production and use thereof
US6784982B1 (en) 1999-11-04 2004-08-31 Regents Of The University Of Minnesota Direct mapping of DNA chips to detector arrays
US6867851B2 (en) * 1999-11-04 2005-03-15 Regents Of The University Of Minnesota Scanning of biological samples
US6642046B1 (en) * 1999-12-09 2003-11-04 Motorola, Inc. Method and apparatus for performing biological reactions on a substrate surface
US6800439B1 (en) 2000-01-06 2004-10-05 Affymetrix, Inc. Methods for improved array preparation
US6458526B1 (en) 2000-01-28 2002-10-01 Agilent Technologies, Inc. Method and apparatus to inhibit bubble formation in a fluid
EP1186659A4 (en) * 2000-03-16 2002-07-17 Matsushita Electric Ind Co Ltd Nucleotide detector, process for producing the same and process for forming fine particle membrane
US6806361B1 (en) 2000-03-17 2004-10-19 Affymetrix, Inc. Methods of enhancing functional performance of nucleic acid arrays
US6833450B1 (en) 2000-03-17 2004-12-21 Affymetrix, Inc. Phosphite ester oxidation in nucleic acid array preparation
EP1284421A4 (en) * 2000-05-12 2005-12-28 Kyowa Hakko Kogyo Kk Method of constructing polynucleotide microarray, apparatus for the construction and polynucleotide microarray
US7005259B1 (en) * 2000-06-01 2006-02-28 Affymetrix, Inc. Methods for array preparation using substrate rotation
ATE319087T1 (en) 2000-06-21 2006-03-15 Bioarray Solutions Ltd MULTI-ANALYTICAL MOLECULAR ANALYSIS BY USING APPLICATION-SPECIFIC RANDOM PARTICLE ARRAYS
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US20040161789A1 (en) * 2000-08-30 2004-08-19 Tanner Cameron W. Porous inorganic substrate for high-density arrays
CA2421732A1 (en) * 2000-09-11 2002-03-14 Affymetrix, Inc. Photocleavable protecting groups
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
US20020037359A1 (en) * 2000-09-25 2002-03-28 Mutz Mitchell W. Focused acoustic energy in the preparation of peptide arrays
US20060141507A1 (en) * 2000-09-27 2006-06-29 Kronick Mel N Manufacture and use of non-standard size microarray slides
US6864097B1 (en) 2000-09-27 2005-03-08 Agilent Technologies, Inc. Arrays and their reading
DE10051396A1 (en) 2000-10-17 2002-04-18 Febit Ferrarius Biotech Gmbh An integrated synthesis and identification of an analyte, comprises particles immobilized at a carrier to be coupled to receptors in a structured pattern to give receptor arrays for biochemical reactions
US6835534B2 (en) 2000-10-27 2004-12-28 The Penn State Research Foundation Chemical functionalization nanolithography
US6528264B1 (en) * 2000-11-01 2003-03-04 Corning Incorporated Polymer support for DNA immobilization
US20020150887A1 (en) * 2000-11-09 2002-10-17 National Institute Of Advanced Industrial Science And Technology Methods and nucleic acid probes for molecular genetic analysis of polluted environments and environmental samples
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7117095B2 (en) * 2000-11-21 2006-10-03 Affymetrix, Inc. Methods for selecting nucleic acid probes
US20020075490A1 (en) * 2000-12-20 2002-06-20 Affymetrix, Inc. System and method for addressable light-directed microarray printing
WO2002052045A1 (en) * 2000-12-26 2002-07-04 Aviva Biosciences Active and biocompatible platforms prepared by polymerization of surface coating films
DE60030306T2 (en) * 2000-12-28 2007-08-30 Roche Diagnostics Gmbh Method, system and cartridge for processing a nucleic acid sample by oscillation of the cartridge
US6870011B2 (en) 2001-01-24 2005-03-22 Arizona Chemical Company Hydrocarbon-terminated polyether-polyamide block copolymers and uses thereof
US6399713B1 (en) 2001-01-24 2002-06-04 Arizona Chemical Company Hydrocarbon-terminated polyether-polyamide block copolymers and uses thereof
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
ATE485766T1 (en) 2001-06-12 2010-11-15 Pelikan Technologies Inc ELECTRICAL ACTUATING ELEMENT FOR A LANCET
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7025774B2 (en) 2001-06-12 2006-04-11 Pelikan Technologies, Inc. Tissue penetration device
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
US6649348B2 (en) * 2001-06-29 2003-11-18 Agilent Technologies Inc. Methods for manufacturing arrays
US10272409B2 (en) 2001-07-11 2019-04-30 Michael E. Hogan Methods and devices based upon a novel form of nucleic acid duplex on a surface
DE60231408D1 (en) * 2001-07-11 2009-04-16 Baylor College Medicine METHOD AND DEVICES BASED ON A NEW FORM OF A NUCLEIC ACID ELEMENT ON A SURFACE
US7297553B2 (en) 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
AU2002322458A1 (en) * 2001-07-13 2003-01-29 Nanosphere, Inc. Method for immobilizing molecules onto surfaces
US6916541B2 (en) * 2001-09-07 2005-07-12 Penn State Research Foundation Modified substrates for the attachment of biomolecules
US7439346B2 (en) 2001-10-12 2008-10-21 Perkinelmer Las Inc. Nucleic acids arrays and methods of use therefor
WO2003091426A1 (en) 2001-10-12 2003-11-06 Spectral Genomics, Inc. Compilations of nucleic acids and arrays and methods of using them
WO2003034064A2 (en) * 2001-10-12 2003-04-24 Duke University Image analysis of high-density synthetic dna microarrays
AU2002334772A1 (en) * 2001-10-12 2003-04-28 Duke University Methods for image analysis of high-density synthetic dna microarrays
WO2003034029A2 (en) 2001-10-15 2003-04-24 Bioarray Solutions, Ltd. Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection
US20030073089A1 (en) * 2001-10-16 2003-04-17 Mauze Ganapati R. Companion cartridge for disposable diagnostic sensing platforms
CN1281324C (en) * 2001-12-19 2006-10-25 阿菲梅特里克斯公司 Manufacturing process for array plate assembly
US7335153B2 (en) * 2001-12-28 2008-02-26 Bio Array Solutions Ltd. Arrays of microparticles and methods of preparation thereof
US7422851B2 (en) * 2002-01-31 2008-09-09 Nimblegen Systems, Inc. Correction for illumination non-uniformity during the synthesis of arrays of oligomers
US7083975B2 (en) * 2002-02-01 2006-08-01 Roland Green Microarray synthesis instrument and method
US20030162283A1 (en) * 2002-02-22 2003-08-28 Hitachi, Ltd. Circulating type biochemical reaction apparatus
US6916621B2 (en) 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
US6773888B2 (en) 2002-04-08 2004-08-10 Affymetrix, Inc. Photoactivatable silane compounds and methods for their synthesis and use
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7892185B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
EP1497418B1 (en) 2002-04-19 2012-10-17 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7217512B2 (en) * 2002-05-09 2007-05-15 Corning Incorporated Reagent and method for attaching target molecules to a surface
KR100451663B1 (en) * 2002-05-15 2004-10-08 한국전자통신연구원 Programmable mask and a method for fabricating biomolecule array using the same
US20070275411A1 (en) 2006-05-25 2007-11-29 Mcgall Glenn H Silane mixtures
US7332273B2 (en) * 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays
US7220573B2 (en) * 2002-06-21 2007-05-22 Agilent Technologies, Inc. Array assay devices and methods of using the same
WO2004003233A1 (en) * 2002-06-28 2004-01-08 Rosetta Inpharmatics Llc Methods to assess quality of microarrays
US7504215B2 (en) 2002-07-12 2009-03-17 Affymetrix, Inc. Nucleic acid labeling methods
US20040101444A1 (en) * 2002-07-15 2004-05-27 Xeotron Corporation Apparatus and method for fluid delivery to a hybridization station
US7452712B2 (en) * 2002-07-30 2008-11-18 Applied Biosystems Inc. Sample block apparatus and method of maintaining a microcard on a sample block
GB0217963D0 (en) * 2002-08-02 2002-09-11 Cyclops Genome Sciences Ltd Purification of nucleic acids
US20040142864A1 (en) * 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
US20040101894A1 (en) 2002-10-01 2004-05-27 Thomas Albert Microarrays having multiple oligonucleotides in single array features
US20040076961A1 (en) * 2002-10-21 2004-04-22 Lewis Mark A. Biomolecule retaining material and methods for attaching biomolecules to a surface
US7195908B2 (en) * 2002-10-31 2007-03-27 Corning Incorporated Supports treated with triamine for immobilizing biomolecules
US7526114B2 (en) 2002-11-15 2009-04-28 Bioarray Solutions Ltd. Analysis, secure access to, and transmission of array images
US20040137606A1 (en) * 2002-12-11 2004-07-15 Jung Moon Youn Programmable mask for forming biomolecule or polymer array and fabrication method of biomolecule or polymer array using the same
US20040180368A1 (en) * 2002-12-23 2004-09-16 Affymetrix, Inc. Method for producing a high density nucleic acid array using activators
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US20040152085A1 (en) * 2003-02-04 2004-08-05 Veridian Systems Division Surface for collection and/or purification of nucleic acids
US7223851B2 (en) * 2003-02-06 2007-05-29 General Dynamics Advanced Information Systems, Inc. Nucleic acid-binding polymers
JP2007524374A (en) * 2003-02-28 2007-08-30 プレキシコン,インコーポレーテッド PYK2 crystal structure and use
ES2713024T3 (en) 2003-03-06 2019-05-17 Basf Enzymes Llc Amylases, nucleic acids that encode them and methods for their manufacture and use
US20040175504A1 (en) * 2003-03-06 2004-09-09 Zyomyx, Inc. Substrate processing apparatus and method for the controlled formation of layers including self-assembled monolayers
EP1601332A4 (en) 2003-03-07 2012-05-02 Verenium Corp Hydrolases, nucleic acids encoding them and mehods for making and using them
JP2004279196A (en) * 2003-03-14 2004-10-07 Dainippon Printing Co Ltd Substrate for bio-micro-array and bio-micro-array
ES2545639T3 (en) 2003-04-04 2015-09-14 Basf Enzymes Llc Pectate liases, nucleic acids that encode them and methods for their preparation and use
ATE476137T1 (en) 2003-05-30 2010-08-15 Pelikan Technologies Inc METHOD AND DEVICE FOR INJECTING LIQUID
WO2004107964A2 (en) 2003-06-06 2004-12-16 Pelikan Technologies, Inc. Blood harvesting device with electronic control
EP3305919A1 (en) 2003-06-10 2018-04-11 The Trustees of Boston University Detection methods for disorders of the lung
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7960148B2 (en) 2003-07-02 2011-06-14 Verenium Corporation Glucanases, nucleic acids encoding them and methods for making and using them
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US20050048571A1 (en) * 2003-07-29 2005-03-03 Danielson Paul S. Porous glass substrates with reduced auto-fluorescence
CA2535526C (en) 2003-08-11 2015-09-29 Diversa Corporation Laccases, nucleic acids encoding them and methods for making and using them
US20050164300A1 (en) * 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US7927796B2 (en) 2003-09-18 2011-04-19 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
TW200521436A (en) 2003-09-22 2005-07-01 Bioarray Solutions Ltd Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
WO2005042763A2 (en) 2003-10-28 2005-05-12 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
JP2007509629A (en) 2003-10-29 2007-04-19 バイオアレイ ソリューションズ リミテッド Complex nucleic acid analysis by cleavage of double-stranded DNA
EP1678329A4 (en) * 2003-10-30 2008-07-02 Tufts New England Medical Ct Prenatal diagnosis using cell-free fetal dna in amniotic fluid
FR2861608B1 (en) * 2003-10-31 2005-12-23 Commissariat Energie Atomique WORKING DEVICE COMPRISING WORKED AREAS, LABORATORY ON CHIP AND MICROSYSTEM
JP4790621B2 (en) 2003-11-26 2011-10-12 アドバンディーエックス, インコーポレイテッド Peptide nucleic acid probes for analysis of specific Staphylococcus species
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
US20070066641A1 (en) * 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
EP1547678B1 (en) * 2003-12-22 2016-07-13 Affymetrix, Inc. Process for high-yield synthesis of nucleic acid arrays
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
CA2497324A1 (en) 2004-02-17 2005-08-17 Affymetrix, Inc. Methods for fragmenting and labelling dna
US20050214778A1 (en) * 2004-03-29 2005-09-29 Peck Bill J Methods for in situ generation of nucleic acid arrays
US20050214777A1 (en) * 2004-03-29 2005-09-29 Peck Bill J Methods for in situ generation of nucleic acid arrays
US7384779B2 (en) * 2004-04-12 2008-06-10 Corning Incorporated Porous substrate plates and the use thereof
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
WO2005113834A2 (en) * 2004-05-20 2005-12-01 Quest Diagnostics Investments Incorporated Single label comparative hybridization
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EA013993B1 (en) 2004-06-16 2010-08-30 Верениум Корпорейшн Compositions and methods for enzymatic de-colorization of chlorophyll
EP1755597A2 (en) * 2004-06-17 2007-02-28 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP4654627B2 (en) * 2004-07-26 2011-03-23 セイコーエプソン株式会社 Chemical adsorption film forming method and chemical adsorption film
FR2873697B1 (en) * 2004-07-28 2006-10-27 Commissariat Energie Atomique PHOTOLABILE PROTECTIVE GROUPING COUPLING AGENTS AND THEIR USES, IN PARTICULAR FOR THE FUNCTIONALIZATION OF SOLID SUPPORTS
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
KR20060012686A (en) 2004-08-04 2006-02-09 한국전자통신연구원 Programmable mask and a method for fabricating biomolecule array using the same
AU2005279795A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl PDE4B inhibitors
US20060073506A1 (en) 2004-09-17 2006-04-06 Affymetrix, Inc. Methods for identifying biological samples
US20060073511A1 (en) 2004-10-05 2006-04-06 Affymetrix, Inc. Methods for amplifying and analyzing nucleic acids
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
JP2006126204A (en) 2004-10-29 2006-05-18 Affymetrix Inc Automated method for manufacturing polymer array
JP4928075B2 (en) * 2004-12-24 2012-05-09 日本曹達株式会社 Organic thin film surface property conversion method
US20060147943A1 (en) * 2004-12-30 2006-07-06 Lewis Mark A Substrates having pendant epoxide groups for binding biomolecules and methods of making and using thereof
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
US7547775B2 (en) 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
DE602006018861D1 (en) * 2005-01-27 2011-01-27 Quest Diagnostics Invest Inc FAST COMPARATIVE GENOM HYBRIDIZATION
WO2006099207A2 (en) 2005-03-10 2006-09-21 Diversa Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2861310A1 (en) 2005-03-15 2006-09-28 Bp Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
US20080020941A1 (en) 2005-03-24 2008-01-24 Jimpei Tabata Biomolecule-immobilized plate and method for fabricating biomolecule-immobilized plate
AU2006236621B2 (en) 2005-04-14 2011-10-06 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
WO2007013896A2 (en) * 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
HUE027370T2 (en) * 2005-06-22 2016-10-28 Plexxikon Inc Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
US20060292559A1 (en) * 2005-06-23 2006-12-28 Beckman Coulter, Inc. Cell-based microarrays, and methods for their preparation and use
WO2007016502A2 (en) 2005-08-02 2007-02-08 Wisconsin Alumni Research Foundation Synthesis of arrays of oligonucleotides and other chain molecules
US20070059742A1 (en) * 2005-09-09 2007-03-15 Stover Axel G Process of stripping a microarray for reuse
EP1939621B1 (en) * 2005-09-16 2014-11-19 Azbil Corporation Method for manufacturing substrate for biochip, and method for manufacturing biochip
US8076074B2 (en) 2005-11-29 2011-12-13 Quest Diagnostics Investments Incorporated Balanced translocation in comparative hybridization
US7634363B2 (en) * 2005-12-07 2009-12-15 Affymetrix, Inc. Methods for high throughput genotyping
EP1795965B1 (en) * 2005-12-08 2012-05-16 Electronics and Telecommunications Research Institute Programmable mask for fabricating biomolecule array or polymer array
US20070154946A1 (en) * 2005-12-29 2007-07-05 Rajasekaran John J Massively parallel synthesis of biopolymeric arrays
EP1979088A2 (en) 2005-12-29 2008-10-15 Affymetrix, Inc. Use of acid scavengers for the synthesis of standard length and long-mer nucleic acid arrays
EP1987358A4 (en) * 2006-01-26 2013-12-04 California Inst Of Techn Mechanically induced trapping of molecular interactions
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp Esterases and related nucleic acids and methods
MY160772A (en) 2006-02-10 2017-03-15 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BRPI0707784B1 (en) 2006-02-14 2018-05-22 Verenium Corporation ISOLATED, SYNTHETIC OR RECOMBINANT NUCLEIC ACID, EXPRESSION CASSETTE, CLONING VECTOR OR VEHICLE, TRANSFORMED ISOLATED HOST CELL, AND METHOD FOR PRODUCTION OF A RECOMBINANT POLYPEPTIDE
US8043837B2 (en) 2006-03-07 2011-10-25 Cargill, Incorporated Aldolases, nucleic acids encoding them and methods for making and using them
ATE548450T1 (en) 2006-03-07 2012-03-15 Verenium Corp ALDOLASES, NUCLEIC ACIDS FOR ENCODING THEM AND METHODS FOR THEIR PRODUCTION AND USE
JP2009529329A (en) 2006-03-09 2009-08-20 トラスティーズ オブ ボストン ユニバーシティ Methods for diagnosis and prognosis for lung diseases using gene expression profiles of nasal epithelial cells
US20070224616A1 (en) * 2006-03-24 2007-09-27 Erdogan Gulari Method for forming molecular sequences on surfaces
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
CN101528766A (en) 2006-08-04 2009-09-09 维莱尼姆公司 Glucanases, nucleic acids encoding them and methods for making and using them
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp Organ-specific proteins and methods of their use
CA2663001A1 (en) 2006-09-21 2008-03-27 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP2617729B1 (en) 2006-09-21 2016-03-16 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
US9845494B2 (en) 2006-10-18 2017-12-19 Affymetrix, Inc. Enzymatic methods for genotyping on arrays
RU2446402C2 (en) 2006-10-24 2012-03-27 Конинклейке Филипс Электроникс Н.В. Detection of target molecules in sample
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US8293684B2 (en) * 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
US7622295B2 (en) 2006-12-19 2009-11-24 Edelmira Cabezas Molecular microarrays and helical peptides
DK3101128T3 (en) 2006-12-21 2019-07-08 Basf Enzymes Llc AMYLASES AND GLUCOAMYLASES, NUCLEAR ACIDS CODING FOR THESE, AND METHODS OF MANUFACTURE AND USE THEREOF
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (en) * 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
RU2009122670A (en) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) COMPOUNDS AND METHODS FOR MODULATION OF KINASES AND INDICATIONS FOR THEIR USE
WO2008095033A2 (en) 2007-01-30 2008-08-07 Verenium Corporation Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
KR100827449B1 (en) 2007-02-07 2008-05-07 삼성전자주식회사 Photolabile compound, oligomer probe array and substrate for oligomer probe array with the same and the method of fabricating the same
JP4850855B2 (en) * 2007-03-22 2012-01-11 信越化学工業株式会社 Manufacturing method of substrate for producing microarray
JP4850854B2 (en) * 2007-03-22 2012-01-11 信越化学工業株式会社 Manufacturing method of substrate for producing microarray
US7572990B2 (en) * 2007-03-30 2009-08-11 Intermec Ip Corp. Keypad overlay membrane
EP2147100B1 (en) 2007-04-27 2017-06-07 The Regents of The University of California Plant co2 sensors, nucleic acids encoding them, and methods for making and using them
US8200440B2 (en) 2007-05-18 2012-06-12 Affymetrix, Inc. System, method, and computer software product for genotype determination using probe array data
PL2170776T3 (en) * 2007-06-28 2019-07-31 Prime Synthesis, Inc. Method for preparing a polymer-coated controlled porosity glass particle
NZ582772A (en) 2007-07-17 2012-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US7507539B2 (en) * 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
EP2198000A4 (en) * 2007-09-17 2013-02-20 Supramolecular nanostamping printing device
KR101387633B1 (en) * 2007-10-02 2014-04-22 삼성전자 주식회사 Binary-coupled type probe array, biochip, and fabricating method of the same
US8486680B2 (en) 2007-10-03 2013-07-16 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
CN104651381A (en) 2008-01-03 2015-05-27 巴斯夫酶有限责任公司 Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
CA2710807C (en) 2008-03-11 2015-09-08 Kyeong Man Hong Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using snp array
EP2107125A1 (en) 2008-03-31 2009-10-07 Eppendorf Array Technologies SA (EAT) Real-time PCR of targets on a micro-array
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
US20110118125A1 (en) * 2008-05-03 2011-05-19 Tufts Medical Center, Inc. Neonatal salivary genomics
EP2145895B1 (en) 2008-07-08 2013-10-30 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Process for the manufacturing of glycochips
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
AU2009285644B2 (en) 2008-08-29 2015-08-20 Janssen Biotech, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010054195A2 (en) 2008-11-07 2010-05-14 Centocor Ortho Biotech Inc. Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
CN102439454B (en) 2009-02-11 2015-05-13 卡里斯Mpi公司 Molecular profiling of tumors
EP3282021A1 (en) 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
TWI404719B (en) * 2009-04-03 2013-08-11 Hoffmann La Roche Compositions and uses thereof
BRPI1011160A8 (en) 2009-05-21 2018-01-02 Verenium Corp PHYTASES, PROTEIN PREPARATION INCLUDING THEM, AND THEIR USES
US20100298171A1 (en) * 2009-05-22 2010-11-25 Affymetrix, Inc. Apparatus for polymer synthesis
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
CN102630250A (en) * 2009-09-25 2012-08-08 基因诊断测试公司 Multiplex (+/-) stranded arrays and assays for detecting chromosomal abnormalities associated with cancer and other diseases
UA109884C2 (en) 2009-10-16 2015-10-26 A POLYPEPTIDE THAT HAS THE ACTIVITY OF THE PHOSPHATIDYLINOSYTOL-SPECIFIC PHOSPHOLIPASE C, NUCLEIC ACID, AND METHOD OF METHOD
UA111708C2 (en) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. METHOD OF OIL REFINING
US20120277112A1 (en) 2009-10-19 2012-11-01 Stichting Het Nederlands Kanker Instituut Predicting response to anti-cancer therapy via array comparative genomic hybridization
US20120316080A1 (en) 2009-10-19 2012-12-13 Stichting Het Nederlands Kanker Instiuut Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization
US20120322677A1 (en) 2009-10-19 2012-12-20 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
AU2010315400B2 (en) 2009-10-27 2016-07-21 Caris Mpi, Inc. Molecular profiling for personalized medicine
CN106220623A (en) 2009-11-06 2016-12-14 普莱希科公司 Compounds and methods for and indication thereof for kinases regulation
US8501122B2 (en) 2009-12-08 2013-08-06 Affymetrix, Inc. Manufacturing and processing polymer arrays
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US20110143966A1 (en) * 2009-12-15 2011-06-16 Affymetrix, Inc. Surface Modifications and Methods for their Synthesis and Use
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2012038837A2 (en) 2010-09-20 2012-03-29 Stichting Het Nederlands Kanker Instituut Methods for predicting response to anti-cancer therapy in cancer patients
BR112013008347A2 (en) 2010-10-06 2016-06-14 Bp Corp North America Inc cbh variant polypeptides i
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
US8759036B2 (en) 2011-03-21 2014-06-24 Affymetrix, Inc. Methods for synthesizing pools of probes
WO2012158957A2 (en) 2011-05-17 2012-11-22 Plexxikon Inc. Kinase modulation and indications therefor
EP2820174B1 (en) 2012-02-27 2019-12-25 The University of North Carolina at Chapel Hill Methods and uses for molecular tags
CA2865575C (en) 2012-02-27 2024-01-16 Cellular Research, Inc. Compositions and kits for molecular counting
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
EP2722105A1 (en) * 2012-10-22 2014-04-23 Universität Wien Method of in situ synthesizing microarrays
US9370087B2 (en) * 2012-11-15 2016-06-14 James Andrew Leskosek Plasma gate
US9267171B2 (en) 2013-02-28 2016-02-23 New York University DNA photolithography with cinnamate crosslinkers
US10535420B2 (en) 2013-03-15 2020-01-14 Affymetrix, Inc. Systems and methods for probe design to detect the presence of simple and complex indels
KR102126275B1 (en) 2013-05-03 2020-06-25 삼성디스플레이 주식회사 Apparatus for aligning a substrate and appratus for cutting a substrate using the same
SG10201806890VA (en) 2013-08-28 2018-09-27 Cellular Res Inc Massively parallel single cell analysis
KR20150078515A (en) * 2013-12-31 2015-07-08 삼성디스플레이 주식회사 Measuring method for reaction ratio of reactive mesogen
US9387451B2 (en) 2014-02-03 2016-07-12 International Business Machines Corporation Flow cell array and uses thereof
ES2913205T3 (en) 2014-05-13 2022-06-01 Bioatla Inc Conditionally active biological proteins
EP3146094B1 (en) 2014-05-23 2019-08-28 Centrillion Technology Holdings Corporation Oligonucleotide probe inversion process for in situ synthesized probe arrays
KR20230172625A (en) 2014-08-28 2023-12-22 바이오아트라, 인코퍼레이티드 Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2016130572A2 (en) 2015-02-10 2016-08-18 Dana-Farber Cancer Institute, Inc. Methods of determining levels of exposure to radiation and uses thereof
EP3262217A4 (en) 2015-02-24 2018-07-18 BioAtla LLC Conditionally active biological proteins
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3130682B1 (en) * 2015-08-13 2020-03-18 Centrillion Technology Holdings Corporation Methods for generating polymer arrays
US10695735B2 (en) 2015-08-18 2020-06-30 Centrillion Technology Holdings Corporation Probe inversion process for in situ synthesized probe arrays
IL296418A (en) 2015-10-18 2022-11-01 Affymetrix Inc Multiallelic genotyping of single nucleotide polymorphisms and indels
BR112018011475A2 (en) 2015-12-07 2018-12-04 Plexxikon Inc compounds and methods for kinase modulation and indication for kinase
SI3455261T1 (en) 2016-05-13 2023-01-31 Bioatla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
TW201815766A (en) 2016-09-22 2018-05-01 美商普雷辛肯公司 Compounds and methods for IDO and TDO modulation, and indications therefor
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
US20190366292A1 (en) * 2018-05-29 2019-12-05 Centrillion Technologies, Inc. Increasing Efficiency Of Photochemical Reactions On Substrates
JP2022512080A (en) 2018-11-30 2022-02-02 カリス エムピーアイ インコーポレイテッド Next Generation Molecular Profiling
EP4069865A4 (en) 2019-12-02 2023-12-20 Caris MPI, Inc. Pan-cancer platinum response predictor

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016855A (en) * 1974-09-04 1977-04-12 Hitachi, Ltd. Grinding method
US4401796A (en) * 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4716852A (en) * 1985-04-08 1988-01-05 Hitachi, Ltd. Apparatus for thin film formation using photo-induced chemical reaction
US4728502A (en) * 1984-05-02 1988-03-01 Hamill Brendan J Apparatus for the chemical synthesis of oligonucleotides
US5100775A (en) * 1988-03-16 1992-03-31 Smyczek Peter J Method for conducting nucleic acid hybridization in chamber with precise fluid delivery
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5202231A (en) * 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5242974A (en) * 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324633A (en) * 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5324483A (en) * 1992-10-08 1994-06-28 Warner-Lambert Company Apparatus for multiple simultaneous synthesis
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5451500A (en) * 1989-11-17 1995-09-19 Gene Tec Corporation Device for processing biological specimens for analysis of nucleic acids
US5489678A (en) * 1989-06-07 1996-02-06 Affymax Technologies N.V. Photolabile nucleoside and peptide protecting groups
US5508197A (en) * 1994-07-25 1996-04-16 The Regents, University Of California High-speed thermal cycling system and method of use
US5525464A (en) * 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5532128A (en) * 1991-11-19 1996-07-02 Houston Advanced Research Center Multi-site detection apparatus
US5534328A (en) * 1993-12-02 1996-07-09 E. I. Du Pont De Nemours And Company Integrated chemical processing apparatus and processes for the preparation thereof
US5541314A (en) * 1993-02-11 1996-07-30 University Of Georgia Research Foundation, Inc. Method for automated synthesis of oligonucleotides
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5609305A (en) * 1994-09-19 1997-03-11 Vortec Corporation Apparatus for providing an air curtain
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5650327A (en) * 1990-03-02 1997-07-22 Ventana Medical Systems, Inc. Method for mixing reagent and sample mounted on a slide
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5764518A (en) * 1994-12-28 1998-06-09 Collins; Charles M. Self reproducing fundamental fabricating machine system
US5814700A (en) * 1993-10-22 1998-09-29 The Board Of Trustees Of The Leland Stanford Junior University Method for polymer synthesis in a reaction well
US5814365A (en) * 1997-08-15 1998-09-29 Micro C Technologies, Inc. Reactor and method of processing a semiconductor substate
US5902723A (en) * 1989-06-07 1999-05-11 Dower; William J. Analysis of surface immobilized polymers utilizing microfluorescence detection
US5945334A (en) * 1994-06-08 1999-08-31 Affymetrix, Inc. Apparatus for packaging a chip
US5958342A (en) * 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US5958760A (en) * 1995-03-28 1999-09-28 Medical Research Council Sample processing device with a chamber forming member
US5959098A (en) * 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US6015531A (en) * 1996-06-07 2000-01-18 Bio Merieux Single-use analysis card comprising a liquid flow duct
US6034775A (en) * 1996-10-09 2000-03-07 Symyx Technologies, Inc. Optical systems and methods for rapid screening of libraries of different materials
US6040193A (en) * 1991-11-22 2000-03-21 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US6043080A (en) * 1995-06-29 2000-03-28 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6057100A (en) * 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
US6114122A (en) * 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US6168948B1 (en) * 1995-06-29 2001-01-02 Affymetrix, Inc. Miniaturized genetic analysis systems and methods
US6180351B1 (en) * 1999-07-22 2001-01-30 Agilent Technologies Inc. Chemical array fabrication with identifier
US6232072B1 (en) * 1999-10-15 2001-05-15 Agilent Technologies, Inc. Biopolymer array inspection
US6242266B1 (en) * 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
US6251595B1 (en) * 1998-06-18 2001-06-26 Agilent Technologies, Inc. Methods and devices for carrying out chemical reactions
US6258593B1 (en) * 1999-06-30 2001-07-10 Agilent Technologies Inc. Apparatus for conducting chemical or biochemical reactions on a solid surface within an enclosed chamber
US6274091B1 (en) * 1995-09-22 2001-08-14 Berlex Laboratories, Inc. Apparatus and process for multiple chemical reactions
US6384210B1 (en) * 1997-03-20 2002-05-07 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6382693B1 (en) * 1999-11-17 2002-05-07 Torstein Ljungmann Device for automatically attaching cover slips to microscope slides
US6399365B2 (en) * 1994-06-08 2002-06-04 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
US20020111741A1 (en) * 2001-02-15 2002-08-15 Klaus Abraham-Fuchs Network for evaluating data obtained in a biochip measurement device
US6440669B1 (en) * 1999-11-10 2002-08-27 Agilent Technologies, Inc. Methods for applying small volumes of reagents
US6448066B1 (en) * 1998-12-07 2002-09-10 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Rotary thermocycling apparatus
US20030003222A1 (en) * 2001-06-29 2003-01-02 Bass Jay K. Methods for manufacturing arrays
US20030003504A1 (en) * 2001-06-29 2003-01-02 Bass Jay K. Flow cell for chemical reactions
US6517079B1 (en) * 1998-10-12 2003-02-11 Winfried Sommereisen Gas seal for continuous thermal treatment facilities operated with a protective gas atmosphere
US6524650B1 (en) * 1997-03-21 2003-02-25 Kokusai Electric Co., Ltd. Substrate processing apparatus and method
US6544775B2 (en) * 1997-02-21 2003-04-08 Merckle Gmbh Automated macromolecule synthesizing process and device
US20030112295A1 (en) * 2001-12-18 2003-06-19 Daquino Lawrence J. Pulse jet print head assembly having multiple reservoirs and methods for use in the manufacture of biopolymeric arrays
US20030118716A1 (en) * 2001-12-24 2003-06-26 Bass Jay K. Small volume chambers
US6599693B1 (en) * 2000-07-31 2003-07-29 Agilent Technologies Inc. Array fabrication
US20030143329A1 (en) * 2002-01-30 2003-07-31 Shchegrova Svetlana V. Error correction in array fabrication
US20030143756A1 (en) * 2002-01-30 2003-07-31 Fisher William D. Multi-directional deposition in array fabrication
US20040002072A1 (en) * 1998-09-09 2004-01-01 Barth Phillip W Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US20040005614A1 (en) * 2002-05-17 2004-01-08 Nurith Kurn Methods for fragmentation, labeling and immobilization of nucleic acids
US20040009608A1 (en) * 2002-07-10 2004-01-15 Caren Michael P. Arrays with positioning control
US6696298B2 (en) * 2001-12-07 2004-02-24 Biosearch Technologies, Inc. Multi-channel reagent dispensing apparatus
US6706875B1 (en) * 1996-04-17 2004-03-16 Affyemtrix, Inc. Substrate preparation process
US6720186B1 (en) * 1998-04-03 2004-04-13 Symyx Technologies, Inc. Method of research for creating and testing novel catalysts, reactions and polymers
US6749814B1 (en) * 1999-03-03 2004-06-15 Symyx Technologies, Inc. Chemical processing microsystems comprising parallel flow microreactors and methods for using same
US6867050B2 (en) * 2001-05-16 2005-03-15 Academia Sinica Apparatus and methods for chemical synthesis
US6875280B2 (en) * 2000-02-10 2005-04-05 Hitachi Kokusai Electric Inc Substrate processing apparatus and substrate processing method

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180739A (en) 1977-12-23 1979-12-25 Varian Associates, Inc. Thermostatable flow cell for fluorescence measurements
US4294800A (en) 1978-10-30 1981-10-13 Tavlarides Lawrence L Liquid jet recycle reactor
AU581669B2 (en) * 1984-06-13 1989-03-02 Applied Research Systems Ars Holding N.V. Photometric instruments, their use in methods of optical analysis, and ancillary devices therefor
US4751170A (en) * 1985-07-26 1988-06-14 Nippon Telegraph And Telephone Corporation Silylation method onto surface of polymer membrane and pattern formation process by the utilization of silylation method
US4963245A (en) 1986-05-02 1990-10-16 Ciba Corning Diagnostics Corp. Unitary multiple electrode sensor
US5175209A (en) 1987-01-06 1992-12-29 Baylor College Of Medicine Porous wafer for segmented synthesis of biopolymers
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8827853D0 (en) * 1988-11-29 1988-12-29 Ares Serono Res & Dev Ltd Sensor for optical assay
US6955915B2 (en) 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
CA2097708A1 (en) * 1990-12-06 1992-06-07 Stephen P. A. Fodor Very large scale immobilized polymer synthesis
AU2422492A (en) * 1991-08-07 1993-03-02 H & N Instruments, Inc. Synthesis of chain chemical compounds
US5449754A (en) 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US5187096A (en) 1991-08-08 1993-02-16 Rensselaer Polytechnic Institute Cell substrate electrical impedance sensor with multiple electrode array
US5846708A (en) * 1991-11-19 1998-12-08 Massachusetts Institiute Of Technology Optical and electrical methods and apparatus for molecule detection
WO1994010128A1 (en) * 1992-11-02 1994-05-11 Affymax Technologies N.V. Novel photoreactive protecting groups
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
DE69430679T2 (en) 1993-02-03 2002-12-19 Histaggen Inc A method of storing a ligand in a releasable container and a method of releasing a ligand therefrom
JP3954092B2 (en) * 1993-06-25 2007-08-08 アフィメトリックス インコーポレイテッド Nucleic acid sequence hybridization and sequencing
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6165778A (en) 1993-11-02 2000-12-26 Affymax Technologies N.V. Reaction vessel agitation apparatus
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5985356A (en) 1994-10-18 1999-11-16 The Regents Of The University Of California Combinatorial synthesis of novel materials
US5846396A (en) 1994-11-10 1998-12-08 Sarnoff Corporation Liquid distribution system
EP0729021A1 (en) 1995-02-25 1996-08-28 Roche Diagnostics GmbH Device for treating samples on microscope slides
US6239273B1 (en) 1995-02-27 2001-05-29 Affymetrix, Inc. Printing molecular library arrays
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US6132580A (en) 1995-09-28 2000-10-17 The Regents Of The University Of California Miniature reaction chamber and devices incorporating same
US6660233B1 (en) 1996-01-16 2003-12-09 Beckman Coulter, Inc. Analytical biochemistry system with robotically carried bioarray
EP0880405B1 (en) 1996-01-23 1999-07-28 Novartis AG Device and process for the synthetization of macromolecules
US5981733A (en) 1996-09-16 1999-11-09 Incyte Pharmaceuticals, Inc. Apparatus for the chemical synthesis of molecular arrays
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6126904A (en) 1997-03-07 2000-10-03 Argonaut Technologies, Inc. Apparatus and methods for the preparation of chemical compounds
JP3498201B2 (en) 1997-08-27 2004-02-16 アークレイ株式会社 Vacuum generator and sample analyzer using the same
US6150147A (en) 1998-02-06 2000-11-21 Affymetrix, Inc. Biological array fabrication methods with reduction of static charge
US6165069A (en) 1998-03-11 2000-12-26 Digideal Corporation Automated system for playing live casino table games having tabletop changeable playing card displays and monitoring security features
EP0977240A1 (en) 1998-07-30 2000-02-02 IMEC vzw System, method and apparatus for processing semiconductors
CA2294572A1 (en) 1999-01-27 2000-07-27 Affymetrix, Inc. Genetic compositions and methods
US6323043B1 (en) 1999-04-30 2001-11-27 Agilent Technologies, Inc. Fabricating biopolymer arrays
US6306599B1 (en) 1999-07-16 2001-10-23 Agilent Technologies Inc. Biopolymer arrays and their fabrication
JP2001267991A (en) 2000-03-16 2001-09-28 Sony Corp Transmitter, transmission method, communication system and communication method
US6613893B1 (en) 2000-07-31 2003-09-02 Agilent Technologies Inc. Array fabrication
US6656740B1 (en) 2000-10-31 2003-12-02 Agilent Technologies, Inc. Pressure variation in array fabrication
US20030232140A1 (en) 2002-06-14 2003-12-18 Joseph Remick Methods for reagent removal in flow chambers
US7332273B2 (en) 2002-06-20 2008-02-19 Affymetrix, Inc. Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays

Patent Citations (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016855A (en) * 1974-09-04 1977-04-12 Hitachi, Ltd. Grinding method
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) * 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4401796A (en) * 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4507433A (en) * 1983-10-07 1985-03-26 The Johns Hopkins University Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4728502A (en) * 1984-05-02 1988-03-01 Hamill Brendan J Apparatus for the chemical synthesis of oligonucleotides
US4716852A (en) * 1985-04-08 1988-01-05 Hitachi, Ltd. Apparatus for thin film formation using photo-induced chemical reaction
US5667972A (en) * 1987-04-01 1997-09-16 Hyseg, Inc. Method of sequencing of genoms by hybridization of oligonucleotide probes
US5525464A (en) * 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) * 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5492806A (en) * 1987-04-01 1996-02-20 Hyseq, Inc. Method of determining an ordered sequence of subfragments of a nucleic acid fragment by hybridization of oligonucleotide probes
US5100775A (en) * 1988-03-16 1992-03-31 Smyczek Peter J Method for conducting nucleic acid hybridization in chamber with precise fluid delivery
US5489678A (en) * 1989-06-07 1996-02-06 Affymax Technologies N.V. Photolabile nucleoside and peptide protecting groups
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5445934A (en) * 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5902723A (en) * 1989-06-07 1999-05-11 Dower; William J. Analysis of surface immobilized polymers utilizing microfluorescence detection
US6225625B1 (en) * 1989-06-07 2001-05-01 Affymetrix, Inc. Signal detection methods and apparatus
US5510270A (en) * 1989-06-07 1996-04-23 Affymax Technologies N.V. Synthesis and screening of immobilized oligonucleotide arrays
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5451500A (en) * 1989-11-17 1995-09-19 Gene Tec Corporation Device for processing biological specimens for analysis of nucleic acids
US5650327A (en) * 1990-03-02 1997-07-22 Ventana Medical Systems, Inc. Method for mixing reagent and sample mounted on a slide
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5532128A (en) * 1991-11-19 1996-07-02 Houston Advanced Research Center Multi-site detection apparatus
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US6040193A (en) * 1991-11-22 2000-03-21 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5242974A (en) * 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5324633A (en) * 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) * 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
US5324483A (en) * 1992-10-08 1994-06-28 Warner-Lambert Company Apparatus for multiple simultaneous synthesis
US5541314A (en) * 1993-02-11 1996-07-30 University Of Georgia Research Foundation, Inc. Method for automated synthesis of oligonucleotides
US5814700A (en) * 1993-10-22 1998-09-29 The Board Of Trustees Of The Leland Stanford Junior University Method for polymer synthesis in a reaction well
US5534328A (en) * 1993-12-02 1996-07-09 E. I. Du Pont De Nemours And Company Integrated chemical processing apparatus and processes for the preparation thereof
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5945334A (en) * 1994-06-08 1999-08-31 Affymetrix, Inc. Apparatus for packaging a chip
US6399365B2 (en) * 1994-06-08 2002-06-04 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US5508197A (en) * 1994-07-25 1996-04-16 The Regents, University Of California High-speed thermal cycling system and method of use
US5609305A (en) * 1994-09-19 1997-03-11 Vortec Corporation Apparatus for providing an air curtain
US5556752A (en) * 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5764518A (en) * 1994-12-28 1998-06-09 Collins; Charles M. Self reproducing fundamental fabricating machine system
US5958760A (en) * 1995-03-28 1999-09-28 Medical Research Council Sample processing device with a chamber forming member
US6395536B2 (en) * 1995-03-28 2002-05-28 Medical Research Council Sample processing device with a chamber forming member
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US6197595B1 (en) * 1995-06-29 2001-03-06 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6043080A (en) * 1995-06-29 2000-03-28 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6168948B1 (en) * 1995-06-29 2001-01-02 Affymetrix, Inc. Miniaturized genetic analysis systems and methods
US6274091B1 (en) * 1995-09-22 2001-08-14 Berlex Laboratories, Inc. Apparatus and process for multiple chemical reactions
US6114122A (en) * 1996-03-26 2000-09-05 Affymetrix, Inc. Fluidics station with a mounting system and method of using
US20050181396A1 (en) * 1996-04-17 2005-08-18 Affymetrix, Inc. Substrate preparation process
US20050181431A1 (en) * 1996-04-17 2005-08-18 Affymetrix, Inc. Substrate preparation process
US6706875B1 (en) * 1996-04-17 2004-03-16 Affyemtrix, Inc. Substrate preparation process
US20060160099A1 (en) * 1996-04-17 2006-07-20 Affymetrix, Inc. Substrate preparation process
US5959098A (en) * 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US20040105932A1 (en) * 1996-04-17 2004-06-03 Affymetrix, Inc. Substrate preparation process
US20060008840A1 (en) * 1996-04-17 2006-01-12 Affymetrix, Inc. Substrate preparation process
US5958342A (en) * 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US6015531A (en) * 1996-06-07 2000-01-18 Bio Merieux Single-use analysis card comprising a liquid flow duct
US6057100A (en) * 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
US6034775A (en) * 1996-10-09 2000-03-07 Symyx Technologies, Inc. Optical systems and methods for rapid screening of libraries of different materials
US6544775B2 (en) * 1997-02-21 2003-04-08 Merckle Gmbh Automated macromolecule synthesizing process and device
US6384210B1 (en) * 1997-03-20 2002-05-07 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6524650B1 (en) * 1997-03-21 2003-02-25 Kokusai Electric Co., Ltd. Substrate processing apparatus and method
USRE37546E1 (en) * 1997-08-15 2002-02-12 Micro C Technologies, Inc. Reactor and method of processing a semiconductor substrate
US5814365A (en) * 1997-08-15 1998-09-29 Micro C Technologies, Inc. Reactor and method of processing a semiconductor substate
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
US6720186B1 (en) * 1998-04-03 2004-04-13 Symyx Technologies, Inc. Method of research for creating and testing novel catalysts, reactions and polymers
US6251595B1 (en) * 1998-06-18 2001-06-26 Agilent Technologies, Inc. Methods and devices for carrying out chemical reactions
US20040002072A1 (en) * 1998-09-09 2004-01-01 Barth Phillip W Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US7026124B2 (en) * 1998-09-09 2006-04-11 Agilent Technologies, Inc. Method and multiple reservoir apparatus for fabrication of biomolecular arrays
US6517079B1 (en) * 1998-10-12 2003-02-11 Winfried Sommereisen Gas seal for continuous thermal treatment facilities operated with a protective gas atmosphere
US6448066B1 (en) * 1998-12-07 2002-09-10 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Rotary thermocycling apparatus
US6749814B1 (en) * 1999-03-03 2004-06-15 Symyx Technologies, Inc. Chemical processing microsystems comprising parallel flow microreactors and methods for using same
US6372483B2 (en) * 1999-04-30 2002-04-16 Agilent Technologies, Inc. Preparation of biopolymer arrays
US6242266B1 (en) * 1999-04-30 2001-06-05 Agilent Technologies Inc. Preparation of biopolymer arrays
US6258593B1 (en) * 1999-06-30 2001-07-10 Agilent Technologies Inc. Apparatus for conducting chemical or biochemical reactions on a solid surface within an enclosed chamber
US6180351B1 (en) * 1999-07-22 2001-01-30 Agilent Technologies Inc. Chemical array fabrication with identifier
US6589739B2 (en) * 1999-10-15 2003-07-08 Agilent Technologies Inc. Biopolymer array inspection
US6232072B1 (en) * 1999-10-15 2001-05-15 Agilent Technologies, Inc. Biopolymer array inspection
US6440669B1 (en) * 1999-11-10 2002-08-27 Agilent Technologies, Inc. Methods for applying small volumes of reagents
US6382693B1 (en) * 1999-11-17 2002-05-07 Torstein Ljungmann Device for automatically attaching cover slips to microscope slides
US6875280B2 (en) * 2000-02-10 2005-04-05 Hitachi Kokusai Electric Inc Substrate processing apparatus and substrate processing method
US6599693B1 (en) * 2000-07-31 2003-07-29 Agilent Technologies Inc. Array fabrication
US20020111741A1 (en) * 2001-02-15 2002-08-15 Klaus Abraham-Fuchs Network for evaluating data obtained in a biochip measurement device
US6867050B2 (en) * 2001-05-16 2005-03-15 Academia Sinica Apparatus and methods for chemical synthesis
US6713023B2 (en) * 2001-06-29 2004-03-30 Agilent Technologies, Inc. Flow cell for chemical reactions
US20030003222A1 (en) * 2001-06-29 2003-01-02 Bass Jay K. Methods for manufacturing arrays
US20040077006A1 (en) * 2001-06-29 2004-04-22 Bass Jay K. Methods for manufacturing arrays
US20030003504A1 (en) * 2001-06-29 2003-01-02 Bass Jay K. Flow cell for chemical reactions
US6696298B2 (en) * 2001-12-07 2004-02-24 Biosearch Technologies, Inc. Multi-channel reagent dispensing apparatus
US20030112295A1 (en) * 2001-12-18 2003-06-19 Daquino Lawrence J. Pulse jet print head assembly having multiple reservoirs and methods for use in the manufacture of biopolymeric arrays
US6935727B2 (en) * 2001-12-18 2005-08-30 Agilent Technologies, Inc. Pulse jet print head assembly having multiple reservoirs and methods for use in the manufacture of biopolymeric arrays
US20050084952A1 (en) * 2001-12-24 2005-04-21 Bass Jay K. Small volume chambers
US20030118716A1 (en) * 2001-12-24 2003-06-26 Bass Jay K. Small volume chambers
US20030143329A1 (en) * 2002-01-30 2003-07-31 Shchegrova Svetlana V. Error correction in array fabrication
US20030143756A1 (en) * 2002-01-30 2003-07-31 Fisher William D. Multi-directional deposition in array fabrication
US20040005614A1 (en) * 2002-05-17 2004-01-08 Nurith Kurn Methods for fragmentation, labeling and immobilization of nucleic acids
US20040009608A1 (en) * 2002-07-10 2004-01-15 Caren Michael P. Arrays with positioning control

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134677A1 (en) * 2005-12-09 2007-06-14 Changhan Kim Light directed DNA synthesis using inverse capping for error reduction
US7994098B2 (en) * 2005-12-09 2011-08-09 Wisconsin Alumni Research Foundation Light directed DNA synthesis using inverse capping for error reduction
US11371086B2 (en) 2010-04-05 2022-06-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10982268B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11767550B2 (en) 2010-04-05 2023-09-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10914730B2 (en) 2010-04-05 2021-02-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11761030B2 (en) 2010-04-05 2023-09-19 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10962532B2 (en) 2010-04-05 2021-03-30 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11384386B2 (en) 2010-04-05 2022-07-12 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10983113B2 (en) 2010-04-05 2021-04-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US10996219B2 (en) 2010-04-05 2021-05-04 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001878B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11001879B1 (en) 2010-04-05 2021-05-11 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11008607B2 (en) 2010-04-05 2021-05-18 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11732292B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays correlating target nucleic acid to tissue section location
US11067567B2 (en) 2010-04-05 2021-07-20 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11156603B2 (en) 2010-04-05 2021-10-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11733238B2 (en) 2010-04-05 2023-08-22 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11208684B2 (en) 2010-04-05 2021-12-28 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11634756B2 (en) 2010-04-05 2023-04-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11560587B2 (en) 2010-04-05 2023-01-24 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11549138B2 (en) 2010-04-05 2023-01-10 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11313856B2 (en) 2010-04-05 2022-04-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11542543B2 (en) 2010-04-05 2023-01-03 Prognosys Biosciences, Inc. System for analyzing targets of a tissue section
US11519022B2 (en) 2010-04-05 2022-12-06 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11365442B2 (en) 2010-04-05 2022-06-21 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11293917B2 (en) 2010-04-05 2022-04-05 Prognosys Biosciences, Inc. Systems for analyzing target biological molecules via sample imaging and delivery of probes to substrate wells
US11479810B1 (en) 2010-04-05 2022-10-25 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11866770B2 (en) 2010-04-05 2024-01-09 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11401545B2 (en) 2010-04-05 2022-08-02 Prognosys Biosciences, Inc. Spatially encoded biological assays
US11479809B2 (en) 2011-04-13 2022-10-25 Spatial Transcriptomics Ab Methods of detecting analytes
US11795498B2 (en) 2011-04-13 2023-10-24 10X Genomics Sweden Ab Methods of detecting analytes
US11352659B2 (en) 2011-04-13 2022-06-07 Spatial Transcriptomics Ab Methods of detecting analytes
US11788122B2 (en) 2011-04-13 2023-10-17 10X Genomics Sweden Ab Methods of detecting analytes
US20190024153A1 (en) * 2011-04-13 2019-01-24 Spatial Transcriptomics Ab Method and product for localized or spatial detection of nucleic acid in a tissue sample
US8960686B2 (en) * 2011-09-30 2015-02-24 Electro Scientific Industries, Inc. Controlled surface roughness in vacuum retention
US20130082448A1 (en) * 2011-09-30 2013-04-04 Electro Scientific Industries, Inc. Controlled Surface Roughness in Vacuum Retention
US11821024B2 (en) 2013-06-25 2023-11-21 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11753674B2 (en) 2013-06-25 2023-09-12 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11359228B2 (en) 2013-06-25 2022-06-14 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11618918B2 (en) 2013-06-25 2023-04-04 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11286515B2 (en) 2013-06-25 2022-03-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US10927403B2 (en) 2013-06-25 2021-02-23 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11046996B1 (en) 2013-06-25 2021-06-29 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US11299774B2 (en) 2015-04-10 2022-04-12 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11739372B2 (en) 2015-04-10 2023-08-29 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11613773B2 (en) 2015-04-10 2023-03-28 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11162132B2 (en) 2015-04-10 2021-11-02 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11390912B2 (en) 2015-04-10 2022-07-19 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
US11753675B2 (en) 2019-01-06 2023-09-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries

Also Published As

Publication number Publication date
US20130059763A1 (en) 2013-03-07
US6307042B1 (en) 2001-10-23
CA2251755A1 (en) 1997-10-23
AU2804797A (en) 1997-11-07
US5959098A (en) 1999-09-28
EP0950112A4 (en) 2004-12-15
US8637434B2 (en) 2014-01-28
EP0950112A1 (en) 1999-10-20
US8309496B2 (en) 2012-11-13
US20100331217A1 (en) 2010-12-30
CA2251755C (en) 2010-09-14
JP2000508542A (en) 2000-07-11
WO1997039151A1 (en) 1997-10-23
US20120071361A1 (en) 2012-03-22
US8067578B2 (en) 2011-11-29
JP2006258806A (en) 2006-09-28

Similar Documents

Publication Publication Date Title
US8637434B2 (en) System for photolithographic synthesis of polymer arrays
US6706875B1 (en) Substrate preparation process
US6506558B1 (en) Very large scale immobilized polymer synthesis
US6420169B1 (en) Apparatus for forming polynucleotides or polypeptides
US6150147A (en) Biological array fabrication methods with reduction of static charge
US20050208537A1 (en) Very large scale immobilized polymer synthesis
US5510270A (en) Synthesis and screening of immobilized oligonucleotide arrays
US6406844B1 (en) Very large scale immobilized polymer synthesis
US7550410B2 (en) Method and apparatus for combinatorial chemistry
US8227253B2 (en) Oxide layers on silicon substrates for effective confocal laser microscopy
US20010049108A1 (en) Methods for reducing non-specific binding to an oligonucleotide array
US20100298171A1 (en) Apparatus for polymer synthesis
US20030232343A1 (en) Methods for testing reagent distribution in reaction chambers

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION